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ABSTRACT
The leading cause of death worldwide is cardiovascular disease (CVD). Myocardial
infarction (MI) (i.e., heart attack) makes up ~8.5% of CVD and is a common cause of heart
failure with a 40% five-year mortality after the first MI. This highlights a substantial
patient population and an urgent need to develop new therapeutic strategies (e.g.,
regenerative cell therapies). Moreover, this also indicates that current models may not
sufficiently recapitulate human cardiac tissue. To date, drug development strategies have
largely depended on high throughput 2D cell models and pre-clinical testing in animal
models of MI leading to minimal improvements in the heart failure treatment paradigm
over the past 20 years. Relevant human cardiac models would provide insight into human
cardiac tissue physiology and maturation while also providing an advanced in vitro
screening tool to explore heart failure pathogenesis. Cardiac tissue engineering has
allowed for advances in the development of cardiac constructs by combining
developments in biomaterials, 3D microtissue culture, and human induced pluripotent
stem cells (hiPSC) technology. Notably, approaches that mimic the natural processes in
the body (i.e., biomimetic) have led to further insight into cardiac physiology. Here, I have
pursued biomimetic strategies to create a biomimetic model of human cardiac tissue
using hiPSC-derived cardiomyocytes (hiPSC-CMs). Throughout this development, I
explored the role of the matrix microenvironment on cell behavior using functionalized
alginate, the influence of pacemaker-like exogenous electrical stimulation on the
maturation

of hiPSC-CM

spheroids with endogenous
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electrically

conductive

nanomaterials, and the development of vascularized, functional cardiac organoids by
mimicking the coronary vasculogenesis stage of cardiac development. The research
established here provided a biomimetic groundwork for future development into in vitro
human cardiac tissue models for applications in basic research, drug discovery, and cell
therapy.
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CHAPTER ONE
THE NEED FOR BIOMIMETIC CARDIAC MODELS
Introduction
Cardiovascular disease is the leading cause of death and disability worldwide, claiming
more lives than all types of cancers combined.1 Ischemic heart disease (IHD) and
myocardial infarction (MI) are major contributors to cardiovascular morbidity and
mortality.2 The treatment of the heart failure from myocardial infarction has slowly
evolved over the past decades. A major turning point for restoring heart function was the
scientific evidence that thrombus formation led to myocardial infarction and not vice
versa.3-5 After myocardial infarction, the affected cardiomyocytes begin to die and are
replaced with a collagenous scar within weeks. The adjacent myocardium continues to
create tension on the scar region with every beat, causing the damaged ventricular wall
to thin and dilate. With a larger ventricular volume but less functional myocardium, the
heart can no longer maintain cardiac output and eventually leads to heart failure. This led
to the, now common, practice of reperfusion therapy upon arriving to the hospital.
Despite restored blood flow, the lack of sufficient regeneration to replace damaged tissue
and the constant demand to pump blood to the entire body causes the heart to
progressively fail.6
Today the most common treatment is to reduce demand on the heart with
therapeutic strategies (e.g, beta-blockers) or completely replace the heart with either a
heart transplant (limited by donor supply) or with a left ventricular assist device (LVAD).
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Despite prolonging life, this status quo for heart failure treatment remains limited by not
achieving a restoration of heart function through regeneration of myocardium. Presently,
the only long-term solution is cardiac transplantation, a procedure severely limited by the
shortage of donor heart and by cost.7,8 Due to the limited regeneration capacity of adult
human hearts, the human induced pluripotent stem cell (hiPSC) has emerged as a
powerful cell source for cardiac repair due to its proven capacity to produce patientspecific functional cardiomyocytes.9-13 In addition, recent progress in cardiac
differentiation of hiPSCs allows for the derivation of the large amount of patient-specific
human cardiomyocytes (~1x109 cells/patient), including from heart failure patients,
needed for the idealized cardiac repair or large scale drug screening.14-18 Despite the
progress in heart failure treatment in the last 50 years, notably less progress has been
made in the last decade to advance the heart failure therapeutic paradigm.19,20
Development of a biomimetic model to recapitulate the tissue-level dynamics of human
ventricular cardiac tissues would provide a valuable tool to further investigate the
physiology and pathology of human hearts and their diseases.

Applications in Basic Research
Although hiPSC-CMs provide a human cardiomyocyte model, the complexity of
the multi-cellular nature and developmental stage of adult ventricular myocardium has
led to significant challenges in modeling human cardiac tissue in vitro. The current
cardiomyocytes derived from hESCs and hiPSCs retain an immature phenotype, including
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poor contraction, metabolism, structure, and electrophysiology.21-24 During embryonic
development, environmental factors (e.g., extracellular matrix- ECM, growth factors,
mechanical and electrical stimulation) have major effects on the maturation of
cardiomyocytes. To mimic the maturation process in vitro, hESC- and hiPSC-derived
cardiomyocytes have been mixed with scaffolding materials (e.g., Matrigel and collagen
type I gel) to prepare cardiac tissue-engineered constructs and then conditioned with
electrical and/or mechanical stimulation.21,25-27 While these scaffolds can provide tissuelike 3D microenvironments, current scaffolding materials lack the matched
physical/chemical/biological properties with the native extracellular environments during
heart development. On the other hand, scaffold-free, 3D cardiac spheroids have emerged
as promising model systems to mimic cardiac tissues by providing a consistent, high
throughput method to produce microtissue with biomimetic cell densities that rely on
self-assembly mechanisms and endogenous scaffolding material production (i.e.,
ECM).28,29
Various tissue-engineering strategies have been utilized to mimic adult host
ventricular myocardium to accelerate phenotypic development of hiPSC-CMs.21,30-36 To
this end, several groups have used electrical stimulation as an exogenous approach to
recapitulate the natural pacemaker-initiated excitation of cardiomyocyte contraction to
advance the function of hESC/hiPSC-CMs.21,35,37-42 Eng and others demonstrated that
electrical conditioning of 3D cardiac embryoid bodies promotes cellular maturity of hiPSCCMs and affects intrinsic beating characteristics.39 Likewise, electrical nanomaterials have
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provided an endogenous means of improving electrical conductivities of cardiac
microtissues.43-45
A combination of tissue-engineered strategies may be required to advance the
functional assembly of hiPSC-CMs. In vitro methods, including mechanical and exogenous
electrical stimulation, 3D microtissue culture, and capillary-like nutrient/drug delivery,
have targeted physiologically relevant features that improved in vitro cardiomyocyte
development.25,39,46-49 For example, Thavandiran and coworkers combined the aligned
features of the myocardium with electrical stimulation to improve the functional
development of cardiac microtissues.50 To mimic myocardial nutrient exchange, Mathur
and coworkers showed that microfabricated channels surrounding CM constructs
provided capillary-like diffusion that improved the physiological relevance of drug
screening.46 To improve cell viability and integration after transplantation into infarcted
hearts, Stevens and coworkers fabricated pre-vascularized cardiac patches that can
connect to the host vasculature.51 In the most recent pursuit of ventricular cardiac tissue
maturation, Ronaldson-Bouchard and others used a fibrin-based anisotropic hiPSC-CM
microtissue model with 25% dermal fibroblasts to construct a microtissue that was
electrically stimulated at increasing speeds that resulted in major hallmarks in mature
ventricular cardiomyocytes including sarcomere M-line ultrastructures, ventricular-like
electrophysiology and calcium handling, T-tubules, and oxidative phosphorylation shifts
in metabolism.52 In this study, they provided evidence that earlier hiPSC-CM in vitro age
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increased its in vitro maturation potential in a shorter time, suggesting hiPSC-CM
development may involve several stages of lineage commitment.
While previous approaches allow for focused study on hiPSC-CM function and
maturation, there has been limited progress towards the development of an organotypic
functional 3D cardiac model of the working myocardium. The heart is composed of more
than simply cardiomyocytes and fibroblasts and independent studies have supported the
benefit of additional cell types in improving overall tissue function, such as improved
conduction velocity or vascularization.32,39,51,53-55 The human induced pluripotent stem
cell (hiPSC)-enabled development of human organoids has provided a powerful platform
for isogenic disease modeling and investigation of developmental biology that inherently
contains a variety of cell types.56-58 To this end, a variety of functional tissue organoids
(e.g., kidney, liver, brain) have been developed with the purpose of recapitulating major
organ functions and structures, yet few studies have focused on the development of
human cardiac organoids. A biomimetic approach for human organoid design may
provide an accessible multi-dimensional in vitro model that can give further insight into
tissue development without the need for more expensive, less human-specific animal
models of heart tissue.

Applications in Drug Discovery
Despite improvements in heart failure therapies in the past 50 years, it was only
recently that the PARADIGM-HF trial proved to be the first in 30 years to show a new drug
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outperforming treatment developed in the late 1980s.59,60 From 2003 to 2011, the
likelihood of FDA approval of cardiovascular disease therapies from Phase I was 7%, which
is below the average likelihood for all major disease categories (10%), and had the lowest
success rate from Phase II (26%).61 In addition to clinical trial design, this has been, in part,
attributed to translational discrepancies of preclinical data to outcomes in humans. 62,63
While many single pathways (e.g., B-AR biased ligands) and contributing cell types (e.g.,
epicardial cell) in heart failure have been thoroughly studied in single cell systems, the
tissue-level response is only screened in the context of preclinical/clinical models.
Although preclinical models provide a whole-organism context to evaluate novel
therapies, tissue-specific characteristics and disease progression have notable differences
across species, especially in smaller mammals (e.g. mouse).64-66
Given the differences between species, recent progress in human induced
pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) technology has aimed to
incorporate hiPSC-CM 2D models to drug development/safety pipelines.67,68 Current
standards for drug cardiotoxicity evaluation focus on detection of delayed ventricular
repolarization, which is strongly associated with fatal ventricular arrhythmias, including
torsades de pointes.69 hERG channel blockade and QT interval prolongation in
electrocardiograms have been used as the industry standard targets for detection. The
evaluation methods usually involve overexpressed non-cardiac cell types (e.g., hERGtransfected CHO cells) and electrocardiogram assays in animal models (e.g. Langendorffperfused rabbit hearts).70-73 While these methods have successfully reduced drug
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withdrawals, they also limited the pace and productivity of drug evaluation by eliminating
potentially effective drugs that operate through alternative pathways (e.g., multi-channel
effects).69,74 Developing novel high throughput drug cardiotoxicity screening systems
using hiPSC-CMs with the improved clinical relevance would greatly accelerate the pace
of therapeutic discovery as it can allow for robust derivation of patient-specific human
cardiomyocytes (hiPSC-CMs).15,16,75-78 To this end, several reports have shown the
feasibility of the utilization of the conventional 2D hiPSC-CM culture system for drug
arrhythmogenic tests.79-84 In addition, tissue engineering strategies have been employed
to assemble hiPSC-CMs into 3D cardiac (micro-)tissues to mimic structural features of
myocardium (e.g., cell alignment, capillary-like media flow) to improve their physiological
relevance, drug cardiotoxicity predictability and reduce drug response variation.26,46,85,86
However, the lack of control in the hiPSC-CM assembly process hinders the formation of
proper cell-cell conjunctions and leads to the compromised cardiac functions (e.g.,
unsynchronized contraction). Further, the drug response data found in human adult
ventricular tissue slices differs significantly from the existing hiPSC-CM systems. This has
been, at least partially, attributed to the overall immature phenotype of the current
hiPSC-CMs.87
This highlights an unmet need to develop a biomimetic in vitro human model that
incorporates tissue-level properties to provide a representative screening platform that
shares functional and species similarities to humans prior to animal studies. This would
reduce novel candidates earlier in the pipeline and thereby accelerate and improve
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accuracy of heart failure drug development. Given the patient-specific nature of induced
pluripotent stem cell (iPSC) technology, the majority of translational iPSC-based organoid
work has focused on genetic disorders to treat with gene-targeted approaches (e.g.,
CRISPR-Cas9) or to serve as a patient-specific drug screening platform.88-92 In addition to
heart failure, congenital heart disease occurs in ~1% of live births, ~10% of aborted
fetuses, and is the leading cause of mortality from birth defects.93,94 Biomimetic cardiac
model design can also contribute to this significant medical need by incorporating patientspecific iPSC-cardiac models to address genetic mutation disorders.95-101 For example,
Wang and others provided new insight into the pathogenesis of Barth syndrome that
linked this mitochondrial cardiomyopathy with contractile dysfunction that was
facilitated by a tissue-level hiPSC-CM model.102

Applications in Cell Therapy
In addition to purely in vitro models, biomimetic human cardiac models also hold
promise in the design of an advanced cell therapy vehicles to maximize their regenerative
capacity. The field of cell therapy provides an injection-based strategy (i.e., intravenous,
intracoronary, or intramyocardial delivery) to regenerate lost myocardium that avoids the
highly invasive surgery needed for heart transplantation, LVAD insertion, and proposed
tissue engineered patch strategies.103 Traditionally, adult stem cells (e.g., mesenchymal
stem cells) have been a common source of exploration due to their multipotency and
availability in adults. Additionally, advances in induced pluripotent stem cell (iPSC)
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technology has furthered this potential with a patient-specific cell source, avoiding life
time immunosuppressant therapy in the case of heart transplants and/or allogeneic
cells.100,104
The guiding principal for cardiac cell therapy has largely been focused on the
pluripotency and proliferative capacity of the injected cells over other strategies, such as
mimicking naturally occurring regenerative/survival mechanisms. The initial research
evaluation of the efficacy of embryonic stem cells (ESCs) showed a trend of cell survival
and modest improved cardiac function in the rat infarct model. 105-108 However, in-depth
analysis of ESC transplantation in the uninjured and injured heart has shown teratoma
formation in allogeneic and syngeneic recipients and increased immunological
response.109-111 These results indicate that 1) the heart may not provide sufficient signals
for in situ differentiation of pluripotent stem cells, 2) an ESC-based method would require
a level of immunosuppressant therapy, and 3) a more differentiated cell type may be
necessary for successful integration and long term benefits.
Based on the ground work in pluripotent and multipotent stem cell
transplantation in infarcted hearts, it can be reasoned that cells with a cardiac-committed
lineage may have the most regenerative potential due to their ability to differentiate into
cells important for cardiac repair, such as cardiomyocytes and endothelial cells.112 For the
extent of this discussion, cardiac-committed cells will not be fully defined, but include
cardiopoietic cell strategies (e.g., c-kit+ stem cells, cardiosphere-derived cells). To explore
the therapeutic benefit of a cardiac-committed stem cell population, Menasche’s group
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in 2005 conducted a preclinical study using cardiac-committed mouse ESCs in an infarcted
sheep model that showed differentiation into cardiomyocytes and an increase in ejection
fraction from 39% to 45.6% after 1, whereas media-inject controls decreased from 43%
to 33.1%.113 Marban’s group then investigated the efficacy of cardiosphere-derived cells
expanded from percutaneous endomyocardial biopsy specimens in a porcine model that
showed an increase in ejection fraction from ~41% to 44% after 8 weeks while the PBS
injected control changed from 42% to 36%.114 These studies helped to launch human
cardiac-committed cells to human trials to make up the next generation of cell therapy
strategies for heart failure.115
Most recently, the C-CURE trial investigated the efficacy of cardiopoietic stem cell
derived from mesenchymal stem cells in chronic heart failure patients using an
endoventricular guided catheter delivery of 600-1,200 x 106 cells that can
electromechanically map viable and dysfunctional myocardium for precision-mapped
injection.116 This cell therapy resulted in significant improvements in ejection fraction
(from ~27% to ~34% in treated) with no improvements in standard-of-care controls.
Overall, there seems to be improvements in function with cardiac-committed cell therapy
in the short term analysis of these early stage approaches, but more trials on larger
populations must be conducted to obtain a more accurate representation of treatment
efficacies. Furthermore, the number of cells needed for current cell therapy strategies
emphasize the need for improved methods for cell retention.
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Heart failure after myocardial infarction is caused in part by the inability of the
sufficient force generation due to lack of healthy myocardium. With this aspect of the
problem in sight and with improved protocols for cardiomyocyte differentiation, many
groups have explored the use of stem cell-derived cardiomyocytes as the cell source for
cardiac cell therapy. This method does not depend on in situ differentiation after
transplantation and therefore theoretically could accelerate the regeneration of forcegenerating myocardium. Initial studies using neonatal rat cardiomyocytes results
validated the basis for the use of stem cell-derived cardiomyocytes, as they are also not
fully matured cardiomyocytes.24,30 Initial studies of human embryonic stem cell-derived
cardiomyocyte

(hESC-CM)

electromechanical

cell

integration

therapy
of

after

confirmed

their

transplantation

into

survivability

and

uninjured

and

electrophysiologically silenced.117-119 Based on the previous research in smaller animal
models and the progression of stem cell-derived cardiomyocyte culture (both hESC-CMs
and hiPSC-CMs), a large animal model was explored recently to evaluate the feasibility of
mass production of stem cell-derived cardiomyocytes and efficacy of intramyocardial
delivery in a non-human primate model (macaque, 100-150 BPM), of myocardial
ischemia-reperfusion injury.120 This study involved injection of 1 x 109 hESC-CMs that
showed substantial remuscularization (averaging 40% of infarct volume), perfusion by
host vasculature, and graft-host electromechanical junctions that increased over 84 days
after injection. Functional metrics (e.g., ejection fraction) among hearts receiving hESCCM showed no significant trends given the limited injured after ischemia-reperfusion
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compared to an infarction model. However, it must be considered that sample sizes of
this study were 1 at 14 days, 2 at 28 days, and 1 at 84 days, statistically limiting any
conclusions on efficacy. In regards to the electrophysiology, all animals showed no
arrhythmias prior to injection, but all developed arrhythmias after receiving hESC-CMs
(i.e., premature ventricular contractions and periods of ventricular tachycardia). Most
notably, this data contrasts with the previous work in small animal models and has led to
increased discussion about stem cell-derived cardiomyocyte safety concerns.121 This also
emphasizes the need to further understand the capacity of stem cell-derived
cardiomyocytes, which may require improved in vitro models to increased understanding
of hiPSC-CM maturation prior to injection or other strategies to promote favorable
integration.
Given the diverse approaches for cardiac cell and biomaterial therapy with modest
improvements, a multi-dimensional approach may be ideal solution. Many groups are
exploring combining cell types and technologies to address each obstacle for successful
retention and integration. Developmental mechanisms for vascularization of forming
heart has inspired the use of epicardial-derived progenitor cells in conjunction with
cardiac progenitor cells that has shown to be more angiogenic and resistant to hypoxia
leading to improvements ejection fraction in mice.122 Multicellular aggregates with
controlled assembly or hybrid cell types have been more frequent in efforts to take
advantage of resistant cell types and pro-angiogenic features for improved integration.123126

With enhanced technology and techniques (e.g., RNA-seq, microarrays) to analyze
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large amounts of data and combinations of data, the injection-based therapy approach
to cardiac repair may not be only dependent on what cell type is best, but what
combination of cells, materials, and factors has the strongest biomimetic rationale to
withstand and regenerate the harsh cardiac injury environment.
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CHAPTER ONE
UNDERSTANDING THE CELL MICROENVIRONMENT THROUGH BIOINK INK
DEVELOPMENT FOR BIOPRINTING
Introduction
Three-dimensional (3D) bioprinting technology has provided an enhanced
feasibility and precision for tissue engineered construct fabrication.127-135 Compared with
the traditional tissue fabrication methods, 3D bioprinting offers a reproducible, scalable
fabrication methodology with precise 3D control. It allows for the fabrication of
mechanically supportive 3D structures with bioactive/cellular components for a variety of
biomedical applications, including regenerative medicine, in vitro disease models, and the
exploration of fundamental cell and tissue-level mechanisms.136-143 For tissue
engineering, the ideal 3D-printed construct would be a growth-directing structure on
which cells could migrate and proliferate to form a functional tissue. While genetics can
control cell fate, the research in this field has proven to be tedious and rather complex.144
In addition to the difficulty of using genetic tools to direct cell fate, epigenetics has shown
that covalent and noncovalent modifications (e.g., DNA methylation), both to the DNA
and histone protein organization in chromatin, act as a liaison between the inherited
genotype and resulting phenotype.145,146 Without diving into the genetic and epigenetic
world, the local environment of the cell, or microenvironment, is the natural grounds for
influencing cell fate, as seen in developmental biology.147 It is the extracellular matrix
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(ECM) of the cellular microenvironment that serves as a platform for mechanical and
chemical cues, which can be created in vitro through 3D printing.
To facilitate tissue formation, alginates have been extensively utilized as bioink to
provide a matrix scaffold to direct a specific 3D cell growth because it can robustly form
cell-compatible hydrogels in physiological conditions. In addition, it can be modified for a
variety of tissue engineering applications, including bone, vascular, and adipose tissue
engineering.127,148-157 However, native alginate is a bioinert material (i.e., lack of celladhesive moieties) with limited biodegradation.135,150,153 Mooney and coworkers have
shown that chemical modification of alginate through oxidation allows for controlled
degradation.158-160 Due to this desirable characteristic for tissue engineering applications,
oxidized alginate holds great potential as ink for bioprinting. However, little previous
research has explored the applications of oxidized alginates in bioprinting.
In this study, we prepared a library of 30 different alginate solutions with varied
oxidation percentages and concentrations to develop a tunable bioink platform for
bioprinting that can be modified for a wide range of tissue engineering applications. To
this end, we have analyzed two key physical properties (i.e., viscosity and density) for the
alginate solutions in the library and systematically investigated the effects of those
physical properties of the alginates on their printability using a piston-driven, liquiddispensing system and human adipose-derived stem cells (hADSCs). hADSCs were
selected in this study because of their high proliferation rates, a persistent multipotency,
and a well characterized morphology in 2D culture.161 This has allowed for the
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identification of a suitable range of material properties of alginates for bioink
development. Further, the alginate-based bioinks were shown to be capable of
modulating important stem cell behavior, such as proliferation and spreading, without
affecting their printability and structural integrity after 8 days in cell culture (Fig. 1.1). The
research reported here will accelerate the development of alginate-based bioink for
tissue-specific tissue engineering applications.

Figure 1.1 Schematic representation of biodegradable oxidized alginate as bioink for
bioprinting. A bioink consisting of RGD-modified oxidized alginate hADSCs was printed
in a define lattice structure on a gelatin substrate to crosslink the hydrogel. The
constructs were then evaluated over an 8-day period for cellular behavior (i.e., cell
proliferation and spreading).
Results and Discussion
Alginate has been widely used as a cell encapsulation material and in tissue
engineering scaffolds.148,162 However, native alginate is a bio-inert material with limited
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biodegradation. To improve this, Mooney’s group introduced a controllable degradation
process using oxidized alginates reported in Bouhadir et al. 2001, which showed a
promising capability as scaffold for tissue engineering applications.158,160,163 These
biodegradable alginates thus have great potential to develop a bioink platform for 3D
bioprinting.
In 3D printing, there are multiple, unique dispensing systems to achieve high
resolution, and each system has specific requirements for the optimal ink.164 Among the
various liquid-dispensing systems, piston-driven deposition has recently received
significant attention because it offers a significantly high fabrication speed and is capable
of fabricating anatomically shaped, clinically relevant-sized constructs.165,166 They require
a bioink with a suitable density and viscosity as well as the capability to retain printing
fidelity and high cell viability post-printing.167 In this study, we used a custom-made,
piston-driven deposition system, as a test bed to examine the printability of
biodegradable alginates. The printability here is defined as having high printing resolution
and fidelity, a homogeneous cell distribution, and high cell viability post-printing. In
addition, a lattice structure was utilized as our standard to evaluate printing resolution
and fidelity in this study because it has been shown to promote cell viability and cell
function (i.e. proliferation), offering the possibility of long-term culture in vitro without
the assistance of a bioreactor.168
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Initial efforts focused on the oxidized alginate previously utilized for tissue
engineering applications, such as 5% ox.-2% conc. (i.e., alginate with 5% oxidation and 2%
(w/w) concentration).158 However, these alginate solutions did not provide sufficient
printing resolution for a lattice structure due to its low viscosity (Fig. 1.3b, top). Also,
alternating the oxidization percentage between 0% (non-degradable), 1%, 3%, 5%, and
10% proved to be inadequate to increase resolution for a 2% concentration solution.
Meanwhile, other reported attempts to increase resolution while maintaining high cell
viability in literature have used higher concentrations.168 Therefore, a range of
concentrations (2%, 5%, 8%, 10%, 15%, and 20%) mixed with different oxidation levels
was designed to create a library composed of 30 different alginates (Fig. 1.2). Using the
three criteria for printability evaluation (i.e., homogenous cell distribution, high printing

Figure 1.2. Density-based analysis on printability of different alginate solutions. (a)
Density (mean ± SD) measurements of each sample with successful cell suspension
results (green). Red denotes alginate compositions that did not completely dissolve
into solution after 2 days. The other materials (white) were unable to maintain a
homogenous cell distribution. (b) Calcein-stained hADSCs in the 5% ox.-10% conc.
(left) and 5% ox.-2% conc. (right) material with and without successful cell suspension,
respectively (scale bar= 500 µm).
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resolution, and high cell viability post-printing)168-170, we systematically examined the
material properties and printability of these alginates with hADSCs as a model cell line
using a piston-driven, liquid-dispensing system.
Density and cell suspension tests of different alginate solutions. Homogeneity of
cell distribution after printing is critical for the ideal bioink. To achieve a homogeneous
cell suspension throughout the whole printing process, the density of the biomaterial
should be close to or above that of the examined cell type.171 By altering oxidation and
concentration, a matrix of alginate densities was made (Fig. 1.2a). With increasing
concentration and decreasing degree of oxidation, the densities of alginates showed an
increasing trend. Given a printing operation time of 3 hours, we identified the range of
materials that keep cells homogenously distributed for printing with a piston-driven
deposition system (Fig. 1.2a, green), which was verified by fluorescently labeled cell
suspension tests (Fig. 1.2b). The results of this experiment and density measurements of
all 30 materials confirm that a density around 1.05 g/cm3 can maintain a homogeneous
cell suspension for hADSCs. This is in agreement with the study by Lin and others that
optimized a polyethylene glycol (PEG)-based hydrogel with 37.5% Percoll to attain the
needed density to suspend hADSCs.171 Density, thus, can define a limit for bioprinting
alginate solutions. The individual cell density and biomaterial density must be taken into
account when applying a density-based selection to other systems. It is important to note
that a wider range of densities around 1.05 g/cm3 can maintain a hADSC suspension within
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a 3 hour printing process time without significant cell movement, due to the relatively
high viscosity that slows the process of cell movement.

Figure 1.3. Viscosity-based analysis on printability of different alginate solutions. (a)
Viscosity values of various alginate solutions with a range of concentrations and
oxidation levels that passed the density requirement shown with a favorable area for
higher resolution bioprinting with hADSCs (green). Red denotes alginate compositions
that did not completely dissolved into solution after 2 days. The other materials were
either too viscous to prepare for printing or failed the density test (white). (b) Using
dots as the functional unit of liquid-dispensing strategies and a representation of
resolution, a printed dot array (5×5) shows examples of low printing resolution (top),
high printing resolution (low) (scale bar= 1 mm). (c) A plot of areas of dots versus
viscosity shows a direct relationship between printability and viscosity of alginate
samples. Guiding lines represent general flow of data.
Viscosities of 30 different alginate solutions. Given that viscosity plays an
important role in a liquid-dispensing printer164, its effects on printability (i.e., printing
resolution) were examined to determine a viscosity-based range for oxidized alginate ink.
We found that altering oxidation and concentration resulted in a practical method of
controlling the viscosity of degradable alginates. A similar pattern to the density
measurements was observed: as the concentration increased or the degree of oxidation
decreased, the viscosity showed an increasing trend (Fig. 1.3a). In addition, we have
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printed 5×5 arrays of dots using different biodegradable alginates to examine the effect
of viscosity on dot fidelity and size, which determines printing resolution. As shown in
Figure 1.3b and Figure 1.3c, there is an optimal range of viscosity (i.e., ~200 mm2/s to
~3000 mm2/s) for the improved printing resolution independent of concentration and
oxidation degree of alginate solution. This indicates the critical role of viscosity in printing
resolution for a piston-driven, liquid-dispensing system. At the low viscosity end (i.e.,
<200 mm2/s), low concentration alginates produced larger dots when compared with
alginates within the optimal range of viscosities (Fig. 1.3c). On the other hand, an upper
threshold (i.e., >3000 mm2/s) also exists due to the increased liquid handling difficulty
after a certain viscosity value (Fig. 1.3c). It is known that high viscosity can alter liquiddispensing characteristics of the solution. For example, Schuurman and coworkers
reported that high viscosity materials can form filaments rather than droplets when
depositing.172 Notably, alginate solutions with viscosities between ~200 mm2/s and ~400
mm2/s typically had densities lower than the threshold necessary for maintaining
homogenous cell suspension (i.e., <1.05g/mL). The viscosity range suitable for high
printability was therefore refined to ~400 mm2/s to ~3000 mm2/s. The alginate solutions
within the optimal range of viscosity are highlighted in green in Figure 1.3a. The data
presented in Figure 1.3a will enhance the available viscosity data on alginates used in
other bioink development research with liquid-dispensing systems.173-175
hADSC viability in the printed alginate. Cell viability, as one of the standards of
biocompatibility for bioink, was analyzed after printing.170 To examine the effect of
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printing on cells, viabilities were assayed immediately following the printing process (Figs.
1.4a and 1.4b). A compromised cell viability (<90%) was found in the high viscosity
alginates (>3000 mm2/s), while high cell viability (>90%) was found in the alginate
solutions with the optimal/medium viscosity (~400 mm2/s to ~3000 mm2/s). The
decreased cell viability in the high viscosity alginate samples was attributed to the limited

Figure 1.4. Cell viability assay of density and viscosity criterion-filtered samples. (a)
Samples of high viability (>90%) right after printing (green). (b) The fluorescent
pictures of live-dead assay after printing: (i) high cell viability sample (e.g. 5% ox.-15%
conc.) and (ii) low cell viability sample (e.g. 5% ox.-20% conc.) (scale bar= 100 µm). (c)
Cell viability assay at day 8. Except the 5% ox.-20% conc. sample (0% viability), the
remaining four samples showed high viabilities (>95%) after 8 days in culture (scale
bar= 100 µm).
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nutrient transport (i.e., diffusivity). Viability assays were performed again after 8 days in
cell culture, as shown in Figure 1.4c. The alginates with optimal/medium viscosity (i.e.,
~400 mm2/s to ~3000 mm2/s) again exhibited high viability (>90%), whereas the alginates
with high viscosity showed a negligible viability (0%). The results indicate that alginates
with high viscosity, although printable, may create an environment with poor nutrient
transport, resulting in compromised cell viability, in accordance with previous
studies.176,177 Given the importance of maintaining high cell viability post-printing, it is a
key parameter to include when defining the range of engineered alginates for bioink.
Summary of the oxidized alginates based on three printability criteria. The
capacity to maintain homogenous cell suspension (influenced by the densities of alginates
samples) and achieving high printing resolution and viability (both influenced by the
viscosities of samples) are the three criteria for our bioink selection. Based on these
criteria, a new table was assembled to highlight the printable alginate solutions (Fig. 1.5).
It is important to note that these highlighted alginates can serve as base materials to

Figure 1.5. Summary table of the preferable range of alginate samples with high
printability (green) based on the three established printability criteria (i.e.,
homogeneous cell suspension, high printing resolution, and high cell viability).
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develop bioinks with desired physical/chemical/biological properties for tissue-specific
tissue engineering applications.160 Further, the density, viscosity, and viability analysis
allowed for the identification of a suitable range of material properties of alginate
solutions to be applied to bioprinting. This can provide a guideline for developing next
generation of alginate-based bioink for 3D bioprinting-facilitated tissue engineering.
Notably, Mooney and coworkers have demonstrated the independent control of elastic
moduli and degradation rates of alginate hydrogels by creating binary alginate
hydrogels.178
Printing lattice-structured, cell-laden alginate hydrogels and cell culture. Lattice
structures have been shown to support higher cell viability and proliferation rate because
they offer a conducive environment for nutrient supply and waste excretion.168 In this
study, we designed a point-to-point protocol to produce cell-laden hydrogels with a
lattice structure of 7 columns and 7 rows. They have optimal expected dimensions of
12.6 mm x 12.6 mm (X, Y) based on a printing design dimension of 12 mm × 12 mm (from
the center of dot placement) and a Z dimension limited to one layer (Fig. 1.6a). To
examine the effects of the biodegradability of oxidized alginate, we selected samples with
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Figure 1.6. Lattice structures printed with bioprinting-compatible materials and their
dimensional change in 8 days. (a) Initial design of lattice structure. (b) Pictures of
printed lattice structures (5% ox.-10% conc. sample) at day 0, day 4, day 8 shows
printed structures highly matched the initial design with apparent dimensional
changes after 8 days in culture (scale bar= 2 mm). (c) Normalized comparison between
the initial design (12.6 mm x 12.6 mm) and the X and Y dimensions of the lattice
structures (0% ox.-8% conc., 5% ox.-10% conc., 5% ox.-15% conc. ) after 8 days in
culture. All values are mean ± SD. Asterisk denotes significant difference between day
0 and day 8.
low degradable (0% ox.), medium degradable (5% ox.), and high degradable (10% ox.)
characteristics. The density, viscosity, and viability analysis allow for the selection of the
appropriate concentrations for each alginate sample (0% ox.-8% conc., 5% ox. -10% conc.,
5% ox.-15% conc., 10% ox.-15% conc.) to be printed with suspended hADSCs. Although
these four materials have significant differences in their physical properties (i.e., density
and viscosity) (Figs. 1.2 and 1.3), they all can be successfully printed into latticestructured, cell-laden hydrogels with homogeneous cell distribution (Figs. 1.6 and 1.7a).

25

Notably, the dimensions of all the printed lattice structures were within 10% of the
optimal expected dimensions (i.e., 12.6 mm x 12.6 mm) (Fig. 1.6c), which can be defined
as accurately printed structures.179
All lattice structures were cultured for 8 days. For the samples that maintained
measurable structures, the changes in length and width were measured at day 0, day 4,
and day 8, and the extent of dimensional changes were determined (Fig. 1.6c). The 0%
ox.-8% conc., 5% ox.-10% conc., and 5% ox.-15% conc. samples remained intact through
8 days in culture, and the rapid degradation of 10% ox.-15% conc. alginate resulted in
almost complete fracture of the structure by day 8.158 Further, no significant change in
dimension (Y dimension, p=0.10; X dimension, p=0.27) was observed in the 0% ox.-8%
conc. sample from day 0 to day 8 (Fig. 1.6c), whereas a significant dimensional decrease
(Y dimension, p<0.05; X dimension, p<0.05) was observed in the 5% ox.-10% conc. and
the 5% ox.-15% conc. samples from day 0 to day 8. The decrease in dimension of the
oxidized alginate samples was attributed to their biodegradation and cell activities. This
consistent decrease should be considered, especially for dimension-specific designs when
using dynamic or prolonged culture methods.
hADSC spreading and proliferation assays in printed lattice structures. In
addition to maintaining cell viability, a bioink platform should allow for the modulation of
cell behaviors. In this study, proliferation and spreading of hADSCs were examined due to
their important roles in tissue engineering applications. In particular, cell spreading can
be used to modulate self-renewal and differentiation of hADSCs.180-182 Cell-adhesive RGD
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peptide, a widely known cell attachment promoter molecule150,183-185, was conjugated to
alginate bioink in this study to promote cell proliferation and spreading (Fig. 1.9). DAPI
staining for nuclei and phalloidin staining for actin were used to characterize the cell
behavior in each structure (Fig. 1.7a). As shown in Figure 1.7a, 1.7b, and 1.7c, the oxidized
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Figure 1.7 (previous page). hADSC behavior in the lattice structures. (a) Cell spreading
with fluorescent staining (phalloidin) for actin at day 0, 4, and 8 (scale bar= 100 µm).
(b) hADSC proliferation index and spreading assays based on fluorescent staining
(phalloidin and DAPI stain) at day 8. Proliferation index was calculated as the cell
number of each day divided by the original cell number on day 0 for the 0% ox.-8%
conc. alginate sample for relative comparison. Cell area was calculated as total cell
area divided by the number of cells normalized over the values at day 0 for the 0%
ox.-8% conc. alginate sample. All values are mean ± SD.
alginate bioinks (i.e., 5% ox.-10% conc., 5% ox.-15% conc., and 10% ox.-15% conc.
samples) can effectively promote cell proliferation and spreading when compared to the
non-oxidized alginate bioink (i.e., 0% ox.-8% conc. alginate). Quantitatively, the cell
proliferation percentages after 8 days in culture were 173% for the 0% ox.-8% conc.
alginate, 232% for the 5% ox.-10% conc. alginate, 248% for the 5% ox.-15% conc. alginate
(Fig. 1.7b), and 190% for the 10% ox.-15% conc. alginate at day 4. For cell spreading, the
average cell size did not change significantly after 8 days in culture for the 0% ox.-8% conc.
alginate, while cell size increased 25% for the 5% ox.-10% conc. alginate, 161% for the 5%
ox.-15% conc. alginate at day 8, and 69% for the 10% ox.-15% conc. alginate at day 4 (Fig.
1.7c). The low cell proliferation and cell spreading in the 0% ox.-8% conc. alginate
assumed to be attributed to its persistent low porosity given its limited degradability. In
contrast, the significant increase in cell proliferation and spreading in the 5% ox.-15%
conc. alginate was assumed to be attributed to the increasing porosity associated with its
degradation. The vast difference in cell spreading among alginate bioinks with varied
oxidation degree and concentration (i.e., 0% ox.-8% conc., 5% ox.-10% conc., and 5% ox.15% conc. samples) demonstrates their great potential in printing scaffolds tailored for
specific tissue engineering applications. For example, the 0% ox.-8% conc. alginate
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induced a round cell morphology that can be applied to chondrogenesis, while the 5% ox.15% conc. alginate was associated with an increased spreading phenotype that could
facilitate osteogenesis.186-191 In addition, the cell-matrix-interactions between hADSCs
and alginates were investigated using αvβ3 integrin immunofluorescent staining as shown
in Figure 1.10. The RGD conjugation was found to promote integrin expression at all three
dates (i.e., day 0, day 4 and day 8). Interestingly, the αvβ3 integrin expression was found
on day 8 for alginate samples without RGD conjugation, which was attributed to the ECM
secreted by hADSCs, consistent with previous research.192
Figure 1.8 is a 3D picture showing a portion of a lattice structure from the 5% ox.15% conc. oxidized alginate with hADSCs after 8 days in culture. The distribution of the
observed spreading cells confirmed that the homogenous cell distribution in the alginatebased bioink pre-printing was maintained in the lattice structure after 8 days in cell
culture. Summarizing the results shown in Figure 1.6 and Figure 1.7, the alginate-based
bioinks are capable of modulating hADSC proliferation and spreading without affecting

Figure 1.8. A computer-rendered 3D picture of a portion of the printed lattice
structure made by the best supporting hADSC material, 5% ox.-15% conc. oxidized
alginate, showing multiple layers of spreading cells within the hydrogel.
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structural integrity after 8 days in culture, apart from the highly degradable alginate
sample, 10% ox.-15% conc. This creates a solid foundation for the development of
alginate-based bioink for 3D bioprinting-tailored tissue engineering scaffolds.

Conclusion
The primary characteristics influencing the printability of oxidized alginate as ink
for bioprinting was defined by its ability to hold a homogeneous cell suspension, have
high printing resolution, and support high cell viability. According to these factors, an ideal
printable range for using oxidized alginate as a bioink platform was established. Further,
by mimicking the adhesive cues (i.e., RGD) present in ECM, these alginate-based bioinks
were shown to be capable of modulating hADSC functions without affecting their
printability and structure integrity after cell culture. The introduction of oxidized alginate
to bioprinting has led to the creation of a tunable bioink platform for a range of tissue
fabrications. Based on our findings, the observed functional relationship between the
material properties (i.e., viscosity and density) of alginate and its printability allows for an
enhanced progression in alginate bioink development for liquid-dispensing printing.
When using other cell types, metabolic demands may require an altered density and
viscosity of oxidized alginate to allow for optimal diffusion of nutrients. Apart from
diffusion limitations, the Ca2+ concentration used in the gelation process may also affect
Ca2+-sensitive cell types, such as chondrocytes.193 This Ca2+ concentration can be adjusted
to achieve higher viability, though a prolonged gelation time may affect the printing

30

fidelity and total printing time.194 Future studies in bioprinting technology and a widened
understanding of self-assembly mechanisms between cells may reshape the demands for
ink printability.

Materials and Methods
Materials. Sodium alginate was purchased from FMC BioPolymer (Philadelphia,
PA). Ethylene glycol was purchased from Mallinckrodt Baker, Inc. (Phillipsburg, NJ). All
other chemicals used for this study were purchased from Sigma-Aldrich (St. Louis, MO)
unless otherwise stated.
Alginate synthesis and oxidation. Sodium alginate was prepared using the method
established by Bouhadir and others.158 Briefly, 1 g sodium alginate was dissolved in 100
mL of distilled water. Sodium periodate was used as the oxidizing reagent and was added
at room temperature in varying quantities, based on the desired percent oxidation (at
oxidation percentage of 1%, 3%, 5%, 10%, w/w). The reaction was terminated by the
addition of ethylene glycol after 24 hours. Sodium chloride (3 g) was then dissolved in the
solution. Excess amount of ethyl alcohol was added to the solution (2:1 ratio),
precipitating the oxidized alginates. The solution was centrifuged to collect the
precipitates, and the ethanol wash was repeated. The oxidized alginate pellets were then
lyophilized and stored at -20°C.
RGD-alginate conjugation. To promote cell attachment and spreading, RGD
peptides have been conjugated into oxidized alginates using a similar method as
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Mooney’s group, reported in Rowley et al. 1999: utilizing aqueous carbodiimide chemistry
with G4RGDSP-OH (International Peptides, Louisville, KY).150 The final modification
percentage of RGD to alginate was 1% (w/w).
Identification of viscosity and density. Aqueous alginate solutions (at oxidation
percentage of 0%, 1%, 3%, 5%, 10% w/w) of varying concentration (2%, 5%, 8%, 10%, 15%,
20% w/w) were made using a weight to total-weight ratio. To test viscosity, approximately
8 mL of varying alginate solutions were made and tested three times by Cannon-Fenske
Opaque Calibrated viscometers (Cannon® Instrument Company, Inc, USA) at 40 °C.
Viscosity values were calculated according to Poiseuille’s law associated with the
calibrated viscometers and then converted to kinematic viscosities by dividing by density.
The density of the alginate solutions were calculated by measuring the mass of 1 mL of
alginate aqueous solution three times and then averaged.
Preparation of Ca2+-containing gelatin substrate for 3D-printing alginate
hydrogels. To avoid reduced viability with high Ca2+ concentration solutions, a calcium
substrate was prepared for alginate, as done previously.194 Briefly, a 100 mM CaCl2 gelatin
solution was prepared by combining calcium chloride dehydrate, sodium chloride (0.9
wt%), and porcine gelatin (2 wt%) in distilled water and boiled for 2 minutes. Aliquots of
5 mL of gelatin were put into standard petri dishes to gel in a refrigerator overnight.
Titanium dioxide (0.3% wt%) was added to the same solution and stirred for 10 min to
increase the opacity of the resulting surface. 3 mL of the gelatin/TiO2 mixture was spread

32

evenly across the surface of the previously prepared gelatin plates and put in the
refrigerator overnight to be used within 3 days.
Printing process of alginate hydrogels. Aqueous alginate samples were prepared
according to a weight to total-weight ratio using either distilled water (for density and
viscosity tests) or cell medium (for dot analysis and cell studies) using the same
preparation protocol. The bioink (with cells for cell study) were then loaded into a printercompatible syringe. All printing was performed on the Palmetto Printer, a custom-made,
piston-driven deposition system, on a temperature-controlled plate at 4 °C. Droplet
volume was maintained at 230 nL with a dispensing speed of 10 µL/sec.
For dot analysis, a 5×5 dot array was printed for each sample and left to gel for 40
min before macroscopic imaging with the Olympus SZX16 stereomicroscope.
For lattice structure fabrication, single layer, cell-laden, lattice structures were
printed with 7 columns and 7 rows using a point-to-point strategy to print every other dot
with optimal expected dimensions of 12.6 mm x 12.6 mm (X, Y), which is a result of a
printing design with dimensions of 12 mm × 12 mm (from the center of dot placement)
(Fig. 1.3a). In liquid-dispensing printing, the point-to-point method allows for accurate
control of design-specific structures. The bioink used for the structures were alginate
solutions of 0% ox.-8% conc., 5% ox.-10% conc., 5% ox.-15% conc., 5% ox.-20% conc., 10%
ox.-15% conc. Following printing, 8 mL of media was added to the gelatin plate and put in
the incubator for approximately 30 min, melting the Ca2+-containing gelatin to maximize
alginate crosslinking. Lattice structures were then transferred to individual wells in a 6-
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well plate for extended culture. Macroscopic pictures were taken with the Olympus SZX16
stereomicroscope, and media was changed every 4 days for 8 days.
Cell culture and cell behavior studies. Human adipose-derived stem cells (hADSC)
(Lonza, Basel, Switzerland) were used to investigate the effects of the alginate gel’s
oxidation and concentration on cell viability, attachment, and proliferation. The cells were
cultured in low glucose DMEM with 10% FBS and 1% penicillin-streptomycin, 1%
glutamine, and 1% antimycin (Gibco Life Technologies, Grand Island, NY). At >80%
confluency, cells were detached using trypLE Express (Gibco Life Technologies) and
passaged. All experiments were conducted using passage 5 (P5) hADSCs. Aqueous
alginate solutions of varying oxidation and concentration were prepared using the cell
culture medium and mixed with detached cells at a concentration of 1.3 million cells per
mL. The samples were loaded into printer syringes, transported to the printer, and then
printed as described in the previous section.
hADSC suspension tests were performed by mixing aqueous alginate samples
(made with media) of varying concentrations with live cells (1 mL of 1.3 million cells per
mL) labeled with Calcein, AM (Gibco Life Technologies). The samples were loaded into
NMR tubes and were left stationary for 3 hours. Then, each solution was partitioned from
top to bottom into 5 parts, and the number of cells in each part was counted
microscopically and analyzed. The macroscopic images were taken with the Olympus
SZX16 stereomicroscope.
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The cell-seeded hydrogels were assessed for cell viability post-printing using the
live/dead cell viability assay kit from Invitrogen Life Technologies (Grand Island, NY)
following the protocol of the kit. The cell viability percentage was calculated as the
number of live cells (green-stained) over the total number of cells (green and red).
Viability assays were performed for the printed structures again after 8 days of culture
using portions of each structure. High viscosity samples of each oxidation (0% ox.-10%
conc., 1% ox.-10% conc., 3% ox.-15% conc., 10% ox.-20% conc.) were later tested using
the same post-printing method. All the fluorescent pictures were taken by Leica TCS SP5
AOBS Confocal Microscope System.
The lattice structures of five samples (0% ox.-8% conc., 5% ox.-10% conc., 5% ox.15% conc., 5% ox.-20% conc., 10% ox.-15% conc.) were printed with hADSCs following the
protocol above. Cell proliferation and morphology for these samples were assessed at day
0, day 4, and day 8 using portions of each structure with a fluorescent DAPI and phalloidin
staining kit from Invitrogen Life Technologies (Grand Island, NY) by following the kit
protocol. For cell proliferation analysis, the following cell counting method was utilized
on each of the given days. At least 3 different pictures (600 µm x 600 µm, z-layer thickness
≈ 100 µm) were taken of the respective hydrogel samples, and the cell number in 3
random areas (200 µm x 200 µm, >10 cells/area) of each picture were manually counted
based on DAPI and phalloidin staining. Proliferation index was calculated as the cell
number of each day of each sample divided by the original cell number on day 0 for the
0% ox.-8% conc. alginate sample. For cell morphology, fluorescent images of each sample
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(at least 4 random pictures per sample, 600 µm x 600 µm per picture) were taken by the
Leica TCS SP5 AOBS Confocal Microscope System using Z-stack parameters of 30 optical
slices over a 300 µm depth. Cell sizes were measured through ImageJ threshold-based
edge detection tools as a total cell area divided by the number of cells normalized over
the values at day 0 for the 0% ox.-8% conc. alginate sample (Fig. 1.4c). The cell-matrix
interactions between hADSCs and alginates were studied using mouse primary antibody
for αvβ3 integrin (Abcam, Cambridge, MA) and rat (anti-mouse) secondary antibody, Alexa
Fluor 546 (Invitrogen, Carlsbad, CA), both at 1:200 ratio.
Rebuilt 3D image for printed lattice structure. The cells in the printed lattice
structure were stained with fluorescently labeled phalloidin and imagined by Leica TCS
SP5 AOBS Confocal Microscope System. These images were rebuilt into a 3D rendering
using Amira software.
Statistical analysis. The results were expressed as the mean ± standard deviation
(SD) and analyzed using JMP 11 and Excel statistical software. Lattice dimensions were
compared between day 0, day 4, and day 8 by a Student’s t-test. Dot analysis, viscosities,
and densities were analyzed separately using unpaired Student’s t-tests. A confidence
interval of 95% was used.
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Supporting Information
Figure 1.9

Figure 1.9. A proof-of-concept analysis of the necessity of 1% (w/w) RGD peptideconjugated alginate for changing cell function. In 5% ox.-10% conc. alginate hydrogel,
hADSCs exhibited higher spreading after 8 days of culture. Scale bar = 100 µm.
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Figure 1.10

Figure 1.10. αvβ3 integrin expression of hADSCs in alginate hydrogels with and without
RGD conjugation at day 0, day 4, and day 8. Samples include 0% ox.-8% conc. without RGD
conjugation, 0% ox.-8% conc. with RGD conjugation, and 5% ox.-15% conc. with RGD
conjugation oxidized alginates. Blue – DAPI nuclear stain; Green – αvβ3 integrin (scale
bars= 15 µm).
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Table 1.1.
Viability of the alginate samples at day 0, day 4, and day 8.
Sample name
0% ox.5% ox.5% ox.8% conc.
10% conc.
15% conc.
Time point
Day 0
96%
98%
98%

5% ox.20% conc.

10% ox.15% conc.

19%

96%

Day 4

93%

92%

96%

3%

92%

Day 8

92%

90%

95%

0%

-
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CHAPTER THREE
NANOENGINEERED SOLUTIONS TO FACILITATE HUMAN CARDIAC MICROTISSUE
DEVELOPMENT
Introduction
While biomaterials can provide molecular/mechanical signals to promote cell
adhesion, proliferation, and enhance extracellular matrix (i.e., ECM) protein deposition
and tissue formation195,196, scaffold-based approach faces numerous challenges. Apart
from potential biocompatibility issues, one of the key challenges of using engineered
biomaterials (e.g., functionalized alginate) is that identification of the ideal material
depends on a sufficient understanding of the role of targeted processes in directing cell
behavior.197 In the context of cardiac embryonic development, environmental factors
(e.g., extracellular matrix, growth factors, mechanical and electrical stimulation) have
major effects on the maturation of cardiomyocytes. To mimic the maturation process in
vitro, stem cell-derived cardiomyocytes have been mixed with scaffolding materials (e.g.,
Matrigel and collagen type I gel) to prepare cardiac tissue-engineered constructs and then
conditioned with electrical and/or mechanical stimulation.21,25-27 While these scaffolds
can provide tissue-like 3D microenvironments, current scaffolding materials lack the
matched physical/chemical/biological properties

with the native extracellular

environments during heart development. On the other hand, scaffold-free, 3D cardiac
spherical microtissues (i.e., spheroids) have emerged as promising model systems to
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mimic cardiac tissues by leveraging the ability of cells to self-assemble into microtissues
at a high cell density with endogenous ECM production.28,29
As physiological cardiac microtissue maturation depends on synchronized
contractile activity, we previously developed a method to incorporate a trace amount of
electrically conductive silicon nanowires (e-SiNWs) into otherwise scaffold-free, human
induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) spheroids that
significantly advanced the structural and contractile maturation of the cardiomyocytes
across a range of viable sizes.45,198 This approach has a distinct advantage of only using a
minimal amount of e-SiNWs (0.004% w/v), minimizing the adverse effects of traditional
scaffolds, such as the unmatched physical/chemical/biological properties with the native
extracellular environments during heart development. e-SiNWs were selected because of
their controllable electrical conductivity, tunable dimensions, and convenient surface
tailorability.199,200 In this study, n-type SiNWs (Diameter ≈ 100 nm; length ≈ 10 m;
Silane/Phosphane = 500) were prepared according to the previously established
protocol201 to obtain a high conductivity (150 - 500 S/m) and to avoid cell
internalization.44,202 Although SiNWs might not be well known as biocompatible materials,
in vitro biocompatibility studies have shown no significant cytotoxic effects for both
undoped and n-type SiNWs203,204. Further, the recent research showed SiNWs are
biodegradable, and their degradation products are found mainly in the form of Si(OH)4
and are metabolically tolerant in vivo205-209. This makes them advantageous over other
non-biodegradable, electrically conductive nanomaterials (e.g., gold nanowires, carbon
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nanotubes and nanofibers), especially for potential in vivo applications. We reasoned that
the incorporation of e-SiNWs in cardiac spheroids facilitated the formation of an
electrically

conductive

network,

and

provided

synchronized

and

improved

electrical/mechanical signals to advance structural and contractile maturation of the
cardiomyocytes.
While nanowired spheroid culture of hiPSC-CM significantly improved the
contractile development, extended culture did not further improve cardiac maturation.45
Enhanced maturation of hiPSC-CMs in vitro is a critical barrier for understanding the
translational potential of patient-specific hiPSC-CMs for drug screening and/or cell
therapy strategies to repair the damaged heart. To derive hiPSC-CMs suitable for cell
transplantation, various tissue-engineering strategies have been utilized to mimic adult
host ventricular myocardium to accelerate phenotypic development of hiPSC-CMs.21,30-36
Particularly, several groups have used electrical stimulation as an exogenous approach to
recapitulate the natural pacemaker-initiated excitation of cardiomyocyte contraction to
advance the function of hESC/hiPSC-CMs.21,35,37-42
We reasoned that exogenous electrical stimulation could synergize with the
endogenous benefits of nanowired spheroids to improve the functional development of
hiPSC-CMs in cardiac spheroids. To this end, we developed a viable strategy to electrically
stimulate nanowired hiPSC cardiac spheroids and examined the effects of electrical
stimulation and silicon nanowires on the functions of spheroids. Herein, for the first time,
we show that the synergy of exogenous electrical stimulation and nanowires to hiPSC
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cardiac spheroids 1) enhanced microtissue development through formation of functional
cell-cell junctions, 2) improved development of contractile properties of hiPSC-CMs, and
3) decreased the endogenous spontaneous beat rate for reduced arrhythmogenic
potential. Through tissue- and cell-level examination of cardiac spheroids, the progress
here contributes to the fundamental understanding of hiPSC cardiac microtissue
development and addresses the need for an advanced, functional cardiac cell therapy
vehicle for future cardiac tissue repair.

Results and Discussion
Development of electrically stimulated, nanowired hiPSC-CM spheroids. In the
adult heart, ventricular cardiomyocytes contract regularly due to the depolarizing
electrical propagation originating in the sino-atrial node of the heart. To mimic this
stimulation for contraction, cardiac tissue engineering strategies have utilized electrical
pacing to develop and maintain cardiomyocyte function.35,38,39,41,210-212 During our
previous development of nanowired cardiac spheroids, electrical stimulation (3.75 V/cm,
1 Hz, 2 ms) successfully maintained contractile function when applied to scaffold-free
spheroids composed of enriched neonatal rat cardiomyocytes (i.e., <25% fibroblasts). 45
Based on electrical stimulation protocols for human cardiac tissue constructs established
in previous studies and a spheroid size within the diffusional limit (i.e., 150 µm radius),
we empirically developed a viable electrical stimulation protocol (2.5 V/cm, 1 Hz, 5 ms)
that supports optimal hiPSC cardiac spheroid viability and function (Figure 2.1, 2.6).40,41
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Compared to unstimulated and unwired spheroids at Day 0 (NC-D0), treatment groups
consisted of spheroids in prolonged culture (Day 19 - D19): unstimulated and unwired

Figure 2.1. Development of electrical stimulation for nanowired hiPSC cardiac
spheroids. (A) The schematic diagram of the stimulation setup shows cardiac spheroids
cultured in non-adhesive agarose molds between carbon electrodes. (B) Transmission
electron micrograph details the structure of n-type doped silicon nanowires. (C)
Nanowired hiPSC cardiac spheroids assemble by Day 0 in non-adhesive agarose molds.
(D) Transmission electron micrograph of spheroid section depicts nanowire location in
extracellular space; asterisk - nanowire location, triangle – cell membrane. (E) The
timeline of in vitro conditioning indicates specified electrical stimulation parameters
and time points. Electrical stimulation and nanowires do not significantly change
spheroid assembly indicated by consistent (F) spheroid size and (G) laminin expression;
dotted line represents spheroid edge; red-laminin, yellow-silicon nanowires. NC-D0 unwired and unstimulated at Day 0; NC – unwired and unstimulated at Day 19; WC –
wired and unstimulated at Day 19; NS – unwired and stimulated at Day 19; WS – wired
and stimulated at Day 19.
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(NC) spheroids, unstimulated and wired (WC) spheroids, stimulated and unwired (NS)
spheroids, and stimulated and wired (WS) spheroids. The nanowired hiPSC cardiac
spheroids were prepared as described in our previous study.45 Briefly, n-type SiNWs
(Diameter ≈ 100 nm; length ≈ 10 m; Silane/Phosphane = 500) were mixed with hiPSCCMs at a ratio 1:1 and seeded into agarose microwells to prepare nanowired spheroids
(Figure 2.1A-2.1C). The length of the e-SiNWs was selected to inhibit cell internalization
(Figure 2.1D), and the doping ratio and diameter of the e-SiNWs were chosen to obtain a
high conductivity (150 - 500 S/m) to create highly electrically conductive
microenvironments within spheroids.44,202 While unstimulated (i.e., NC and WC)
spheroids showed spontaneous beating, stimulated (i.e., NS and WS) spheroids displayed
successful pacing throughout the entirety of the experiment. High viability validated the
biocompatibility of silicon nanowires and electrical stimulation condition for prolonged
spheroid culture (Figure 2.6A, 2.6B). Constant decrease in spheroid size and uniform
laminin production indicated similar microtissue formation processes among each
condition (Figure 2.1F, 2.1G, 2.6C).
Electrical stimulation and nanowires improve cell-cell junctions. Proper
propagation of electrical and mechanical signals in the heart is a tightly regulated process
dependent on functional cell-cell junctions between cardiomyocytes. Functionally mature
human cardiomyocyte junctions develop throughout postnatal childhood and are
characterized by localized expression of electrically conductive channel proteins, such as
connexin-43 (Cx43), supported by mechanical junction proteins, such as N-cadherin (N-
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cad) and Zonula Occludens-1 (ZO-1).213-216 As shown in the Figure 2.2A-E, all the treatment
groups showed significantly improved expression of cellular junctions (i.e., Cx-43 and Ncad) than NC-D0 spheroids, which indicates the benefits of prolonged microtissue culture.
In addition, WC and NS spheroids showed the enhanced expression of phenotypic
immunofluorescent Cx43 punctii per nuclei when compared with unwired, unstimulated
NC spheroids at D19 (Figure 2.2A, 2.2B), indicating the beneficial role of nanowires and
electrical stimulation in the formation of electrically conductive cellular junctions.
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Figure 2.2 (previous page). Synergistic contribution of electrical stimulation and
nanowires to cellular junction formation. (A and B) Connexin-43 (Cx43)
immunofluorescent staining shows an increased number of phenotypic punctii per
nuclei in stimulated conditions; red-Cx43, yellow-nanowires; + = significant difference
with NC-D0, * = significant difference with unstimulated spheroids (p<0.05). (C and D)
N-cadherin (N-cad) expression shows significantly higher staining per nuceli at the
intercellular border in WS spheroids; green-N-cad, yellow-nanowires; * - significant
difference (p<0.05). (E) The junction index is the product (i.e., size of the circle) of the
normalized (to NC-D0) Cx43 and N-cad expression per nuclei and represents the
synergistic benefit in WS for cellular junction formation. (F) Representative staining
for WS spheroids shows colocalization of Cx43 with N-cad and ZO-1 (Zonula
Occludens-1), suggesting formation of functional cardiomyocyte junctions. NC-D0 unwired and unstimulated at Day 0; NC – unwired and unstimulated at Day 19; WC –
wired and unstimulated at Day 19; NS – unwired and stimulated at Day 19; WS – wired
and stimulated at Day 19.
Further, significantly more Cx43 expression was found in the WS spheroids than both WC
and NS spheroids and demonstrated the synergy between nanowires and electrical
stimulation. Also, the WS spheroids showed a significant increase in N-cad expression per
nuclei when compared with the remaining groups (Figure 2.2C, 2.2D). The expression of
Cx43 and N-cad per nuclei allowed for the development of a cellular junction index that
supports the synergy of electrical stimulation and nanowires in WS spheroids for
cardiomyocyte junction formation (Figure 2.2E). Colocalized staining of Cx43 with N-cad
and ZO-1 in WS spheroids showed not only expression of key junction proteins but also
suggests functional cardiomyocyte junctions for enhanced electrical and mechanical
coupling (Figure 2.2F). Enhanced junction formation seen in WS spheroids may facilitate
their stable integration upon coupling with the host myocardium after transplantation.
Enhanced contractile development in electrically stimulated, nanowired
spheroids. Improved junction formation supports cardiomyocyte coupling for contractile
signal propagation. Spheroids were sectioned and stained with alpha sarcomeric actinin
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Figure 2.3. Nanowires influence sarcomeric organization in hiPSC cardiac spheroids.
(A) αSA immunofluorescent staining shows minimal sarcomeric organization at Day 0.
(B-F) All conditions showed significantly increased αSA-stained structures at Day 19
compared to NC-D0. The addition of nanowires further increases αSA expression
based on αSA-positive area per spheroid area. green- αSA, blue-DAPI nuclear stain.
(G and H) High magnification αSA-stained images and qualitative scoring show
highest quality of sarcomere formation in WC and WS spheroids. + = significantly
different from other groups; * = significantly different from unwired groups (p<0.05).
NC-D0 - unwired and unstimulated at Day 0; NC – unwired and unstimulated at Day
19; WC – wired and unstimulated at Day 19; NS – unwired and stimulated at Day 19;
WS – wired and stimulated at Day 19.
(αSA) to visualize the sarcomeric organization, the structural units that support
cardiomyocyte contraction. Consistent with the cell-cell junction staining, all the
treatment groups showed significantly more αSA-stained structures than that of NC-D0
spheroids (Figure 2.3). In addition, WC and WS spheroids showed enhanced αSA-positive
structures compared to NC and NS spheroids, while electrical stimulation alone (i.e., NS)
did not change the amount of αSA-positive structures significantly from NC spheroids
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(Figure 2.3A-F). Further, high magnification αSA images showed visible formation of
sarcomeric banding in WC and WS spheroids and a lack of sarcomeric banding in NS
spheroids (Figure 2.3G, 2.3H). This finding supported the critical role of e-SiNWs to
improve contractile protein organization in electrically stimulated hiPSC-CM spheroids.
This was further supported by the significant increases in expression of the sarcoplasmic
reticulum ryanodine receptor (RYR2) in the WC and WS spheroids (Figure 2.7), which
regulates intracellular calcium release required for cardiomyocyte contraction.
The benefits of nanowires for improved contractile characteristics were consistent
with the genotypic and phenotypic characterization of treated hiPSC-CM spheroids.
Genetically, the nanowired spheroids (i.e., WC, WS) exhibited increased ratio of beta
myosin heavy chain (β-MHC; MYH7) to alpha myosin heavy chain (α-MHC; MYH6) (Figure
2.4A). Individually, β-MHC expression increases significantly compared to Day 0 in
nanowired groups, while α-MHC did not change significantly (Figure 2.7). This isoform
trend is consistent with in vivo maturation of human cardiomyocytes and the nonfailing
adult human heart.24,217 The increase in β-MHC/α-MHC gene ratio has been reported to
translate to the myosin protein shift and favors lower cellular ATPase activity.218-220 This
property may be an energetically favorable condition for transplanting cells into the
energy-limited conditions of a damaged heart. In contrast, the NS group showed
significantly lower β-MHC/α-MHC ratio compared to the other groups. This suggests a
limitation of electrical stimulation alone for contractile development of hiPSC cardiac
spheroids. These findings were supported by immunofluorescent analysis of cardiac
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Figure 2.4. Nanowires and electrical stimulation affect development of contractile
machinery in hiPSC cardiac spheroids. (A) Nanowires increase the ratio of beta myosin
heavy chain (MYH7) to alpha myosin heavy chain (MYH6) expression, and NC, WC,
and WS show statistical significance compared to NS. (B and C) Immunofluorescent
expression of cardiac troponin I (cTnI) shows significant increases in nanowired
conditions, indicating signs of contractile machinery maturation; red-cTnI. * =
significant difference from marked or remaining groups (p<0.05). NC-D0 - unwired and
unstimulated at Day 0; NC – unwired and unstimulated at Day 19; WC – wired and
unstimulated at Day 19; NS – unwired and stimulated at Day 19; WS – wired and
stimulated at Day 19.
troponin I (cTnI), a key indicator of contractile protein maturation (Figure 2.4B, 2.4C).
While nanowired spheroids showed the improvement in cTnI expression when compared
with their unwired spheroids, the electrical stimulation alone lead to the reduced cTnI
expression. The significantly higher density of cTnI in the WS spheroids indicated a critical
role of nanowires in promoting contractile development of hiPSC cardiac spheroids under
electrical stimulation.221,222
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Subtype specification of hiPSC-CM using electrical stimulation and nanowires.
While current hiPSC-CMs are composed of heterogeneous subpopulations (i.e.,
ventricular-like, atrial-like, nodal-like cardiomyocytes), the observed improved contractile
machinery suggests a shift towards a working myocardial phenotype. Specifically,
electrical stimulation of hiPSC cardiac spheroids significantly increased ventricular myosin
light chain (MYL2) over unstimulated spheroids (Figure 2.5A, left). No change was
observed in atrial myosin light chain (MYL4), indicating an increase in overall ventricularlike contractile genotype of stimulated spheroids (Figure 2.5A). This was further
supported with ventricular myosin light chain immunofluorescent staining (MLC-2v),
showing significantly higher density of MLC-2v expression per spheroid in the WS
condition (Figure 2.5B, 2.5C). This suggests that exogenous electrical stimulation may
override the endogenous spontaneous electrical signals in hiPSC-CMs to regulate
contraction in a pacemaker-like manner and promote the ventricular-like shift.
The observed shift in cardiomyocyte subpopulation characterization was further
explored using beat rate analysis to examine hiPSC-CM spheroid function. Each spheroid
condition was characterized by spontaneous beating throughout the entirety of the
experiment. While the newly formed NC-D0 spheroids had an average beat rate (± s.e.m.)
of 35.5±3.0 beats per minute (bpm), all the treatment groups showed a reduced
spontaneous beat rate. With the 1 Hz stimulation treatment, the spontaneous beat rate
of NS and WS spheroids significantly decreased to 24.5±2.4 and 25.6±2.8 bpm in
comparison with NC and WC spheroids (30.4±3.4 and 29.2±3.9 bpm, respectively) (Figure
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Figure 2.5. Electrical stimulation and nanowires directly affect subpopulation
specification and beating properties in hiPSC cardiac spheroids. (A) Electrical
stimulation significantly improves gene expression of ventricular myosin light chain
(MYL2), while atrial myosin light chain (MYL4) is unchanged. (B and C)
Immunofluorescent staining of the MYL2 protein, MLC-2v, supports genetic trend
with significantly more expression per area in WS; red-MLC-2v. (D) Electrical
stimulation significantly reduced the spontaneous beat rate of hiPSC cardiac
spheroids compared to unstimulated and NC-D0 spheroids. + = significantly different
from NC-D0; * = significantly different from unstimulated groups (p<0.05). (E)
Electrical stimulation significantly reduced the mRNA expression of HCN4, a
pacemaker gene in the adult heart. The presence of nanowires preserved KCNJ2
expression when under stimulation, an important gene to prevent spontaneous
contraction in adult ventricular cardiomyocytes. * = significantly different from
unmarked groups. NC-D0 - unwired and unstimulated at Day 0; NC – unwired and
unstimulated at Day 19; WC – wired and unstimulated at Day 19; NS – unwired and
stimulated at Day 19; WS – wired and stimulated at Day 19.
2.5D). The potential mechanism of this functional change due to an exogenous electrical
field was explored using genetic analysis of ion channels known to be related to the
spontaneous beating of hiPSC-CMs.24,223 HCN4 is the dominant form of the HCN protein
in nodal cells and contributes to the pacemaking mechanism of the sino-atrial node.24
HCN4 is expressed during fetal ventricular expression but is down-regulated in the
working myocardium during development and virtually absent in adults.224 When
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compared with unstimulated spheroids, electrical stimulation significantly reduced HCN4
expression, suggesting a shift away from a pacemaker-like genotype (Figure 2.5E, left).
This decrease in HCN4 expression combined with a functional decrease in beat rate
indicates a critical role of electrical stimulation in the regulatory mechanism governing
hiPSC-CM spheroid electrical properties. Furthermore, the lack of inward rectifying
channel (KCNJ2) expression has been shown to contribute to the spontaneous beating
phenomenon in hiPSC-CMs.23,225 Notably, under electrical stimulation, the addition of eSiNWs to hiPSC cardiac spheroids was critical to preserve inward rectifying channel
(KCNJ2) gene expression (Figure 2.5E, right). Interestingly, the significant decrease in
KCNJ2 gene expression in NS is in line with the limited contractile development of NS
discussed above. Nevertheless, electrical stimulation can synergize with e-SiNWs to
provide exogenous and endogenous cues to affect the cardiomyocyte subpopulation
specification and significantly decrease the spontaneous beat rate of hiPSC-CM spheroids.
Notably, HERG (KCNH2) showed no significant changes with electrical stimulation at 1 Hz,
which is consistent with the recent studies conducted by Eng and coworkers (Figure 2.7).
They reported an up-regulated HERG expression with a 2 Hz stimulation treatment and
un-changed HERG expression with 1 Hz stimulation.39

Conclusion
To date, transplantation of hiPSC-CMs into damaged hearts have led to limited
improvements in heart functions and increased risk of arrhythmia.115,226-228 These results
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alongside recent research showing enhanced cell retention using cellular aggregates
indicate that hiPSC-CM microtissues with advanced cellular development provide an
attractive cell delivery system for transplantation.114,229,230 Our previous research showed
that addition of e-SiNWs to hiPSC cardiac spheroids creates an electrically conductive
microenvironment and significantly improves the structural and functional development
of hiPSC cardiac spheroids.45 In this study, we demonstrated that the addition of
nanowires to the spheroids is essential for the utilization of electrical stimulation to
improve the functions of hiPSC cardiac spheroids. With nanowires, exogenous electrical
stimulation increases cell-cell junction formation (i.e., Cx-43 and N-cad), improves
development of contractile machinery (i.e., sarcomeric structure, β-MHC/α-MHC gene
ratio and cTnI expression), and preserves KCNJ2 gene expression. In contrast, electrical
stimulation alone (i.e., NS) showed increased Cx43 yet lower N-cad along with reduced
sarcomere development, cTnI expression, β-MHC/α-MHC gene ratio, and KCNJ2 gene
expression. Although it has been reported that electrical stimulation alone can advance
cardiomyocyte development in vitro, the data presented here suggests potential
limitations of the use of electrical stimulation without nanowires in hiPSC cardiac
spheroids for ventricular applications.
Remarkably, electrical stimulation of nanowired spheroids also resulted in a
significant reduction in endogenous, spontaneous beat rate and shifts in cardiomyocyte
subpopulation characterization. These phenomena point to the beneficial functional and
genomic effects of exogenous electrical stimulation to affect the endogenous electrical
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properties of nanowired hiPSC cardiac microtissues. The observed reduction of
spontaneous beat rate and pacemaker-like genotype clearly demonstrates tissue level
functional development that would be beneficial for reduced pacemaking/arrhythmic risk
after transplantation.
In conclusion, we demonstrated, for the first time, that the combination of eSiNWs and electrical stimulation synergistically improves cell junction formation,
increases contractile properties, and reduces the endogenous spontaneous beat rate of
hiPSC-CM spheroids. Enhancing the cell-cell junctions of hiPSC cardiac spheroids in vitro
may lead to improved cellular integration and functional contribution after
transplantation. The increased expression of contractile machinery in vitro indicates an
increased cardiomyocyte developmental age, which has been shown to be advantageous
for transplantation.31,231 Given that many cardiac cell therapies target ventricular
myocardial repair, the observed expression shift towards the ventricular isoform of
myosin light chain shows promise for improved functional integration. Likewise, by
decreasing the spontaneous beat rate in hiPSC cardiac spheroids and directly effecting
genes that regulate the spontaneous beating of hiPSC-CMs, we propose that this in vitro
conditioning model will reduce the arrhythmogenic risk of hiPSC-CMs. In addressing these
underdeveloped properties of hiPSC-CMs with the combination of endogenous
nanomaterials and exogenous stimuli, we hope to contribute to the next generation of
cell therapy approaches for cardiac repair.
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Materials and Methods
Electrically conductive silicon nanowire fabrication and harvesting. Consistent
with our previous work, single-crystalline SiNWs were synthesized using the nanoclustercatalyzed vapor-liquid-solid method described previously in a quartz tube connected to a
gas manifold and vacuum pump and heated by a temperature controlled tube furnace.232
Monodisperse gold nanoparticles (100 nm, Ted Pella) were dispersed on SiO2/silicon
substrates, which were placed within the central region of the quartz tube reactor. The
SiNWs were synthesized at 470-485 oC using silane (SiH4) as the silicon reactant source,
H2 as the carrier gas, and phosphine (PH3, 1000 ppm in H2) as the n-type dopants,
according to the previously established protocol.201 The length and diameter of the eSiNWs were selected to inhibit cell internalization. The doping ratio with a
silane/phosphine ratio of 500 was chosen to obtain a high conductivity (150 - 500 S/m)
compared to cell culture medium (~1.75 S/m) and myocardium (~0.1 S/m) to create
highly electrically conductive microenvironments within spheroids.44,202 In a typical
synthesis of uniform n-type, 100 nm SiNWs, the flow rates of SiH4, PH3 and H2 were 1-2,
2-4 and 60 standard cubic centimeters per minute, respectively, and the total pressure 40
torr. The nanowires were collected from the oxidized silicon substrates by sonication in
isopropanol for 1 min followed by centrifugation to obtain SiNWs with an average
dimension of 100 nm diameter and 10 µm length. The electrical conductivity of the SiNWs
were measured by using four-probe transport measurement.
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cardiomyocytes (hiPSC-CMs) (iCell Cardiomyocytes, Cellular Dynamics International-CDI,
Madison, WI, USA) were cultured according to the manufacturer's protocol. Briefly, hiPSCderived cardiomyocytes were plated on 0.1% gelatin coated 6-well plates in iCell
Cardiomyocyte Plating Medium (CDI) at a density of about 3 × 10 5 to 4.0 × 105 cells/well
and incubated at 37 °C in 5% CO2 for 4 days. Two days after plating, the plating medium
was removed and replaced with 4 mL of iCell Cardiomyocytes Maintenance Medium (CDI).
After 4 days of monolayer pre-culture, cells were detached using trypLE Express (Gibco
Life Technologies, Grand Island, NY) and prepared for spheroid fabrication.
Spheroid fabrication and electrical stimulation. As described in our previous
publication,45 the agarose hydrogel molds were prepared using autoclaved 2% agarose
(Sigma Aldrich, St. Louis, MO) and commercial master micro-molds from Microtissues, Inc
(Providence, RI) as negative replicates to create non-adhesive agarose hydrogels molds
containing 35 concave recesses with hemispheric bottoms (800 m diameter, 800 m
deep) to facilitate the formation of tissue cell spheroids. A suspension of hiPSC-derived
cardiomyocytes were mixed with e-SiNWs in media at a 1:1 ratio (number of cells:number
of SiNWs) for a final concentration of 2.0 x 106 cells/mL. Approximately 75 µl of the cell/eSiNW suspension was pipetted into each agarose mold. After the cells settled into the
recesses of the mold (10 min), additional media was added to submerge the molds in an
8-well plate and exchanged every 2 days for the length of the experiment. Day 0 of the
experiment was marked after 4 days of spheroid assembly. Electrical stimulation (C-Pace
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unit, Ion Optix, Milton, MA) was started on Day 10 (2.5V/cm, 5 ms). A ramp-up method
(Day 1 – 0.5 Hz, Day 2 – 0.75 Hz) was used to bring the frequency of stimulation to 1 Hz
for the remainder of the experiment. Here, Day 19 represents 7±1 days of stimulation at
1 Hz. A scheme of the experimental setup is found in Figure 2.1A and 2.1B.
Beat rate analysis of beating spheroids. Videos of spontaneously beating
spheroids from each group were recorded at room temperature (after temperature
stabilization) without stimulation for each condition starting on Day 0 using Zen 2011
software (Zeiss, Göttingen, Germany). Videos were converted to a series of TIFF format
pictures by Adobe Premiere (Adobe, San Jose, CA). Threshold edge-detecting in ImageJ
software (National Institutes of Health) was used on high contrast spheroid picture series
and graphed to realize beating profiles, from which beats per minute was calculated
(n=15-50 spheroids). Diameter of each spheroid was calculated from the threshold-based
area of high contrast spheroid images (n=15-50 spheroids).
Immunofluorescent analysis. Freshly collected spheroids were flash frozen in
Tissue-Tek OCT compound (Sakura, Torrance, CA). Embedded spheroids were
cryosectioned into 7 µm thickness layers onto glass slides for immunohistochemistry. The
sections were fixed with pre-cooled acetone (-20 °C) for 10 min. After washing (2 times at
5 min) in PBS with 0.1% Triton X-100 (PBST) (Sigma), blocking buffer was made with 10%
serum corresponding to host species of secondary antibody in PBST and added to sections
for 1 hr at room temperature. Sections were incubated with primary antibody diluted in
PBST (1:200): laminin (Sigma), connexin-43 (Sigma), N-cadherin (BD Biosciences, San Jose,
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CA), ZO-1 (Thermo Fisher Scientific, Waltham, MA), alpha sarcomeric actinin (Abcam,
Cambridge, UK), cardiac troponin I (Abcam), MYL2 (Abcam) overnight at 4 °C or 2 hrs at
room temperature. After washing in PBST (2 times at 5 min), tissues were incubated with
complement secondary antibodies diluted in PBST for 1 hr at room temperature. After
washing in PBST (2 times at 5 min), nuclei were counterstained with DAPI (Molecular
Probes/Invitrogen, Eugene, OR) diluted in PBST for 15 min at room temperature.
Following the final wash procedure (PBST, 2 times at 5 min), glass cover slips were added
to the slides using Fluoro-Gel (Electron Microscopy Sciences, Hatfield, PA) and slides were
stored in 4 °C. TCS SP5 AOBS laser scanning confocal microscope (Leica Microsystems,
Inc., Exton, PA) was for imaging. Fluorescent protein expression was calculated as the
antibody-positive fluorescence area coverage divided by the number of nuclei or spheroid
area. Each analysis consisted of 2-3 high resolution images at 400X total magnification of
3-5 spheroids to obtain an accurate representation of the entire spheroid.
TUNEL staining for frozen spheroids section. Roche In Situ Cell Death Detection Kit
(Sigma) was used to determine the viability of cells in the frozen sections of spheroids
based on the Roche protocol. Briefly, the frozen sections of spheroids were fixed with 4%
paraformaldehyde in PBS for 20 min at room temperature. Following washing in PBS for
30 minutes, samples were incubated in a permeabilization solution (0.1% Triton X-100
and 0.1% sodium citrate in PBS) for 2 minutes on ice. Then 50 µl of the TUNEL reaction
mixture were added to samples and incubated at 37 °C for 1 hr. After washing in PBS (2
times at 5 min), nuclei were counterstained with DAPI (Molecular Probes/Invitrogen)
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diluted in PBS for 15 min at ambient temperature. Following the final wash procedure
(PBS, 2 times at 5 min), glass cover slips were added to the slides using Fluoro-Gel
(Electron Microscopy Sciences). TCS SP5 AOBS laser scanning confocal microscope (Leica
Microsystems) was used for imaging.
Gene expression with qRT-PCR. Total RNA was isolated according to the kit and
protocol of an RNeasy Micro Kit (Qiagen, Vinlo, Netherlands) with the addition of the
Homogeneizer Columns (Omega Biotek, Norcross, GA) during the homogenization step
for spheroids. For each group, a minimum of 15 spheroids were used for RNA isolation.
At least 25 ng of total RNA for each group was subjected to cDNA synthesis using the BioRad (Hercules, USA) iScript cDNA synthesis kit. qRT-PCR step was performed using
validated Life Technologies Taqman primers (Thermo Fisher Scientific) in 10 μl reactions
for the targeted genes listed in Table S1. Data was normalized as the change in cycle
threshold (Ct) to the geometric mean of GAPDH and ACTB (dCt) and analyzed using, mRNA
expression = 2^(-dCt). Data was then normalized to NC-D0 gene expression and averaged
across n=3 experiments.
Statistics Analysis. Differences between experimental groups were analyzed using
one-way and two-way ANOVA and Tukey’s post-hoc test, and p<0.05 was considered
significantly difference for all statistical tests.
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Supporting Information
Figure 2.6.

Figure 2.6. hiPSC cardiac spheroid assembly. (A) TUNEL staining of frozen spheroid
sections show high viability; blue-DAPI nuclear stain, green-TUNEL apoptotic nuclei.
(B) Quantification of TUNEL-based viability shows high viability among all groups. (C)
Laminin immunofluorescent staining reveals consistent laminin production
throughout the whole spheroid in each condition; red-laminin, yellow-nanowires. NCD0 - unwired and unstimulated at Day 0; NC – unwired and unstimulated at Day 19;
WC – wired and unstimulated at Day 19; NS – unwired and stimulated at Day 19; WS
– wired and stimulated at Day 19.
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Figure 2.7.

Figure 2.7. Gene expression analysis of hiPSC cardiac spheroids. The analyzed genes
correspond to the following aliases: MYH6 – alpha myosin heavy chain; MYH7 – beta
myosin heavy chain; RYR2 – ryanodine receptor; KCNH2 – HERG channel. + =
significantly different with Day 0; * = significantly different from remaining groups
(p<0.05). NC – unwired and unstimulated at Day 19; WC – wired and unstimulated at
Day 19; NS – unwired and stimulated at Day 19; WS – wired and stimulated at Day 19.
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Table 2.1
Taqman primers used for gene analysis.
Gene symbol
Primer ID
ACTB
Hs01060665_g1
GAPDH
Hs02758991_g1
GJA1
Hs00748445_s1
HCN4
Hs00975492_m1
KCNH2
Hs04234270_g1
KCNJ2
Hs01876357_s1
MYH6
Hs01101425_m1
MYH7
Hs01110632_m1
MYL2
Hs00166405_m1
MYL4
Hs04187281_m1
RYR2
Hs00181461_m1
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CHAPTER FOUR
DEVELOPMENT-DRIVEN INSPIRATION FOR BIOMIMETIC SELF-ASSEMBLY OF HUMAN
CARDIAC ORGANOIDS
Introduction
With the advancement of human induced pluripotent stem cell technologies, the
emerging human organoids have provided a powerful platform to model human organ
development and pathologies, as well as provide cell delivery systems for regenerative
therapy.57,58 Organoids are 3D structures based on the self-organization of stem cellderived organ-specific cell types to recapitulate major tissue/organ structures and
functions. To this end, the development of a variety of functional human organoids (e.g.,
lung, liver, brain) has given novel insight into developmental and pathological
processes.56,89,233-235 Despite the increasing progress in other organ systems, few studies
have focused on the development of a human cardiac organoid.236,237 Recapitulation of
the 3D multicellular structure and function of the developing myocardium remains a
challenge for the development and application of human cardiac organoids.238
Significant advancements, however, have been made in the utilization of human
induced pluripotent stem cell derived-cardiomyocytes (hiPSC-CMs) at the cellular and
genetic level for the development of disease models and drug screening systems.96,239,240
In addition to 2D culture systems, significant resources have been devoted to developing
3D myocardial constructs to support cardiomyocyte development and improve viable
transplantation approaches.241 Strategies have been engineered to target specific
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physiologically relevant features (e.g., multicellular, capillary-like diffusion, electrical
stimulation)

in

the

myocardium

to

improve

cardiomyocyte

functions

and

development.39,46,48-51,242,243 To this end, early cardiac tissue engineering efforts, such as
the work of Kelm and others, demonstrated that cardiac spheroids made from a mixed
cell population derived from neonatal/fetal rodent hearts supported myocardial
extracellular matrix profile and cardiomyocyte sarcomere development.29,244 This has
been supported further by several hiPSC-CM-based studies showing that supporting cell
types provide extracellular matrix microenvironment, incorporate angiogenic signaling,
enhance microtissue assembly, and improve maturation of cardiac microtissues.53-55,245248

Furthermore, the addition of vascular cell types to cardiac microtissues can model

aspects of coronary angiogenesis and provide a functional benefit in heart repair by
connecting to the host vasculature after transplantation.51,244,248,249 By targeting specific
hiPSC-CM functions/properties, tissue-engineered cardiac systems have been
advantageous for the development of more sensitive drug testing models and improved
cell delivery strategies. However, by using “output” structures/functions as the input
design principle, these platforms can exclude tissue/organ-level intricacies that are critical
for modeling cardiac development and pathologies.
While cardiac differentiation of embryoid bodies holds great potential for
cardiovascular organoid production236,237, the intramyocardial organization events in
coronary vasculogenesis provides the biological inspiration for a method of controlled,
scaffold-free human cardiac organoid fabrication using defined cell types. In
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development, after the 4-chamber heart structure has formed, the formation of the
epicardium involves a dynamic process of epithelial-mesenchymal transition of
epicardium-derived cells that migrate into the myocardium and differentiate into vascular
and cardiac interstitial cell types.250-252 Subsequently, the developing ventricular
myocardium undergoes the intramyocardial organization events of coronary
vasculogenesis where a diverse, yet defined, mixture of cardiac cell types (e.g.,
cardiomyocytes, cardiac fibroblasts, vascular cell types) organize into functional
myocardium before anastomosis to the aorta (Figure 3.1A, 3.1B).253-256 At this point in
development, the cardiomyocytes also retain a spontaneous beating property, in part,
due to incomplete sub-type specification of the cardiomyocytes, similar to hiPSC-CMs.24,30
Inspired by these events and the developing/immature characterization of hiPSC-CMs, we
have established a defined, scaffold-free fabrication strategy to assemble vascularized
human cardiac organoids in vitro that recapitulate an array of structural, genetic, and
functional cardiac tissue-level characteristics of the developing myocardium. Through
incorporation of the events of coronary vasculogenesis as the major design principle in
human cardiac organoids, the technology described here provides a powerful platform to
incorporate and investigate the cellular, matrix/material and additional factors required
to promote tissue/organ-level heart development. Furthermore, this platform lays down
the foundation for the development of functional cardiac tissues for tissue-/organ-level
drug screening and advanced cell therapy for heart repair.
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Results and Discussion
Developmental inspiration for cardiac organoid fabrication. The dynamic cellular
organization events of coronary vasculogenesis during heart development (after the 4chamber structure as formed) provided a developmental basis for the fabrication of
cardiac organoids, represented in Figure 3.1A. To prepare human cardiac organoids, we

Figure 3.1. Developmental inspiration for organoid fabrication. (A) In the developing
heart after the 4-chamber structure has formed, the epicardium and subsequent
epithelial-to-mesenchymal transition give rise to a diverse mixture of cardiac cell types.
This stage of intramyocardial organization marks the initial phase of coronary
vasculogenesis. The self-assembly process surrounding this intramyocardial
organization served as inspiration for analogous, self-assembled cardiac organoids
from a defined mixture of cardiac cells prior to blood flow. (B) Hematoxylin and eosinstained mouse embryonic heart sections at embryonic day 13.5 (E13.5) show the 4chamber structure and the epicardium adjacent to the developing ventricular
myocardium (inset). By E15.5 (right), evidence of preliminary coronary vessels
(asterisk) can be seen in the developing ventricular myocardium.
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utilized hiPSC-CMs, human ventricular cardiac fibroblasts (cFBs) and human umbilical vein
endothelial cells (HUVECs) to represent the major cardiac cell types in the developing
myocardium. Due to their immature characteristics, hiPSC-CMs served as an appropriate
cell type to represent cardiomyocytes in the developing myocardium.24 While aligned
cardiac microtissue research has significantly enhanced the understanding of stem cellderived cardiomyocyte mechanical/electrical properties (e.g., contraction force,
conduction velocity)21,48,243,257,258, the cardiac organoid system does not incorporate an
aligned cardiomyocyte design to resemble the developing heart at the stage of coronary
vasculogenesis, in which significant anisotropic cardiomyocyte organization has not been
established (Figure 3.1B). During the spheroid fabrication, the ratio between different
cardiac cells was selected to approximate cell ratios in developing hearts (5:4:1, hiPSCCMs:cFBs:HUVECs).259-261 As an alternate rationale, human cardiac organoids were also
fabricated using the ratio of cells corresponding to adult hearts (3:6:1, hiPSCCMs:cFBs:HUVECs) (Figure 3.2A-C).259-261 The experimental timeline can be seen in Figure
3.8.
By experimental Day 10 (D10), the developing stage ratio cardiac organoids
showed significantly higher contraction amplitude (i.e., fractional area change) and
regularity of beating than adult ratio organoids, which was attributed in part to the higher
hiPSC-CM composition in the developing stage ratio organoids (Figure 3.2D, 3.2E). In
addition, the difference in the contraction profiles was supported by enhanced sarcomere
development (e.g., Z-line formation) in developing stage ratio organoids at D10 when
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compared to adult ratio organoids, which have minimal Z-line formation despite still
having alpha sarcomeric actinin (α-SA)-positive regions (Figure 3.9). This suggested that
the developing stage ratio provided a favorable microenvironment for hiPSC-CM

Figure 3.2. Examination of developmental inspiration for cardiac cell ratio for organoid
fabrication. (A) The ratio of cardiac cell types (by number) changes throughout
development, based on reported literature ref. 259-261. (B, C) A developing stage and
adult stage cell ratios of cardiac cell types represent two organoid fabrication
rationales to support cardiomyocyte development, seen in bright-field images at D0;
n=human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM), human
cardiac ventricular fibroblasts (cFB), human umbilical vein endothelial cells (HUVEC).
(D) Representative contraction profiles for developing stage and adult stage ratio
organoids were constructed from video analysis of spheroid fractional area change. (E)
Analysis of average (±SEM) contraction amplitude (i.e., fractional area change) showed
significant differences at D10; n=8-12 organoids. Developing stage ratio organoids
showed 100% of organoids beating at D10, while adult stage ratio organoids had only
~50% beating. Asterisk represents significant difference, p<0.05.
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development and supported the developmental basis for cardiac organoid fabrication.
This finding is consistent with previous engineered findings showing that cardiac
constructs containing a majority of cardiomyocytes of the construct supports increased
hiPSC-CM functions.32,39,48,243 The developing stage cell ratio for cardiac organoids was
used for the remainder of the experiments.
To examine the effects of media components on organoid formation and
maturation, DMEM/F12 media with varying amounts of FBS was prepared and compared
to a ratiometric combination of cardiomyocyte media (DMEM/F12, 10% FBS), fibroblast
media (FGM-3, defined growth factors, 10% FBS), and endothelial cell media (EGM-2,
defined growth factors, 2% FBS) corresponding to the cell ratio (Figure 3.10). After 4 days
of organoid formation, the cardiac organoids with the ratiometric combination showed
significantly better viability index (i.e., reduced TUNEL-positive apoptotic nuclei) and was
used for the remainder of the experiments.
Phenotypic cellular behavior in human cardiac organoids. Immunofluorescent
analysis using von Willebrand factor (vWF) and CD31 endothelial markers of the cardiac
organoids revealed limited staining and spreading of HUVECs at D0 through D10 (Figure
3.3A). Human adipose-derived stem cells (hADSCs) were added to the cardiac organoid
system to promote endothelial function based on their pericyte-like function and proangiogenic properties.161,262-267 Cardiac organoids with hADSCs were fabricated with 50%
hiPSC-CMs, 29% cFBs, 14% HUVECs, and 7% hADSCs. The relative amount of hADSCs
reflects the limited amount of pericytes in the heart, supported by previous research in
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endothelial-ADSC co-culture systems (Figure 3.3B).245,262 The effects of hADSCs were
noticeable from D0 by enhanced organization of vWF-positive cells (i.e., HUVECs) in a
circular pattern surrounding the inner portion of the organoid (Figure 3.3A). By D10, the
addition of hADSCs increased indications of enhanced endothelial function and/or
viability, described by the increased covered area of vWF-positive structures, and
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Figure 3.3 (previous page). The addition of human adipose derived stem cells improves
biomimetic formation of functional, lumenized vascular networks in cardiac organoids.
(A) The addition of adipose-derived stem cells (+ADSC) led to increased vWF- and
CD31-positive endothelial network formation by D10. Without human adipose-derived
stem cells (-hADSC), cardiac organoids showed limited endothelial staining; n=3
organoids/group per endothelial stain. (B, C) The addition of hADSCs to the
developmentally inspired cardiac organoid fabrication significantly improved the vWFpositive area over spheroid area by D10; n=3 organoids. (D) Lumen-like structures
(asterisk) were observed in D10 cardiac organoids with hADSCs with vWF-positive (red)
endothelial cells within α-SA-positive (green) hiPSC-CMs areas; blue-DAPI. (E)
Significantly more vWF-positive lumen structures were observed per organoid in D10
organoids with hADSCs in comparison to without hADSCs; n=10 organoids per group.
(F) 3D reconstruction of thick sections of D10 cardiac organoids with hADSCs show 3D
structure of a CD31-positive (green) vessel with open lumens (asterisk) supported by
vimentin-positive (red) support cells; blue-DAPI. (G) Evaluation of putative vasculature
showed (i) that culturing cardiac organoids from D0-D10 (before putative vasculature
formation) in an oxygen-reduced environment (10% O2) for 10 days resulted in a
significant decrease in viability in the center, indicated by TUNEL apoptosis assay,
compared to cardiac organoids with formed lumenized vascular networks (D10-D20)
and D10 and D20 controls (21% O2); n=4-7 organoids. (ii) Macrotissue assembly using
five D10 cardiac organoids cultured 10 days (D10-D20) showed minimal TUNEL
expression and displayed extensive vWF-positive endothelial networks across the
whole macrotissue (n=3 macrotissues). Cardiac organoids were fabricated using a
developing stage cell ratio. Asterisk represents significant difference, p<0.05.
promoted EC network formation in cardiac organoids compared to without hADSCs, as
shown by vWF and CD31 staining (Figure 3.3A, 3.3C).
As in coronary vasculogenesis, where vascular cell types and cardiac interstitial
cells form the endothelial plexus in the beating myocardium before connecting to the
future coronary artery253, lumen-like structures with vWF-positive cells were found within
the cardiac organoids bordered by α-SA-positive hiPSC-CMs, although not every vWFpositive cell participated in the lumen formation (Figure 3.3D). Notably, cardiac organoids
with hADSCs showed significantly more vWF-positive lumen structures than without
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hADSCs (Figure 3.3E). 3D reconstruction of thick cardiac organoid sections revealed CD31positive vessel structures supported by vimentin-positive cells (Figure 3.3F). Serial images
of confocal imaging of vWF-stained whole organoids further confirmed the formation of
multiple areas with lumen-like regions in X, Y, and Z perspectives connected by vWFpositive ECs (Figure 3.11). The increase in vWF- and CD31-positive structures and lumen
formation demonstrated the structural functionality of the HUVECs and was largely
attributed to the pro-angiogenic role of hADSCs. This is supported by a growing amount
of research indicating a perivascular origin and properties of mesenchymal stem cells
(e.g., hADSCs), which is consistent with other studies showing the pro-angiogenic
properties of hADSCs

262-266.

In addition, the organizational changes seen after the

addition of hADSCs is consistent with other multicellular research that indicates a higher
order level of self-organization beyond differential cell adhesion dynamics.237,268
Furthermore, vascular endothelial growth factor (VEGF) signaling plays an important role
during coronary vasculogenesis.269 Gene expression of vascular endothelial growth factor
A (VEGFA) and the main VEGF-A receptor 2 (VEGFR2) in cardiac organoids and spheroids
of each individual cell type indicated the potential role in angiogenic signaling within
cardiac organoids between the major VEGF providers (hiPSC-CMs, cFB, hADSCs) and VEGF
receiver (HUVECs) (Figure 3.12).
To evaluate the functionality of the putative vasculature, cardiac organoids were
placed in an oxygen-reduced environment (10%) before (D0) and after (D10) putative
vasculature had formed for 10 days. Cardiac organoids cultured at 10% O2 from D0 (before
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putative vasculature formation) showed a significant increase in TUNEL expression at the
organoid center when compared to cardiac organoids cultured at 10% O2 from D10 (Figure
3.3G(i), 3.13). This strongly indicates the formation of putative vasculature reduces cell
apoptosis in the organoids center, suggesting their function to improve nutrient transport
within the organoids. In addition, we examined whether the putative vasculature in the
cardiac organoids can allow for the fabrication of large viable cardiac tissue engineering
constructs, as oxygen diffusion in the engineered cardiac tissue is limited to a 100-200 µm
range.270,271 To this end, cardiac organoids were cultured for 10 days to form putative
vasculature and then placed in groups of five to form organoid aggregates. Macrotissue
assembly was observed until D20, where the aggregates had formed large macrotissues
(>200 µm radius) with observable increased Z-dimension. TUNEL analysis showed no
significant changes in viability by D20 and immunofluorescent staining revealed large
regions of connected, vWF-positive endothelial cells (i.e., networks) across the organoid
macrotissues (Figure 3.3G(ii), 3.14). The observed enhanced viability in both cases
strongly indicates a functional benefit of putative vasculature, which is consistent with
previous studies incorporating vascular networks in rodent-cell based and scaffold-based
engineered cardiac constructs for improved viability/integration after transplantation
and evident from cardiovascular tissue engineering studies showing large necrotic core in
large scaffold-free constructs without pre-established vasculature.236,272-274 This
improvement may be attributed to the enhanced passive transport of nutrients whereby
the presence of lumens creates a porous construct that increases diffusivity to the center
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of the micro-/macrotissues.275 These data support the functional benefit of recapitulating
the lumenized vascular network of the developing myocardium in the cardiac organoids.
To explore the effects of endothelial cell source on the vasculature formation in
the organoids, we substituted HUVECs with human adipose-derived microvascular
endothelial

cells

(HAMECs)

to

fabricate

cardiac

organoids

due

to

their

microvascular/capillary origin in vivo.276 HAMEC cardiac organoids showed some
evidence of network formation but overall showed less vWF-positive cells than HUVEC
cardiac organoids on D10, while the cardiomyocyte organization was similar in both cases
(Figure 3.15). This is consistent with reduced in vivo vascular network density observed in

Figure 3.4. The addition of human adipose derived stem cells affects biomimetic
cellular organization and introduces immunomodulatory effects. (A) α-SA-positive
(green) hiPSC-CMs were mainly located in the outer region of spheroid cross-sections
with or without hADSCs. The addition of hADSCs showed more homogeneous
distribution of vimentin-positive (red) cells by D10; blue-DAPI. (B) The density of
vimentin-positive staining area within α-SA regions significantly increased in cardiac
organoids with hADSCs; n=3-4 organoids. (C) hADSCs demonstrated
immunomodulatory role by significantly decreasing the expression of IL6 in cardiac
organoids with hADSCs; n=3 experiments, 10-15 organoids/experiment. Cardiac
organoids were fabricated using a developing stage cell ratio. Asterisk represents
significant difference, p<0.05.
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transplanted human dermis-derived microvascular endothelial cells compared to
HUVECs.277 These results may reflect tissue-specific and/or developmental age properties
of the cell source that influence their angiogenic/vasculogenic and structural
functionality.278-281 However, given their facile, readily expandable culture properties and
consistent vasculogenic characteristics in cardiac organoids, HUVECs were used for the
remainder of the experiments.
As for the hiPSC-CM, cFB, and hADSC organization, D0 cardiac organoids with or
without hADSCs showed heterogeneous populations of vimentin-positive cells (i.e., cFBs
and hADSCs) throughout the microtissue (Figure 3.4A). The majority of α-SA-positive
hiPSC-CMs with or without hADSCs organized in the outer regions of the cardiac
organoids. In the native myocardium, adjacent fibroblast-cardiomyocyte interactions are
critical for cardiac development.282 By D10, cardiac organoids with hADSCs displayed an
increased density of vimentin-positive cells in the α-SA-positive (i.e., hiPSC-CMs) regions
of the cardiac organoid (Figure 3.4A, 3.4B). Furthermore, the immunomodulatory
potential of hADSCs was supported by a significant reduction in the pro-inflammatory
interleukin IL6 gene expression in cardiac organoids, compared to organoids without
hADSCs (Figure 3.4C).283
Extracellular matrix (ECM) protein production in human cardiac organoids. In
addition to the phenotypic cellular distribution throughout the cardiac organoid, the
extracellular matrix proteins in the cardiac organoids supported the development of an
organotypic microenvironment. One limitation in hiPSC-CM spheroids (i.e., microtissues
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composed of 100% hiPSC-CMs) is the lack of collagen in the microtissue. While hiPSC-CM
spheroids showed limited collagen I expression throughout the experiment with
disconnected, dotted structures, the cardiac organoids expressed significantly more
collagen I-positive, connected structures indicative of mature, stable collagen fibril
formation (Figure 3.5A). This difference was attributed to the presence of cardiac
fibroblasts in the organoids, as collagen is maintained by the cardiac fibroblasts in the

Figure 3.5. Human cardiac organoids display organotypic extracellular matrix (ECM)
components. (A) Spheroids comprised of 100% hiPSC-CMs (hiPSC-CM spheroids)
showed limited, dotted collagen I immunofluorescent staining, while cardiac organoids
showed significantly increased, connected collagen I structures by D10. (B) hiPSC-CM
spheroids showed overall low levels of fibronectin expression, while cardiac organoids
decreased significantly by D10. Quantification of ECM components was based on the
ratio of ECM-positive covered area divided by total spheroid area. hiPSC-CM-human
induced pluripotent stem cell-derived cardiomyocyte. Cardiac organoids were
fabricated using a developing stage cell ratio; n=3-6 microtissues. Asterisk represents
significant difference, p<0.05.
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native myocardium.282 As shown in the Figure 3.5A, collagen I expression in the organoids
increased from D0 to D10, consistent with results from developing hearts.284
Notably, in cardiac organoids, fibronectin-positive spheroid area decreased
significantly from D0 to D10, while hiPSC-CM spheroids showed overall low levels of
fibronectin-positive structures at D0 and D10 (Figure 3.5B). This may suggest the
formation of non-pathological, ventricular-like extracellular microenvironment to
support development of hiPSC-CMs, as fibronectin has been shown to be more abundant
in atrial than ventricular myocardium, and increased ventricular fibronectin is associated
with pathological cardiac hypertrophy.285,286 The changes in fibronectin in cardiac
organoids (high to low from D0 to D10) may also indicate the increased role of fibronectin
during microtissue formation evidenced by the high levels at D0 and/or the observed role
of fibronectin in myofibril organization in cardiac development.287-290 In addition, the
basement membrane protein (laminin) is produced by hiPSC-CMs and showed strong
immunofluorescent expression in both hiPSC-CM spheroids and cardiac organoids
throughout the experimental timeline (Figure 3.16). Cardiac organoids provide a
biomimetic matrix environment that supports cardiac function and can serve as a model
for biomaterial/construct design in exploring the necessary material components for
cardiac development.
Enhanced cardiomyocyte development within cardiac organoids. Previous work
using hiPSC-CM spheroids has indicated conditioning approaches and extended culture
are required to enhance the contractile properties toward physiological relevance.45,241
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We next explored the effect of cellular and matrix microenvironment as a biomimetic
stimulus in the organoids to promote the contractile properties of hiPSC-CM. During the

Figure 3.6. Human cardiac organoids support contractile development of hiPSC-CMs.
(A) Cardiac organoids showed signs of improved sarcomere development (e.g., Z-line
width) by D10 in comparison to hiPSC-CM spheroids. (B) Ratiometric gene expression
of hiPSC-CM spheroids and cardiac organoids reveal improvements in hiPSC-CM
development within microtissues. Gene expression of cardiac troponin I (TNNNI3) over
slow, skeletal troponin I (TNNNI1) showed greater significant increases in cardiac
organoids, indicating improved contractile maturation of hiPSC-CMs by D10.
Ratiometric expression of myosin light chain ventricular isoform (MYL2) over atrial
isoform (MYL7) showed more significant increases by D10 in cardiac organoids,
indicating improved ventricular specification of hiPSC-CMs; n=3 experiments, 10-15
microtissues/experiment. (C,D) Shifts in gene ratios were supported by increased
cardiac troponin I (cTnI)-positive and ventricular myosin light chain (MLC-2v)-positive
fraction area over α-sarcomeric actinin (α-SA)-positive area (hiPSC-CM-specific areas),
represented by low and high magnification immunofluorescent images; n=3
microtissues. Cardiac organoids were fabricated using a developing stage cell ratio.
hiPSC-CM- human induced pluripotent stem cell-derived cardiomyocyte. Asterisk
represents significant difference, p<0.05.
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process of self-assembly, hiPSC-CM spheroid spontaneous beating started after two days
of spheroid assembly (D-2), while cardiac organoid spontaneous beating started after four
days of spheroid assembly (D0). hiPSC-CM spheroids at D0 showed more phenotypic
banding of α-SA-positive Z-lines than cardiac organoids, however, by D10 the cardiac
organoids showed more enhanced organization (e.g., Z-line width) of sarcomeres than
hiPSC-CM spheroids (Figure 3.6A). Particularly, the presence of Z-line widths greater than
10 µm was observed more frequently among different cardiac organoids (13 out of 19;
n=5 experiments) than in hiPSC-CM spheroids (1 out of 10; n=3 experiments) seen in
Figure 3.17A, supporting the reproducibility of human cardiac organoids.
To further evaluate contractile improvements in cardiac organoids, contractile
maturation and cardiomyocyte subtype specification (i.e., ventricular) were examined. As
an indicator of contractile maturation221 and to evaluate hiPSC-CM-specific development,
ratiometric gene expression of adult cardiac troponin I and immature troponin I (i.e.,
TNNI3/TNNI1) revealed a significant increase in TNNI3/TNNI1 in cardiac organoids and an
insignificant increase in hiPSC-CM spheroids from D0 to D10 (Figure 3.6B). This was
further supported by significantly higher density of cardiac troponin I (cTnI) expression in
the cardiac organoids than hiPSC-CM spheroids, when normalized to the α-SA-positive
area of stained spheroid sections (Figure 3.6C, 3.17B). To examine the cardiac organoids
for working myocardium development, ventricular myosin light chain (protein:MLC2v,
gene:MYL2) and atrial myosin light chain (protein:MLC2a, gene:MYL7) were used for
ratiometric gene expression. At D10 both cardiac organoids and hiPSC-CM spheroids
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showed increased ventricular/atrial (i.e., MYL2/MYL7) expression, though cardiac
organoids showed a significantly greater shift toward ventricular gene expression (Figure
3.6B). In addition, the immunofluorescent expression of MLC2v showed increased
staining density per α-SA-positive regions in cardiac organoids over hiPSC-CM spheroids
(Figure 3.6D, 3.17C). Although both groups show spontaneous beating throughout the
experiment, the observed enhanced sarcomere development, increased adult cardiac
troponin I expression, and a greater ventricular shift in expression supports the
development of hiPSC-CMs in cardiac organoids.
Interestingly, the contraction amplitude of cardiac organoids is significantly lower
than hiPSC-CM spheroids (0.61 ± 0.25% vs. 1.98 ± 1.2%), despite having similar
spontaneous beat rates (cardiac organoids: 36.9 ± 8.0 beats per minute (bpm) vs. hiPSCCM spheroids: 33.8 ± 3.4 bpm) (Figure 3.18). The low contraction amplitude of cardiac
organoids is possibly due to the increased extracellular matrix components (e.g., collagen)
and interstitial cell types, resulting in a denser/stiffer construct that creates an increased
load for cardiomyocyte contraction. This was supported by the improved contractile
structure and gene profile in cardiac organoids despite low contraction amplitude,
highlighting the importance of the multicellular and matrix environment for hiPSC-CM
maturation and ventricular lineage specification seen by others.245,291 It is worth noting
that the observed relationship between cardiomyocyte function and changes in
cellular/ECM components is equally important to cardiac development and maturation as
it is to cardiac pathophysiology, such as in chronic cardiac fibrosis.292,293 The previously
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mentioned data from Figure 3.2D and 3.2E (showing decreased contraction amplitude
with increased fibroblast number) also supports these tissue-level dynamics and offers
evidence of possible pathological applications within a tunable cardiac organoid system.
Human cardiac organoids display phenotypic responses to pharmacological
compounds. For a functional cardiac organoid, the observed phenotypic structure,
organization, and contractile development in D10 cardiac organoids must also be
supported by demonstrated functions of fundamental characteristics of cardiac tissue.
Given that calcium handling in cardiomyocytes is involved in electrical signal generation
and propagation and is intimately involved in the contractile apparatus 24, the explored
improvements in contractile characteristics of cardiac organoids suggested functioning
calcium-handling properties. Membrane calcium channels (e.g., L-type calcium channel)
contribute to the initiation of the calcium-induced calcium-release (CICR) phenomenon in
cardiomyocytes. Verapamil is a multi-channel blocker that causes a decreased calcium
transient peak due to a large calcium L-type channel blockade. However, it has served as
a false-positive arrhythmogenic drug in hERG channel based arrhythmogenic drug
screening.69 Administration of 500 µM of verapamil resulted in a significant decrease in
peak fluorescence and no observed arrhythmogenic activity (Figure 3.7A). This response
validates the phenotypic functionality of L-type calcium channels to support CICR
dynamics for contraction. The initial inward flux of calcium then binds to ryanodine
receptors on the sarcoplasmic reticulum that release the intracellular stores of calcium
located in the sarcoplasmic reticulum to provide enough calcium for contraction. To
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examine the calcium release functionality of cardiac organoids, the ryanodine receptor

Figure 3.7. Human cardiac organoids display phenotypic channel functionality and
organotypic responses to physiological/pathological stimuli. Cardiac organoids showed
functional calcium handling. (A) Verapamil, which blocks the L-type calcium channel,
displayed significant phenotypic reduction of calcium transient amplitude without
inducing arrhythmia in cardiac organoids; n=4 organoids. (B) The use of ryanodine,
known to block the ryanodine receptor of the sarcoplasmic reticulum and reduce
endogenous calcium release, showed a significant decrease in calcium transient
amplitude and a significant increase time to peak calcium; n=3 organoids. (C) Blockade
of the hERG potassium channel using E-4031 showed a significant drop in calcium
transient peak and a significant increase in time to 50% calcium decay; n=3 organoids.
(D) A significant increase in beat rate after application of isoproterenol indicated intact
β-adrenergic signaling in cardiac organoids; n=5 organoids. (E) Cardiac organoids
showed organotypic transcription responses to ischemic stimuli; n=3 experiments; 1015 microtissues/experiment. Cardiac organoids and hiPSC-CM spheroids showed
increased VEGFA expression in response to ischemic stimulus. IL6 expression, a
prominent interleukin in ischemic heart failure, increased in cardiac organoids in
ischemia, while it was not detected in hiPSC-CM spheroids. hiPSC-CM-human induced
pluripotent stem cell-derived cardiomyocytes. Cardiac organoids were fabricated using
a developing stage cell ratio and were used at D10. Asterisk represents significant
difference, p<0.05.
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was blocked using 50 µM ryanodine. Ryanodine receptor blockade resulted in a significant
decrease in peak calcium transient (Figure 3.7B). Also, ryanodine administration
significantly increased time to peak calcium, indicating proper function of the ryanodine
receptor to regulate the intracellular flux of calcium required for contraction. These
results demonstrated the cardiac organoids recapitulate important calcium handling
properties of working human myocardium.
To counter the flux of calcium during contraction, potassium channels, such as the
hERG potassium channel, play a large role in repolarization phase of the cardiac action
potential.24 To examine the repolarization functionality of cardiac organoids, hERG
potassium channels were blocked with 10 µM E-4031. By blocking a major potassium
channel, repolarization is slowed, indicated by an extension in calcium transient decay
time. Blockade of the hERG channel resulted in significantly decreased peak calcium and
a significant phenotypic extension of the time to 50% calcium decay (Figure 3.7C).
Together with calcium handling results, these data showed the cardiac organoids
supported the proper development of tissue-level channel functions.
Human cardiac organoids display phenotypic functionality under physiological
and pathological stimuli. A series of physiologically relevant stimuli showed indications
of a wider range of tissue-level functionality of cardiac organoids beyond drug screening
and electrical property development. Beta-adrenergic signaling is a physiological process
of beat rate regulation by the autonomic nervous system by catecholamines.294 Using
video analysis of the beating rate of cardiac organoids, a beta-adrenergic agonist,
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isoproterenol (1 µM), showed a significant increase in beat rate (Figure 3.7D). This
validates the intact beta-adrenergic signaling pathways in hiPSC-CMs within the cardiac
organoids for physiologically relevant stimulation.
Despite immature characteristics of cardiac organoids compared to adult
ventricular tissue, the presence of fundamental physiological cardiac functions provided
a basis for exploring critical pathways involved in cardiac pathologies, supported by recent
progress using hiPSC-CMs for cardiac pathophysiology insights.102,240,295-297 Particularly,
cardiac organoids have potential to serve as an in vitro cardiac model for ischemic heart
failure, which makes up the majority of cardiovascular-related disorders.298 To evaluate
the initial response to a pathological stimulus, cardiac organoids and hiPSC-CM spheroids
were cultured for 6 hrs in ischemia. While the VEGFA expression in cardiac organoid is
lower than the hiPSC-CM spheroids in a normoxia environment, ischemic stimulus led to
a significant increase in VEGF-A gene expression in the cardiac organoids to similar levels
to that of hiPSC-CM spheroids (Figure 3.7E). Spheroids of each cell type all showed
increases in VEGFA expression under ischemic conditions (Figure 3.19A). hiPSC-CMs and
cFBs showed the highest levels of ischemic VEGFA expression, suggesting their dominant
role in VEGF signaling during ischemic stress. This trend is analogous to increases in VEGF
expression in ischemic cardiac tissue and further supports the biomimetic regulation of
VEGFA expression in cardiac organoids.299 Furthermore, the addition of noncardiomyocytes into the cardiac organoids system incorporated an extended
inflammatory response, namely, IL-6 gene expression, a prominent interleukin up-
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regulated in heart failure. After ischemic insult, IL6 expression increased significantly in
cardiac organoids and was absent in CM spheroids (Figure 3.7E). This was attributed the
presence of cFB in the organoids as single cell spheroid evaluation showed cFBs with the
highest levels of IL-6 gene expression in response to ischemic stimuli (Figure 3.19B). Drugbased and biomimetic stimulation of cardiac organoids can provide a fundamental and
potentially clinically relevant platform to explore the critical pathways involved in cardiac
pathophysiology.

Conclusion
With inspiration from major events in coronary vasculogenesis and a defined
method of microtissue fabrication, we have developed a robust platform to fabricate
vascularized human cardiac organoids that recapitulated the lumenized vascular network
of the developing myocardium, supported hiPSC-CM development and demonstrated
fundamental cardiac tissue-level functions. In contrast to the common organoid
fabrication approach of directed differentiation of embryoid bodies (EBs), the dynamic
cellular organization surrounding coronary vasculogenesis provided the developmental
basis for the use of defined cell types to develop a tunable cardiac organoid system. This
platform provides a consistent and efficient method of human cardiac organoid
fabrication (e.g., 100% beating, consistent cellular organization, and minimal size
variability) that supports high throughput applications (e.g., drug testing) in comparison
to cardiovascular EB differentiation, where there is high variability in size and morphology
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with only ~2%-15% of EBs showing contractile beating.236 Furthermore, while hiPSC-CMs
have been extensively used to model cardiac disorders, other cardiac cell types, such as
cardiac fibroblasts and endothelial cells, are involved in many cardiac pathologies.300,301
The use of a defined cardiac cell mixture for cardiac organoid formation is advantageous
by providing an adaptable system to incorporate and investigate the contribution of each
cardiac cell type, matrix materials, additional factors, and other physiological system
relationships (e.g., immunological cell types) to cardiac developmental/pathological
dynamics at a tissue/organ level.
In addition, similar to developing cardiomyocytes, the spontaneous beating
property of hiPSC-CMs supports contractile development and provided the source of
pacing in the cardiac organoids. To obtain adult stage ventricular maturation, in which
cardiomyocytes do not beat spontaneously, exogenous pacing may be required.
Interestingly, recent optimizations in stem cell-derived cardiomyocyte media suggest that
mature contractile characteristics, such as positive force-frequency, can be achieved
through the supply of defined growth factors.243 Looking toward future applications,
cardiac organoids with lumenized vascular networks provide a tunable foundation to
develop future pre-vascularized, injectable vehicles for regenerative cell therapy to treat
heart failure. In summary, the human cardiac organoid technology presented here
provides a robust platform for the development of the next generation of hiPSC-based
cardiac organoids in pursuit of developmental and pathological insight for regenerative
medicine applications.
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Materials and Methods
Cell culture. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSCCMs) (iCell Cardiomyocytes, Cellular Dynamics International-CDI, Madison, WI, USA) were
cultured according to the manufacturer's protocol. Briefly, hiPSC-derived cardiomyocytes
were plated on 0.1% gelatin coated 6-well plates in iCell Cardiomyocyte Plating Medium
(CDI) and incubated at 37 °C in 5% CO2 for 4 days. Two days after plating, the plating
medium was removed and replaced with 4 mL of iCell Cardiomyocytes Maintenance
Medium (CDI). After 4 days of monolayer pre-culture, cells were detached using trypLE
Express (Gibco Life Technologies, Grand Island, NY) and prepared for spheroid/organoid
fabrication. Human cardiac ventricular fibroblasts (cFBs) (Lonza, Basel, Switzerland) were
cultured in FGM-3 media (Lonza) were used at passage 3-4 for spheroid/organoid
fabrication. Human umbilical vein endothelial cells (HUVECs) (Lonza) were cultured in
EGM-2 media (Lonza) and were used at passage 2-3 for spheroid/organoid fabrication.
Human adipose-derived microvascular endothelial cells (HAMECs) (kind gift from Dr.
Michael Yost) and were cultured in EGM-2 media (Lonza) and were used at passage 5-6
for organoid fabrication. Human adipose-derived stem cells (hADSCs) (Lonza) were
cultured in low glucose Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum
(FBS) and 1% penicillin-streptomycin, 1% glutamine and 1% antimycin (Gibco Life
Technologies, Grand Island, NY). hADSCs were used at passage 3-4 for spheroid/organoid
fabrication. For cFBs, hADSCs, and HUVECs, media was changed every 2 days and were
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passaged using trypLE Express (Gibco) at >80% confluency. An array of media were
evaluated to best support consistent organoid formation and culture, shown in Figure
3.17. The optimal culture media for viable cardiac organoids was comprised of a
ratiometric combination of cell-specific media reflecting the cell ratio of the organoid. In
organoid media, CDI hiPSC-CM Maintenance Media (supplied without glucose) was
substituted with glucose-containing DMEM/F12 media with 10% FBS and 1% nonessential amino acids (Gibco).
Organoid and spheroid fabrication. As described in our previous publication45, the
agarose hydrogel molds were prepared using 2% agarose (Sigma Aldrich, St. Louis, MO)
and master micro-molds from Microtissues, Inc (Providence, RI) as negative replicates to
create non-adhesive agarose hydrogels molds containing 35 microwells with hemispheric
bottoms (800 m diameter, 800 m deep) to facilitate the formation of spherical
microtissues. Molds were soaked in cell/organoid specific media prior to microtissue
fabrication. Working cell suspensions of each cell type were used at ~4.0 x 106 cells/mL to
make organoid cell ratio mixtures and mixed with 1 volume media for a final
concentration of ~2.0 x 106 cells/mL. Approximately 75 µl of the cell suspension was
pipetted into each agarose mold. After the cells settled into the recesses of the mold (10
min), additional media was added to submerge the molds in an 8-well plate and
exchanged every 2 days for the length of the experiment (10 days). Day 0 (D0) of the
experiment was marked after 4 days of spheroid assembly. A scheme of the experimental
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timeline can be found in Figure 3.8. TUNEL staining for apoptotic nuclei revealed that D0
cardiac organoids maintained high viability throughout the microtissue (Figure 3.10).
Contraction analysis of beating spheroids. Videos of spontaneously beating
spheroids from each group were recorded at ~37 °C for each condition using a Carl Zeiss
Axiovert A1 Inverted Microscope and Zen 2011 software (Zeiss, Göttingen, Germany).
Videos were converted to a series of TIFF format pictures by Adobe Premiere (Adobe, San
Jose, CA). Threshold edge-detecting in ImageJ software (National Institutes of Health) was
used on high contrast spheroid picture series and graphed to realize beating profiles of
fractional area change (i.e., contraction amplitude), from which beats per minute and
contraction amplitude was calculated. Contraction amplitudes were calculated as the
percent change in fractional area change amplitude between contraction and relaxation.
Immunofluorescent analysis. Freshly collected spheroids were flash frozen in
Tissue-Tek OCT compound (Sakura, Torrance, CA). Embedded spheroids were
cryosectioned into 7 µm sections onto glass slides. The sections were fixed with cooled
acetone (-20 °C) for 10 min. After washing (2 times at 5 min) in PBS with 0.1% Triton X100 (PBST) (Sigma), blocking buffer was made with 10% serum corresponding to host
species of secondary antibody in PBST and added to sections for 1 hr at room
temperature. Sections were incubated with primary antibody diluted in PBST (1:200)
overnight at 4 °C or 2 hrs at room temperature: rabbit anti-laminin (Sigma), rabbit-anti
collagen type I (Abcam), rabbit anti-fibronectin (Abcam), mouse anti-alpha sarcomeric
actinin (Abcam), rabbit anti-cardiac troponin I – cTnI (Abcam), rabbit anti-MYL2 (MLC-2v)
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(Abcam), rabbit anti-vimentin (Abcam), mouse anti-CD31 (BD Biosciences, San Jose, CA),
rabbit anti-von Willebrand factor (vWF) (Abcam). After washing in PBST (2 times at 5 min),
sections were incubated with complement secondary antibodies diluted in PBST for 1 hr
at room temperature: goat anti-mouse Alexa Fluor 546 (Thermo), goat anti-rabbit Alexa
Fluor 647 (Jackson ImmunoResearch, West Grove, PA). After washing in PBST (2 times at
5 min), nuclei were counterstained with DAPI (Molecular Probes/Invitrogen, Eugene, OR)
diluted in PBST for 15 min at room temperature. Following the final wash procedure
(PBST, 2 times at 5 min), glass cover slips were added to the slides using Fluoro-Gel
(Electron Microscopy Sciences, Hatfield, PA). TCS SP5 AOBS laser scanning confocal
microscope (Leica Microsystems, Inc., Exton, PA) was used for imaging. Imaris software
(Bitplane, Zurich, Switzerland) was used to reconstruct z-stacked confocal images for 3D
visualization. Fluorescent protein expression was calculated as the antibody-positive
fluorescence area coverage: endothelial density was calculated as vWF-positive covered
area divided by spheroid area, lumens per organoid a was calculated as the number of
vWF-positive ring-shaped structures with adjacent DAPI-stained nuclei per organoid,
vimentin density was the ratio of vimentin-positive area within the α-SA-positive area,
ECM fraction area was calculated as the ECM-stain positive area divided by the spheroid
area, and the relative contractile protein amount was calculated as the ratio of cTnI or
MLC-2v area to total α-SA covered area. Each analysis consisted of high resolution images
at 400X total magnification of 3-5 spheroids. Hematoxylin and eosin-stained embryonic
mouse heart sections were a kind gift from the lab of Dr. Russell Norris.
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TUNEL staining for apoptosis. Roche In Situ Cell Death Detection Kit (Sigma) was
used to visualize the viability of cells in frozen sections of cardiac organoids based on the
Roche protocol. Briefly, cardiac organoid frozen sections were fixed with 4%
paraformaldehyde in PBS for 20 min at room temperature. Following washing in PBS for
30 minutes, samples were incubated in a permeabilization solution (0.1% Triton X-100
and 0.1% sodium citrate in PBS) for 2 minutes on ice. Then 50 µl of the TUNEL reaction
mixture were added to samples and incubated at 37 °C for 1 hr. After washing in PBS (2
times at 5 min), nuclei were counterstained with DAPI (Molecular Probes/Invitrogen)
diluted in PBS for 15 min at ambient temperature. Following the final wash procedure
(PBS, 2 times at 5 min), glass cover slips were added to the slides using Fluoro-Gel
(Electron Microscopy Sciences). TCS SP5 AOBS laser scanning confocal microscope (Leica
Microsystems) was used for imaging. TUNEL-based viability index was calculated as [1 –
(TUNEL-positive area / DAPI-positive area)].
Gene expression with qRT-PCR. Total RNA was isolated according to the kit and
protocol of an RNeasy Micro Kit (Qiagen, Vinlo, Netherlands) with the addition of the
Homogenizer Columns (Omega Biotek, Norcross, GA) during the homogenization step for
spheroids. For each group, a minimum of 10 spheroids were used for RNA isolation. At
least 25 ng of total RNA for each group was subjected to cDNA synthesis using the BioRad (Hercules, USA) iScript cDNA synthesis kit. qRT-PCR step was performed using
validated Life Technologies Taqman primers (Thermo Fisher Scientific) in 10 μl reactions
for

targeted

genes:

ACTB

(Hs01060665_g1),
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GAPDH

(Hs02758991_g1),

IL6

(Hs00985639_m1), KDR (VEGFR2, Hs00911700_m1), MYL2 (Hs00166405_m1), MYL7
(Hs01085598_g1),

TNNI1

(Hs00913333_m1),

TNNI3

(Hs00165957_m1),

VEGFA

(Hs00900055_m1). Data was normalized as the change in cycle threshold (Ct) to the
geometric mean of GAPDH and ACTB (dCt) and analyzed using, mRNA expression = 2^(dCt). Data was then averaged across n=3 experiments.
Calcium transient imaging. Life Technologies’s Fluo-4 Direct Calcium Assay Kit (Life
Technologies, Carlsbad, CA) was used to label calcium in the whole organoids based on
the manufacturer protocol. Briefly, organoids stained with a working solution of 1:1
calcium dye solution to media and incubated at 37 °C, 5% CO2, 20% O2 for 30 min. Carl
Zeiss Axiovert A1 Inverted Microscope completed with GFP fluorescence imaging capacity
(Zeiss) was used to collect the videos of the calcium transient of whole spheroids with a
capture rate of 20 frames per second. Finally, we used Zen 2011 software (Zeiss) to
convert videos to a series of TIFF format pictures. Mean gray value of the whole organoid
calcium transient (controlled for area for pre- and post- treatment) was measured using
ImageJ software (National Institutes of Health) to construct calcium transient profiles.
Normalized F/F0 was calculated as the peak calcium fluorescence (F) divided by the start
fluorescence level (F0), then divided by the F/F0 of the baseline transient before
treatment. Time to peak calcium (sec) was calculated as the difference in time between
the peak calcium and the start of the calcium transient. Time to 50% calcium decay (sec)
was calculated as the difference in time between the start of the calcium transient and
the half-peak (F50) of the calcium decay.
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Evaluation of putative vasculature. Oxygen reduction studies were performed at
10% O2 in a hypoxia chamber (C-Chamber, BioSpherix, Parish, NY) for a duration of 10
days. Media was exchanged every 2 days. Microtissues were embedded in OCT,
cryosectioned, and Roche In Situ Cell Death Detection Kit (Sigma) was used to visualize
the viability of cells in frozen sections of cardiac organoids based on the Roche protocol.
Macrotissue assembly was performed in agarose-coated (non-adhesive) 96-well plates.
Five cardiac organoids (developing stage cell ratio) were placed in each well and culture
for 10 days until the macrotissues had an appreciable Z-dimension, observed by pipette
agitation. Organoid aggregate macrotissues were embedded in OCT and cryosectioned
for immunofluorescent analysis. Media was exchanged every day.
Pharmacological, physiological, and pathological stimulus. Pharmacological
compounds were used to block channels of human cardiac organoids and were
performed on single organoids in ultra low-adhesive GravityTRAP Plates (InSphero,
Schlieren, Switzerland) at 37 °C. Freshly prepared stock solutions of verapamil (Sigma),
ryanodine, and E-4031 were diluted in the calcium buffer provided in the calcium staining
kit (Life Technologies). Verapamil (0.5 µM), ryanodine (50 µM), and E-4031 (10 µM) added
to the organoids and calcium signal was video captured after 20 mins. Isoproterenol (1
µM) was added for 10 mins before bright field videos were captured. For ischemic
stimulus, microtissues were rinsed in low glucose DMEM (1 g/L) (Gibco) and placed in
agarose molds in serum-free, low glucose (1 g/L) DMEM and 1% O2 (BioSpherix) for 6 hrs
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to examine the initial response. Controls were cultured at normoxia in cell/organoidspecific media.
Statistics Analysis. Differences between experimental groups were analyzed on
JMP Pro 12 Statistical software (SAS, Cary, NC) using Student’s t-test, matched pairs
comparison, one-way ANOVA, and two-way ANOVA with Tukey’s post-hoc test, and
p<0.05 was considered significantly difference for all statistical tests.
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Supporting Information
Figure 3.8.

Figure 3.8. Experimental timeline of human cardiac organoids. Microtissues (cell typespecific spheroids and cardiac organoids) were pre-cultured for 4 days until
experimental Day 0 (D0). Human cardiac organoids began synchronized, spontaneous
beating on D0 and continued throughout the length of the experiment. Microtissues
were collected for analysis on D10.
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Figure 3.9.

Figure 3.9. The ratio of cells in cardiac organoids influences contractile development.
Developing stage ratio organoids, which contains more cardiomyocytes, supported
improved sarcomere formation (α-SA-positive with sarcomeric banding) in contrast to
adult stage ratio organoids at D10 (α-SA-positive without sarcomeric banding); greenalpha sarcomeric actinin (α-SA), blue-DAPI.
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Figure 3.10.

Figure 3.10. Culture media screening using TUNEL staining (green) for apoptotic nuclei
of D0 cardiac organoids showed significantly better viability index throughout the
microtissues using ratiometric media compared to DMEM/F12 with FBS cultured; n=34 organoids. The ratiometric media was a combination of cardiomyocyte media
(DMEM/F12, 10% FBS, 1% non-essential amino acids), fibroblast media (Lonza FGM3), and endothelial cell media (Lonza EGM-2) corresponding to the developing cell
ratio. Blue – DAPI nuclear stain. Cardiac organoids with a developing stage cell ratio
were used for media screening. Asterisk represents significant difference with control,
p <0.05.
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Figure 3.11.

Figure 3.11. Confocal imaging of immunofluorescently stained whole cardiac organoids
(D10) show lumenized vascular network. (A) Method schematic shows that large Zstack confocal images were collected; serial images were taken every 5 µm across 40
µm of Z depth. (B) Serial vWF (red) and DAPI (blue) images (XY plane) every 5 µm
starting at 40 µm from the top of the spheroids show endothelial cell organization.
Arrows indicate regions showing lumen-like structures in X, Y, and Z perspectives seen
in (C). Cardiac organoids were fabricated using a developing stage cell ratio.
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Figure 3.12.

Figure 3.12. Analysis of individual cell types and cardiac organoids regulation of
angiogenic gene expression in human cardiac organoids at D10. (A) VEGFA gene
expression in cardiac organoids was significantly lower than spheroids of hiPSC-CMs,
cFBs, and hADSCs alone, and significantly higher than that of HUVECs. (B) HUVECs
showed significantly higher levels of VEGFR2 gene expression than all other groups,
while cardiac organoids and hiPSC-CMs showed higher expression than cFBs and
ADSCs. Differences in VEGFA expression between organoids and a ratiometric
theoretical organoid suggested self-regulation of VEGFA signaling between VEGF
providers (hiPSC-CMs, cFBs, hADSCs) and VEGF receivers (HUVECs). Theoretical
organoid expression levels were calculated based on ratiometric combination of gene
expression of the organoid ratio of cell types (50% hiPSC-CM, 29% cFBs, 14% HUVECs,
and 7% hADSCs). Cardiac organoids were fabricated using a developing stage cell ratio;
n=3 experiments; 10-15 microtissues/experiment. hiPSC-CM-human induced
pluripotent stem cell-derived cardiomyocyte, cFB-human adult ventricular cardiac
fibroblast, HUVEC-human umbilical vein endothelial cell, hADSC-human adiposederived stem cell. * significantly higher than remaining, ** significantly different than
remaining, p<0.05.
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Figure 3.13.

Figure 3.13. Evaluation of putative vasculature using an oxygen-reduced environment.
Cardiac organoids were placed in 21% O2 (control) or 10% O2 (oxygen reduction)
starting at D0 until D10 (D0-D10; before formation of putative vasculature) or D10 until
D20 (D10-D20; after formation of putative vasculature). Compared to time-matched
controls at D10 and D20 and vascularized organoids with oxygen reduction, cardiac
organoids without putative vasculature under oxygen reduction showed high presence
of TUNEL apoptosis staining (green); blue-DAPI nuclear stain. Cardiac organoids were
fabricated using a developing stage cell ratio.
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Figure 3.14.

Figure 3.14. Evaluation of putative vasculature using macrotissue assembly. After 10
days of aggregation of five D10 cardiac organoids, the macrotissue reached dimensions
beyond the oxygen tension range of a 100-200 µm radius microtissues. Across all
repeats, there were minimal TUNEL-positive apoptotic nuclei (green); blue-DAPI.
Endothelial vWF-positive (red) staining showed extensive regions of connected,
immunostained endothelial cells (i.e., networks) across the newly formed macrotissue.
Green-alpha sarcomeric actinin, α-SA. Cardiac organoids were fabricated using a
developing stage cell ratio.
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Figure 3.15.

Figure 3.15. Endothelial cell source affect structural functionality. Cardiac organoids
made with human umbilical vein endothelial cells (HUVECs) at a developing stage cell
ratio with human adipose-derived stem cells (hADSCs) show consistently higher
density of vWF-positive (red) cells on D10 compared to cardiac organoids made with
human adipose-derived microvascular endothelial cells (HAMECs) at the same ratio,
while cardiomyocyte organization (green, alpha sarcomeric actinin α-SA-positive) is
consistent between organoids. Both HUVECs and HAMECs show evidence of
endothelial network formation (inset).
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Figure 3.16.

Figure 3.16. Both hiPSC-CM spheroids and cardiac organoids showed
immunofluorescent expression of laminin that did not change significantly over time.
Quantification of ECM components was based on the ratio of ECM-positive covered
area divided by total spheroid area; n=3-6 microtissues. Cardiac organoids with a
developing stage cell ratio were used for media screening. hiPSC-CM-human induced
pluripotent stem cell-derived cardiomyocyte.
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Figure 3.17.

Figure 3.17. Human cardiac organoids support contractile development of hiPSC-CMs.
(A) Cardiac organoids at D10 showed a higher occurrence of the observed extended Zline width (> 10 µm) across different spheroids and experiments. hiPSC-CM spheroids:
n=3 experiments; cardiac organoids: n=5 experiments. (B) Cardiac organoids showed
increased adult cardiac troponin I (cTnI)-positive and (C) ventricular myosin light chain
(MLC-2v)-positive fraction area over α-sarcomeric actinin (α-SA)-positive area (hiPSCCM-specific areas) at D10, represented by low and high magnification
immunofluorescent images, n=3 microtissues. hiPSC-CM-human induced pluripotent
stem cell-derived cardiomyocyte. Cardiac organoids were fabricated using a developing
stage ratio of cells.
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Figure 3.18.

Figure 3.18. Functional analysis of human cardiac organoids and hiPSC-CM spheroids.
(A) At D10, cardiac organoids showed a significantly lower contraction amplitude (i.e.,
fractional area change) than spheroids of 100% hiPSC-CM (hiPSC-CM spheroids); n=2841 microtissues. (B) Cardiac organoids and hiPSC-CM spheroids showed similar beat
rates (beats per minute) on D10; n=23-31 microtissues. Cardiac organoids were
fabricated using a developing stage cell ratio. Asterisk represents significant difference,
p<0.05.
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Figure 3.19.

Figure 3.19. Response of individual cell types to ischemia on D10. (A) hiPSC-CM and cFB
spheroids showed significant increases in VEGFA gene expression in response to 6 hrs
of ischemia (1 g/L glucose, serum-free, 1% O2), contributing to the significant increase
in cardiac organoid expression. (B) cFB-only spheroids showed significant increase in IL6
gene expression. Cardiac organoids were fabricated using a developing stage cell ratio;
n=3 experiments; 10-15 microtissues/experiment. Asterisk represents significant
difference with control, p <0.05.
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CHAPTER FIVE
FUTURE DIRECTION AND OUTLOOK
The development of biomimetic models for cardiac tissue requires the
appropriate understanding of the biological system and necessary strategies to
recapitulate those processes. Throughout this exploration, I gained a unique perspective
into multiple dimensions of biomimicry, from extracellular matrix interactions, to
electrically compatible strategies, and mechanisms of multi-cellular self-assembly. With
an understanding of the strengths of each biomimetic approach, these strategies can be
leveraged for applications in basic research, drug discovery, and cell therapy. As heart
failure poses an imminent challenge to human health, future directions will consist of
adapting these approaches to enhance our understanding of cardiac tissue physiology
and self-assembly, to model cardiac pathological conditions, and to advance the current
cell delivery vehicle for heart repair.
The exploration presented here contributes to the growing knowledge of scaffoldbased and scaffold-free tissue-engineered constructs. With extracellular matrix
remodeling being a hallmark of heart failure pathology, the use of tunable materials, such
as functionalized alginate or electrically conductive silicon nanowires, may provide an
adaptable tool to investigate microenvironment-dependent changes in cell behavior.
Furthermore, given the heterogeneous cell-cell interactions, a multicellular 3D cardiac
organoid model not only provides a robust platform to investigate the role of individual
cells but also provides a tissue-level perspective that incorporates innumerable variables,
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such as synergistic signaling mechanisms between cells, to more accurately model the
complex multicellular environment of heart tissue. This avoids false-positive results from
single cell or 2D systems that are later counteracted, for example, by inhibitory signaling
from other cell types within a tissue/organisms. In the end, improvements in the
treatment of heart failure depends on relevant and accurate models. Pursuing a better in
vitro cardiac tissue model using hiPSC technology will allow for a humanized, personalized
model that can avoid the disadvantages of single cell systems and translational
discrepancies of animal studies for the next generation of cardiovascular research.

109

REFERENCES
1

2

3
4
5
6

7

8

9

10
11

12

13

Heron, M. et al. Deaths: final data for 2006. National vital statistics reports : from
the Centers for Disease Control and Prevention, National Center for Health
Statistics, National Vital Statistics System 57, 1-134 (2009).
Roger, V. L. et al. Heart disease and stroke statistics--2011 update: a report from
the American Heart Association. Circulation 123, e18-e209,
doi:10.1161/CIR.0b013e3182009701 (2011).
Baroldi, G. Acute coronary occlusion as a cause of myocardial infarct and sudden
coronary heart death. Am J Cardiol 16, 859-880 (1965).
Roberts, W. C. Coronary arteries in fatal acute myocardial infarction. Circulation
45, 215-230 (1972).
Fulton, W. F. Pathological concepts in acute coronary thrombosis: relevance to
treatment. Br Heart J 70, 403-408 (1993).
Kikuchi, K. & Poss, K. D. Cardiac regenerative capacity and mechanisms. Annu
Rev Cell Dev Biol 28, 719-741, doi:10.1146/annurev-cellbio-101011-155739
(2012).
Laflamme, M. A. et al. Cardiomyocytes derived from human embryonic stem
cells in pro-survival factors enhance function of infarcted rat hearts. Nature
biotechnology 25, 1015-1024, doi:10.1038/nbt1327 (2007).
Mignone, J. L., Kreutziger, K. L., Paige, S. L. & Murry, C. E. Cardiogenesis from
human embryonic stem cells. Circulation journal : official journal of the Japanese
Circulation Society 74, 2517-2526 (2010).
Hirt, M. N., Hansen, A. & Eschenhagen, T. Cardiac tissue engineering: state of the
art. Circulation research 114, 354-367, doi:10.1161/CIRCRESAHA.114.300522
(2014).
Liau, B., Zhang, D. & Bursac, N. Functional cardiac tissue engineering.
Regenerative medicine 7, 187-206, doi:10.2217/rme.11.122 (2012).
Vunjak-Novakovic, G. et al. Challenges in cardiac tissue engineering. Tissue
engineering. Part B, Reviews 16, 169-187, doi:10.1089/ten.TEB.2009.0352
(2010).
Prowse, A. B. et al. Transforming the promise of pluripotent stem cell-derived
cardiomyocytes to a therapy: challenges and solutions for clinical trials. The
Canadian journal of cardiology 30, 1335-1349, doi:10.1016/j.cjca.2014.08.005
(2014).
Barad, L., Schick, R., Zeevi-Levin, N., Itskovitz-Eldor, J. & Binah, O. Human
embryonic stem cells vs human induced pluripotent stem cells for cardiac repair.
The Canadian journal of cardiology 30, 1279-1287,
doi:10.1016/j.cjca.2014.06.023 (2014).

110

14

15

16
17

18

19

20

21

22

23

24

25

26

Chong, J. J. et al. Human embryonic-stem-cell-derived cardiomyocytes
regenerate non-human primate hearts. Nature, doi:10.1038/nature13233
(2014).
Lian, X. et al. Robust cardiomyocyte differentiation from human pluripotent stem
cells via temporal modulation of canonical Wnt signaling. Proceedings of the
National Academy of Sciences of the United States of America,
doi:10.1073/pnas.1200250109 (2012).
Burridge, P. W. et al. Chemically defined generation of human cardiomyocytes.
Nature methods 11, 855-860, doi:10.1038/nmeth.2999 (2014).
Ye, L. et al. Cardiac repair in a porcine model of acute myocardial infarction with
human induced pluripotent stem cell-derived cardiovascular cells. Cell stem cell
15, 750-761, doi:10.1016/j.stem.2014.11.009 (2014).
Zwi-Dantsis, L. et al. Derivation and cardiomyocyte differentiation of induced
pluripotent stem cells from heart failure patients. European heart journal 34,
1575-1586, doi:10.1093/eurheartj/ehs096 (2013).
Bolli, R. et al. Myocardial protection at a crossroads: the need for translation into
clinical therapy. Circulation research 95, 125-134,
doi:10.1161/01.RES.0000137171.97172.d7 (2004).
Gheorghiade, M. et al. Developing New Treatments for Heart Failure: Focus on
the Heart. Circulation. Heart failure 9,
doi:10.1161/CIRCHEARTFAILURE.115.002727 (2016).
Nunes, S. S. et al. Biowire: a platform for maturation of human pluripotent stem
cell-derived cardiomyocytes. Nature methods 10, 781-787,
doi:10.1038/nmeth.2524 (2013).
Lundy, S. D., Zhu, W. Z., Regnier, M. & Laflamme, M. A. Structural and Functional
Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells. Stem
cells and development, doi:10.1089/scd.2012.0490 (2013).
Lieu, D. K. et al. Mechanism-based facilitated maturation of human pluripotent
stem cell-derived cardiomyocytes. Circ Arrhythm Electrophysiol 6, 191-201,
doi:10.1161/CIRCEP.111.973420 (2013).
van den Heuvel, N. H., van Veen, T. A., Lim, B. & Jonsson, M. K. Lessons from the
heart: mirroring electrophysiological characteristics during cardiac development
to in vitro differentiation of stem cell derived cardiomyocytes. Journal of
molecular and cellular cardiology 67, 12-25, doi:10.1016/j.yjmcc.2013.12.011
(2014).
Kensah, G. et al. Murine and human pluripotent stem cell-derived cardiac bodies
form contractile myocardial tissue in vitro. European heart journal 34, 11341146, doi:10.1093/eurheartj/ehs349 (2013).
Zhang, D. et al. Tissue-engineered cardiac patch for advanced functional
maturation of human ESC-derived cardiomyocytes. Biomaterials 34, 5813-5820,
doi:10.1016/j.biomaterials.2013.04.026 (2013).

111

27

28

29
30

31

32

33

34

35

36

37

38

39

Mihic, A. et al. The effect of cyclic stretch on maturation and 3D tissue formation
of human embryonic stem cell-derived cardiomyocytes. Biomaterials,
doi:10.1016/j.biomaterials.2013.12.052 (2014).
Desroches, B. R. et al. Functional scaffold-free 3-D cardiac microtissues: a novel
model for the investigation of heart cells. American journal of physiology. Heart
and circulatory physiology 302, H2031-2042, doi:10.1152/ajpheart.00743.2011
(2012).
Kelm, J. M. et al. Design of artificial myocardial microtissues. Tissue Eng 10, 201214, doi:10.1089/107632704322791853 (2004).
Yang, X., Pabon, L. & Murry, C. E. Engineering adolescence: maturation of human
pluripotent stem cell-derived cardiomyocytes. Circulation research 114, 511-523,
doi:10.1161/CIRCRESAHA.114.300558 (2014).
Reinecke, H., Zhang, M., Bartosek, T. & Murry, C. E. Survival, integration, and
differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts.
Circulation 100, 193-202 (1999).
Bian, W., Badie, N., Himel, H. D. t. & Bursac, N. Robust T-tubulation and
maturation of cardiomyocytes using tissue-engineered epicardial mimetics.
Biomaterials 35, 3819-3828, doi:10.1016/j.biomaterials.2014.01.045 (2014).
Radisic, M. et al. Biomimetic approach to cardiac tissue engineering: oxygen
carriers and channeled scaffolds. Tissue Eng 12, 2077-2091,
doi:10.1089/ten.2006.12.2077 (2006).
Feric, N. T. & Radisic, M. Maturing human pluripotent stem cell-derived
cardiomyocytes in human engineered cardiac tissues. Adv Drug Deliv Rev 96,
110-134, doi:10.1016/j.addr.2015.04.019 (2016).
Hirt, M. N. et al. Functional improvement and maturation of rat and human
engineered heart tissue by chronic electrical stimulation. Journal of molecular
and cellular cardiology 74, 151-161, doi:10.1016/j.yjmcc.2014.05.009 (2014).
Godier-Furnemont, A. F. et al. Physiologic force-frequency response in
engineered heart muscle by electromechanical stimulation. Biomaterials 60, 8291, doi:10.1016/j.biomaterials.2015.03.055 (2015).
Radisic, M. et al. Functional assembly of engineered myocardium by electrical
stimulation of cardiac myocytes cultured on scaffolds. Proceedings of the
National Academy of Sciences of the United States of America 101, 18129-18134,
doi:10.1073/pnas.0407817101 (2004).
Baumgartner, S. et al. Electrophysiological and morphological maturation of
murine fetal cardiomyocytes during electrical stimulation in vitro. Journal of
cardiovascular pharmacology and therapeutics 20, 104-112,
doi:10.1177/1074248414536273 (2015).
Eng, G. et al. Autonomous beating rate adaptation in human stem cell-derived
cardiomyocytes. Nature communications 7, 10312, doi:10.1038/ncomms10312
(2016).

112

40

41
42

43
44

45

46
47

48
49

50

51

52

53

Tandon, N. et al. Optimization of electrical stimulation parameters for cardiac
tissue engineering. Journal of tissue engineering and regenerative medicine 5,
e115-125, doi:10.1002/term.377 (2011).
Tandon, N. et al. Electrical stimulation systems for cardiac tissue engineering.
Nat Protoc 4, 155-173, doi:10.1038/nprot.2008.183 (2009).
Maidhof, R. et al. Biomimetic perfusion and electrical stimulation applied in
concert improved the assembly of engineered cardiac tissue. Journal of tissue
engineering and regenerative medicine 6, e12-23, doi:10.1002/term.525 (2012).
Dvir, T. et al. Nanowired three-dimensional cardiac patches. Nature
nanotechnology 6, 720-725, doi:10.1038/nnano.2011.160 (2011).
Shin, S. R. et al. Carbon-nanotube-embedded hydrogel sheets for engineering
cardiac constructs and bioactuators. ACS nano 7, 2369-2380,
doi:10.1021/nn305559j (2013).
Tan, Y. et al. Silicon nanowire-induced maturation of cardiomyocytes derived
from human induced pluripotent stem cells. Nano letters 15, 2765-2772,
doi:10.1021/nl502227a (2015).
Mathur, A. et al. Human iPSC-based Cardiac Microphysiological System For Drug
Screening Applications. Scientific reports 5, 8883, doi:10.1038/srep08883 (2015).
Mihic, A. et al. The effect of cyclic stretch on maturation and 3D tissue formation
of human embryonic stem cell-derived cardiomyocytes. Biomaterials 35, 27982808, doi:10.1016/j.biomaterials.2013.12.052 (2014).
Mannhardt, I. et al. Human Engineered Heart Tissue: Analysis of Contractile
Force. Stem cell reports 7, 29-42, doi:10.1016/j.stemcr.2016.04.011 (2016).
Richards, D. J. et al. Nanowires and Electrical Stimulation Synergistically Improve
Functions of hiPSC Cardiac Spheroids. Nano letters 16, 4670-4678,
doi:10.1021/acs.nanolett.6b02093 (2016).
Thavandiran, N. et al. Design and formulation of functional pluripotent stem cellderived cardiac microtissues. Proceedings of the National Academy of Sciences of
the United States of America 110, E4698-4707, doi:10.1073/pnas.1311120110
(2013).
Stevens, K. R. et al. Physiological function and transplantation of scaffold-free
and vascularized human cardiac muscle tissue. Proceedings of the National
Academy of Sciences of the United States of America 106, 16568-16573,
doi:10.1073/pnas.0908381106 (2009).
Ronaldson-Bouchard, K. et al. Advanced maturation of human cardiac tissue
grown from pluripotent stem cells. Nature 556, 239-243, doi:10.1038/s41586018-0016-3 (2018).
Hussain, A., Collins, G., Yip, D. & Cho, C. H. Functional 3-D cardiac co-culture
model using bioactive chitosan nanofiber scaffolds. Biotechnology and
bioengineering 110, 637-647, doi:10.1002/bit.24727 (2013).

113

54

55

56

57
58

59
60

61

62

63
64

65

66
67

Nichol, J. W., Engelmayr, G. C., Jr., Cheng, M. & Freed, L. E. Co-culture induces
alignment in engineered cardiac constructs via MMP-2 expression. Biochemical
and biophysical research communications 373, 360-365,
doi:10.1016/j.bbrc.2008.06.019 (2008).
Saini, H., Navaei, A., Van Putten, A. & Nikkhah, M. 3D cardiac microtissues
encapsulated with the co-culture of cardiomyocytes and cardiac fibroblasts.
Advanced healthcare materials 4, 1961-1971, doi:10.1002/adhm.201500331
(2015).
Baker, L. A., Tiriac, H., Clevers, H. & Tuveson, D. A. Modeling pancreatic cancer
with organoids. Trends Cancer 2, 176-190, doi:10.1016/j.trecan.2016.03.004
(2016).
Clevers, H. Modeling Development and Disease with Organoids. Cell 165, 15861597, doi:10.1016/j.cell.2016.05.082 (2016).
Lancaster, M. A. & Knoblich, J. A. Organogenesis in a dish: modeling
development and disease using organoid technologies. Science 345, 1247125,
doi:10.1126/science.1247125 (2014).
McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart
failure. N Engl J Med 371, 993-1004, doi:10.1056/NEJMoa1409077 (2014).
Sacks, C. A., Jarcho, J. A. & Curfman, G. D. Paradigm shifts in heart-failure
therapy--a timeline. N Engl J Med 371, 989-991, doi:10.1056/NEJMp1410241
(2014).
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical
development success rates for investigational drugs. Nat Biotechnol 32, 40-51,
doi:10.1038/nbt.2786 (2014).
Fine, B. & Vunjak-Novakovic, G. Shortcomings of Animal Models and the Rise of
Engineered Human Cardiac Tissue. Acs Biomater Sci Eng 3, 1884-1897,
doi:10.1021/acsbiomaterials.6b00662 (2017).
Kaye, D. M. & Krum, H. Drug discovery for heart failure: a new era or the end of
the pipeline? Nat Rev Drug Discov 6, 127-139, doi:10.1038/nrd2219 (2007).
Klocke, R., Tian, W., Kuhlmann, M. T. & Nikol, S. Surgical animal models of heart
failure related to coronary heart disease. Cardiovascular research 74, 29-38,
doi:10.1016/j.cardiores.2006.11.026 (2007).
Piacentino, V., 3rd et al. Cellular basis of abnormal calcium transients of failing
human ventricular myocytes. Circulation research 92, 651-658,
doi:10.1161/01.RES.0000062469.83985.9B (2003).
Bers, D. M. Calcium fluxes involved in control of cardiac myocyte contraction.
Circulation research 87, 275-281 (2000).
Blinova, K. et al. Comprehensive Translational Assessment of Human-Induced
Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced
Arrhythmias. Toxicological sciences : an official journal of the Society of
Toxicology 155, 234-247, doi:10.1093/toxsci/kfw200 (2017).

114

68

69

70
71
72

73

74

75

76
77

78

79

80

81

Fermini, B. et al. A New Perspective in the Field of Cardiac Safety Testing through
the Comprehensive In Vitro Proarrhythmia Assay Paradigm. J. Biomol. Screen. 21,
1-11, doi:10.1177/1087057115594589 (2016).
Sager, P. T., Gintant, G., Turner, J. R., Pettit, S. & Stockbridge, N. Rechanneling
the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac
Safety Research Consortium. Am Heart J 167, 292-300,
doi:10.1016/j.ahj.2013.11.004 (2014).
ICH. (2005).
ICH. (2005).
Redfern, W. S. et al. Relationships between preclinical cardiac electrophysiology,
clinical QT interval prolongation and torsade de pointes for a broad range of
drugs: evidence for a provisional safety margin in drug development.
Cardiovascular research 58, 32-45 (2003).
Laverty, H. et al. How can we improve our understanding of cardiovascular safety
liabilities to develop safer medicines? Br J Pharmacol 163, 675-693,
doi:10.1111/j.1476-5381.2011.01255.x (2011).
Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical
industry's grand challenge. Nat Rev Drug Discov 9, 203-214,
doi:10.1038/nrd3078 (2010).
Takahashi, K. et al. Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell 131, 861-872, doi:10.1016/j.cell.2007.11.019
(2007).
Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells.
Science 318, 1917-1920, doi:10.1126/science.1151526 (2007).
Yoshida, Y. & Yamanaka, S. iPS cells: a source of cardiac regeneration. Journal of
molecular and cellular cardiology 50, 327-332, doi:10.1016/j.yjmcc.2010.10.026
(2011).
Spencer, C. I. et al. Calcium transients closely reflect prolonged action potentials
in iPSC models of inherited cardiac arrhythmia. Stem cell reports 3, 269-281,
doi:10.1016/j.stemcr.2014.06.003 (2014).
Yokoo, N. et al. The effects of cardioactive drugs on cardiomyocytes derived
from human induced pluripotent stem cells. Biochemical and biophysical
research communications 387, 482-488, doi:10.1016/j.bbrc.2009.07.052 (2009).
Tanaka, T. et al. In vitro pharmacologic testing using human induced pluripotent
stem cell-derived cardiomyocytes. Biochemical and biophysical research
communications 385, 497-502, doi:10.1016/j.bbrc.2009.05.073 (2009).
Gibson, J. K., Yue, Y., Bronson, J., Palmer, C. & Numann, R. Human stem cellderived cardiomyocytes detect drug-mediated changes in action potentials and
ion currents. J Pharmacol Toxicol Methods 70, 255-267,
doi:10.1016/j.vascn.2014.09.005 (2014).

115

82

83

84

85

86

87
88
89
90
91

92
93

94

95

96

Ma, J. et al. High purity human-induced pluripotent stem cell-derived
cardiomyocytes: electrophysiological properties of action potentials and ionic
currents. American journal of physiology. Heart and circulatory physiology 301,
H2006-2017, doi:10.1152/ajpheart.00694.2011 (2011).
Maddah, M. et al. A Non-invasive Platform for Functional Characterization of
Stem-Cell-Derived Cardiomyocytes with Applications in Cardiotoxicity Testing.
Stem cell reports, doi:10.1016/j.stemcr.2015.02.007 (2015).
Kaneko, T. et al. On-chip in vitro cell-network pre-clinical cardiac toxicity using
spatiotemporal human cardiomyocyte measurement on a chip. Scientific reports
4, 4670, doi:10.1038/srep04670 (2014).
Hansen, A. et al. Development of a drug screening platform based on engineered
heart tissue. Circulation research 107, 35-44,
doi:10.1161/CIRCRESAHA.109.211458 (2010).
Boudou, T. et al. A microfabricated platform to measure and manipulate the
mechanics of engineered cardiac microtissues. Tissue engineering. Part A 18,
910-919, doi:10.1089/ten.TEA.2011.0341 (2012).
Brandenburger, M. et al. Organotypic slice culture from human adult ventricular
myocardium. Cardiovascular research 93, 50-59, doi:10.1093/cvr/cvr259 (2012).
Sinha, G. The organoid architect. Science 357, 746-749,
doi:10.1126/science.357.6353.746 (2017).
Lancaster, M. A. et al. Cerebral organoids model human brain development and
microcephaly. Nature 501, 373-379, doi:10.1038/nature12517 (2013).
Dekkers, J. F. et al. A functional CFTR assay using primary cystic fibrosis intestinal
organoids. Nat Med 19, 939-945, doi:10.1038/nm.3201 (2013).
Schwank, G. et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem
cell organoids of cystic fibrosis patients. Cell stem cell 13, 653-658,
doi:10.1016/j.stem.2013.11.002 (2013).
Chakradhar, S. Put to the test: Organoid-based testing becomes a clinical tool.
Nat Med 23, 796-799, doi:10.1038/nm0717-796 (2017).
Triedman, J. K. & Newburger, J. W. Trends in Congenital Heart Disease: The Next
Decade. Circulation 133, 2716-2733, doi:10.1161/CIRCULATIONAHA.116.023544
(2016).
Benjamin, E. J. et al. Heart Disease and Stroke Statistics-2017 Update: A Report
From the American Heart Association. Circulation 135, e146-e603,
doi:10.1161/CIR.0000000000000485 (2017).
Chanana, A. M., Rhee, J. W. & Wu, J. C. Human-induced pluripotent stem cell
approaches to model inborn and acquired metabolic heart diseases. Curr Opin
Cardiol 31, 266-274, doi:10.1097/HCO.0000000000000277 (2016).
Liang, P. et al. Drug screening using a library of human induced pluripotent stem
cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Circulation 127, 1677-1691, doi:10.1161/CIRCULATIONAHA.113.001883 (2013).

116

97

98

99

100

101

102

103
104

105

106
107

108

109

Lodola, F. et al. Adeno-associated virus-mediated CASQ2 delivery rescues
phenotypic alterations in a patient-specific model of recessive catecholaminergic
polymorphic ventricular tachycardia. Cell Death Dis 7, e2393,
doi:10.1038/cddis.2016.304 (2016).
Ma, D. et al. Generation of patient-specific induced pluripotent stem cell-derived
cardiomyocytes as a cellular model of arrhythmogenic right ventricular
cardiomyopathy. European heart journal 34, 1122-1133,
doi:10.1093/eurheartj/ehs226 (2013).
Matsa, E. et al. Transcriptome Profiling of Patient-Specific Human iPSCCardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro.
Cell stem cell 19, 311-325, doi:10.1016/j.stem.2016.07.006 (2016).
Oh, Y., Wei, H., Ma, D., Sun, X. & Liew, R. Clinical applications of patient-specific
induced pluripotent stem cells in cardiovascular medicine. Heart 98, 443-449,
doi:10.1136/heartjnl-2011-301317 (2012).
Sun, N. et al. Patient-specific induced pluripotent stem cells as a model for
familial dilated cardiomyopathy. Science translational medicine 4, 130ra147,
doi:10.1126/scitranslmed.3003552 (2012).
Wang, G. et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome
with induced pluripotent stem cell and heart-on-chip technologies. Nat Med 20,
616-623, doi:10.1038/nm.3545 (2014).
Segers, V. F. & Lee, R. T. Stem-cell therapy for cardiac disease. Nature 451, 937942, doi:10.1038/nature06800 (2008).
Oh, S. I. et al. Technological progress in generation of induced pluripotent stem
cells for clinical applications. ScientificWorldJournal 2012, 417809,
doi:10.1100/2012/417809 (2012).
Hodgson, D. M. et al. Stable benefit of embryonic stem cell therapy in myocardial
infarction. American journal of physiology. Heart and circulatory physiology 287,
H471-479, doi:10.1152/ajpheart.01247.2003 (2004).
Min, J. Y. et al. Transplantation of embryonic stem cells improves cardiac
function in postinfarcted rats. J Appl Physiol (1985) 92, 288-296 (2002).
Min, J. Y. et al. Long-term improvement of cardiac function in rats after
infarction by transplantation of embryonic stem cells. J Thorac Cardiovasc Surg
125, 361-369, doi:10.1067/mtc.2003.101 (2003).
Singla, D. K. et al. Transplantation of embryonic stem cells into the infarcted
mouse heart: formation of multiple cell types. Journal of molecular and cellular
cardiology 40, 195-200, doi:10.1016/j.yjmcc.2005.09.001 (2006).
Nussbaum, J. et al. Transplantation of undifferentiated murine embryonic stem
cells in the heart: teratoma formation and immune response. FASEB journal :
official publication of the Federation of American Societies for Experimental
Biology 21, 1345-1357, doi:10.1096/fj.06-6769com (2007).

117

110

111

112

113

114

115

116

117

118

119

120

Swijnenburg, R. J. et al. Embryonic stem cell immunogenicity increases upon
differentiation after transplantation into ischemic myocardium. Circulation 112,
I166-172, doi:10.1161/CIRCULATIONAHA.104.525824 (2005).
Caspi, O. et al. Transplantation of human embryonic stem cell-derived
cardiomyocytes improves myocardial performance in infarcted rat hearts.
Journal of the American College of Cardiology 50, 1884-1893,
doi:10.1016/j.jacc.2007.07.054 (2007).
Bearzi, C. et al. Human cardiac stem cells. Proceedings of the National Academy
of Sciences of the United States of America 104, 14068-14073,
doi:10.1073/pnas.0706760104 (2007).
Menard, C. et al. Transplantation of cardiac-committed mouse embryonic stem
cells to infarcted sheep myocardium: a preclinical study. Lancet 366, 1005-1012,
doi:10.1016/S0140-6736(05)67380-1 (2005).
Lee, S. T. et al. Intramyocardial injection of autologous cardiospheres or
cardiosphere-derived cells preserves function and minimizes adverse ventricular
remodeling in pigs with heart failure post-myocardial infarction. Journal of the
American College of Cardiology 57, 455-465, doi:10.1016/j.jacc.2010.07.049
(2011).
Behfar, A., Crespo-Diaz, R., Terzic, A. & Gersh, B. J. Cell therapy for cardiac repair-lessons from clinical trials. Nat Rev Cardiol 11, 232-246,
doi:10.1038/nrcardio.2014.9 (2014).
Bartunek, J. et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE
(Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial
with lineage-specified biologics. Journal of the American College of Cardiology
61, 2329-2338, doi:10.1016/j.jacc.2013.02.071 (2013).
Kehat, I. et al. Electromechanical integration of cardiomyocytes derived from
human embryonic stem cells. Nat Biotechnol 22, 1282-1289,
doi:10.1038/nbt1014 (2004).
Xue, T. et al. Functional integration of electrically active cardiac derivatives from
genetically engineered human embryonic stem cells with quiescent recipient
ventricular cardiomyocytes: insights into the development of cell-based
pacemakers. Circulation 111, 11-20, doi:10.1161/01.CIR.0000151313.18547.A2
(2005).
Laflamme, M. A. et al. Formation of human myocardium in the rat heart from
human embryonic stem cells. The American journal of pathology 167, 663-671,
doi:10.1016/S0002-9440(10)62041-X (2005).
Chong, J. J. et al. Human embryonic-stem-cell-derived cardiomyocytes
regenerate non-human primate hearts. Nature 510, 273-277,
doi:10.1038/nature13233 (2014).

118

121

122

123

124

125

126
127

128
129

130
131

132

133

Anderson, M. E., Goldhaber, J., Houser, S. R., Puceat, M. & Sussman, M. A.
Embryonic stem cell-derived cardiac myocytes are not ready for human trials.
Circulation research 115, 335-338, doi:10.1161/CIRCRESAHA.114.304616 (2014).
Winter, E. M. et al. A new direction for cardiac regeneration therapy: application
of synergistically acting epicardium-derived cells and cardiomyocyte progenitor
cells. Circulation. Heart failure 2, 643-653,
doi:10.1161/CIRCHEARTFAILURE.108.843722 (2009).
Williams, A. R. et al. Enhanced effect of combining human cardiac stem cells and
bone marrow mesenchymal stem cells to reduce infarct size and to restore
cardiac function after myocardial infarction. Circulation 127, 213-223,
doi:10.1161/CIRCULATIONAHA.112.131110 (2013).
Lee, W. Y. et al. Vascularization and restoration of heart function in rat
myocardial infarction using transplantation of human cbMSC/HUVEC core-shell
bodies. Biomaterials 33, 2127-2136, doi:10.1016/j.biomaterials.2011.11.059
(2012).
Kim, J. H. et al. Therapeutic angiogenesis of three-dimensionally cultured
adipose-derived stem cells in rat infarcted hearts. Cytotherapy 15, 542-556,
doi:10.1016/j.jcyt.2012.11.016 (2013).
Quijada, P. et al. Cardiac Stem Cell Hybrids Enhance Myocardial Repair.
Circulation research 117, 695-706, doi:10.1161/CIRCRESAHA.115.306838 (2015).
Lee, M. & Wu, B. M. Recent advances in 3D printing of tissue engineering
scaffolds. Methods in molecular biology 868, 257-267, doi:10.1007/978-1-61779764-4_15 (2012).
Mandrycky, C., Wang, Z., Kim, K. & Kim, D. H. 3D bioprinting for engineering
complex tissues. Biotechnol Adv, doi:10.1016/j.biotechadv.2015.12.011 (2015).
Mironov, V., Kasyanov, V. & Markwald, R. R. Organ printing: from bioprinter to
organ biofabrication line. Curr Opin Biotechnol 22, 667-673,
doi:10.1016/j.copbio.2011.02.006 (2011).
Murphy, S. V. & Atala, A. 3D bioprinting of tissues and organs. Nat Biotechnol 32,
773-785, doi:10.1038/nbt.2958 (2014).
Yeong, W. Y., Chua, C. K., Leong, K. F. & Chandrasekaran, M. Rapid prototyping in
tissue engineering: challenges and potential. Trends Biotechnol 22, 643-652,
doi:10.1016/j.tibtech.2004.10.004 (2004).
Visconti, R. P. et al. Towards organ printing: engineering an intra-organ branched
vascular tree. Expert Opin Biol Ther 10, 409-420,
doi:10.1517/14712590903563352 (2010).
Fedorovich, N. E., Alblas, J., Hennink, W. E., Oner, F. C. & Dhert, W. J. Organ
printing: the future of bone regeneration? Trends Biotechnol 29, 601-606,
doi:10.1016/j.tibtech.2011.07.001 (2011).

119

134

135

136

137

138

139

140

141
142
143
144

145
146
147

148

Kim, S. S. et al. Survival and function of hepatocytes on a novel threedimensional synthetic biodegradable polymer scaffold with an intrinsic network
of channels. Ann Surg 228, 8-13 (1998).
Norotte, C., Marga, F. S., Niklason, L. E. & Forgacs, G. Scaffold-free vascular tissue
engineering using bioprinting. Biomaterials 30, 5910-5917,
doi:10.1016/j.biomaterials.2009.06.034 (2009).
Gao, G. & Cui, X. Three-dimensional bioprinting in tissue engineering and
regenerative medicine. Biotechnology letters, doi:10.1007/s10529-015-1975-1
(2015).
Chang, R., Emami, K., Wu, H. & Sun, W. Biofabrication of a three-dimensional
liver micro-organ as an in vitro drug metabolism model. Biofabrication 2,
045004, doi:10.1088/1758-5082/2/4/045004 (2010).
Marga, F. et al. Toward engineering functional organ modules by additive
manufacturing. Biofabrication 4, 022001, doi:10.1088/1758-5082/4/2/022001
(2012).
Xu, T. et al. Hybrid printing of mechanically and biologically improved constructs
for cartilage tissue engineering applications. Biofabrication 5, 015001,
doi:10.1088/1758-5082/5/1/015001 (2013).
Ebrahimkhani, M. R., Young, C. L., Lauffenburger, D. A., Griffith, L. G. &
Borenstein, J. T. Approaches to in vitro tissue regeneration with application for
human disease modeling and drug development. Drug Discov Today 19, 754-762,
doi:10.1016/j.drudis.2014.04.017 (2014).
Griffith, L. G. & Swartz, M. A. Capturing complex 3D tissue physiology in vitro.
Nat Rev Mol Cell Biol 7, 211-224, doi:10.1038/nrm1858 (2006).
Khetani, S. R. & Bhatia, S. N. Engineering tissues for in vitro applications. Curr
Opin Biotechnol 17, 524-531, doi:10.1016/j.copbio.2006.08.009 (2006).
Raimondi, M. T. Engineered tissue as a model to study cell and tissue function
from a biophysical perspective. Curr Drug Discov Technol 3, 245-268 (2006).
Porteus, M. Translating the lessons from gene therapy to the development of
regenerative medicine. Molecular therapy : the journal of the American Society
of Gene Therapy 19, 439-441, doi:10.1038/mt.2011.14 (2011).
Bernstein, B. E., Meissner, A. & Lander, E. S. The mammalian epigenome. Cell
128, 669-681, doi:10.1016/j.cell.2007.01.033 (2007).
Goldberg, A. D., Allis, C. D. & Bernstein, E. Epigenetics: a landscape takes shape.
Cell 128, 635-638, doi:10.1016/j.cell.2007.02.006 (2007).
Marga, F., Neagu, A., Kosztin, I. & Forgacs, G. Developmental biology and tissue
engineering. Birth Defects Res C Embryo Today 81, 320-328,
doi:10.1002/bdrc.20109 (2007).
Lin, H. R. & Yeh, Y. J. Porous alginate/hydroxyapatite composite scaffolds for
bone tissue engineering: preparation, characterization, and in vitro studies. J
Biomed Mater Res B Appl Biomater 71, 52-65, doi:10.1002/jbm.b.30065 (2004).

120

149

150
151

152

153

154
155
156
157

158

159
160

161

162

Nakamura, M., Iwanaga, S., Henmi, C., Arai, K. & Nishiyama, Y. Biomatrices and
biomaterials for future developments of bioprinting and biofabrication.
Biofabrication 2, 014110, doi:10.1088/1758-5082/2/1/014110 (2010).
Rowley, J. A., Madlambayan, G. & Mooney, D. J. Alginate hydrogels as synthetic
extracellular matrix materials. Biomaterials 20, 45-53 (1999).
Yao, R., Zhang, R., Luan, J. & Lin, F. Alginate and alginate/gelatin microspheres
for human adipose-derived stem cell encapsulation and differentiation.
Biofabrication 4, 025007, doi:10.1088/1758-5082/4/2/025007 (2012).
Xu, C., Chai, W., Huang, Y. & Markwald, R. R. Scaffold-free inkjet printing of
three-dimensional zigzag cellular tubes. Biotechnology and bioengineering 109,
3152-3160, doi:10.1002/bit.24591 (2012).
Billiet, T., Vandenhaute, M., Schelfhout, J., Van Vlierberghe, S. & Dubruel, P. A
review of trends and limitations in hydrogel-rapid prototyping for tissue
engineering. Biomaterials 33, 6020-6041,
doi:10.1016/j.biomaterials.2012.04.050 (2012).
Lewis, K. J. & Anseth, K. S. Hydrogel scaffolds to study cell biology in four
dimensions. MRS Bull 38, 260-268, doi:10.1557/mrs.2013.54 (2013).
Badylak, S. F. The extracellular matrix as a scaffold for tissue reconstruction.
Semin. Cell Dev. Biol. 13, 377-383 (2002).
Kim, B. S. & Mooney, D. J. Development of biocompatible synthetic extracellular
matrices for tissue engineering. Trends Biotechnol 16, 224-230 (1998).
Orive, G., Carcaboso, A. M., Hernandez, R. M., Gascon, A. R. & Pedraz, J. L.
Biocompatibility evaluation of different alginates and alginate-based
microcapsules. Biomacromolecules 6, 927-931, doi:10.1021/bm049380x (2005).
Bouhadir, K. H. et al. Degradation of partially oxidized alginate and its potential
application for tissue engineering. Biotechnol Prog 17, 945-950,
doi:10.1021/bp010070p (2001).
Lee, K. Y. & Mooney, D. J. Alginate: properties and biomedical applications. Prog
Polym Sci 37, 106-126, doi:10.1016/j.progpolymsci.2011.06.003 (2012).
Wang, L., Shansky, J., Borselli, C., Mooney, D. & Vandenburgh, H. Design and
fabrication of a biodegradable, covalently crosslinked shape-memory alginate
scaffold for cell and growth factor delivery. Tissue engineering. Part A 18, 20002007, doi:10.1089/ten.TEA.2011.0663 (2012).
Gimble, J. M., Katz, A. J. & Bunnell, B. A. Adipose-derived stem cells for
regenerative medicine. Circulation research 100, 1249-1260,
doi:10.1161/01.RES.0000265074.83288.09 (2007).
Alsberg, E., Anderson, K. W., Albeiruti, A., Rowley, J. A. & Mooney, D. J.
Engineering growing tissues. Proceedings of the National Academy of Sciences of
the United States of America 99, 12025-12030, doi:10.1073/pnas.192291499
(2002).

121

163

164
165
166

167

168

169

170

171

172

173

174

175

176

Boontheekul, T., Kong, H. J. & Mooney, D. J. Controlling alginate gel degradation
utilizing partial oxidation and bimodal molecular weight distribution.
Biomaterials 26, 2455-2465, doi:10.1016/j.biomaterials.2004.06.044 (2005).
Malda, J. et al. 25th anniversary article: Engineering hydrogels for biofabrication.
Adv Mater 25, 5011-5028, doi:10.1002/adma.201302042 (2013).
Derby, B. Printing and prototyping of tissues and scaffolds. Science 338, 921-926,
doi:10.1126/science.1226340 (2012).
Ferris, C. J., Gilmore, K. G., Wallace, G. G. & In het Panhuis, M. Biofabrication: an
overview of the approaches used for printing of living cells. Appl Microbiol
Biotechnol 97, 4243-4258, doi:10.1007/s00253-013-4853-6 (2013).
Blaeser, A. et al. Biofabrication under fluorocarbon: a novel freeform fabrication
technique to generate high aspect ratio tissue-engineered constructs. Biores
Open Access 2, 374-384, doi:10.1089/biores.2013.0031 (2013).
Gaetani, R. et al. Cardiac tissue engineering using tissue printing technology and
human cardiac progenitor cells. Biomaterials 33, 1782-1790,
doi:10.1016/j.biomaterials.2011.11.003 (2012).
Guillotin, B. et al. Laser assisted bioprinting of engineered tissue with high cell
density and microscale organization. Biomaterials 31, 7250-7256,
doi:10.1016/j.biomaterials.2010.05.055 (2010).
Murphy, S. V., Skardal, A. & Atala, A. Evaluation of hydrogels for bio-printing
applications. Journal of biomedical materials research. Part A 101, 272-284,
doi:10.1002/jbm.a.34326 (2013).
Lin, H. et al. Application of visible light-based projection stereolithography for
live cell-scaffold fabrication with designed architecture. Biomaterials 34, 331339, doi:10.1016/j.biomaterials.2012.09.048 (2013).
Schuurman, W. et al. Gelatin-methacrylamide hydrogels as potential
biomaterials for fabrication of tissue-engineered cartilage constructs. Macromol
Biosci 13, 551-561, doi:10.1002/mabi.201200471 (2013).
Fedorovich, N. E., De Wijn, J. R., Verbout, A. J., Alblas, J. & Dhert, W. J. Threedimensional fiber deposition of cell-laden, viable, patterned constructs for bone
tissue printing. Tissue engineering. Part A 14, 127-133,
doi:10.1089/ten.a.2007.0158 (2008).
Fedorovich, N. E. et al. Biofabrication of osteochondral tissue equivalents by
printing topologically defined, cell-laden hydrogel scaffolds. Tissue engineering.
Part C, Methods 18, 33-44, doi:10.1089/ten.TEC.2011.0060 (2012).
Tirella, A., Orsini, A., Vozzi, G. & Ahluwalia, A. A phase diagram for
microfabrication of geometrically controlled hydrogel scaffolds. Biofabrication 1,
045002, doi:10.1088/1758-5082/1/4/045002 (2009).
Bryant, S. J. & Anseth, K. S. Hydrogel properties influence ECM production by
chondrocytes photoencapsulated in poly(ethylene glycol) hydrogels. J Biomed
Mater Res 59, 63-72 (2002).

122

177

178

179

180
181
182

183
184
185

186
187

188
189

190
191

192

Nicodemus, G. D. & Bryant, S. J. Cell encapsulation in biodegradable hydrogels
for tissue engineering applications. Tissue engineering. Part B, Reviews 14, 149165, doi:10.1089/ten.teb.2007.0332 (2008).
Kong, H. J., Kaigler, D., Kim, K. & Mooney, D. J. Controlling rigidity and
degradation of alginate hydrogels via molecular weight distribution.
Biomacromolecules 5, 1720-1727, doi:10.1021/bm049879r (2004).
Kang, K. H., Hockaday, L. A. & Butcher, J. T. Quantitative optimization of solid
freeform deposition of aqueous hydrogels. Biofabrication 5, 035001,
doi:10.1088/1758-5082/5/3/035001 (2013).
Tholpady, S. S. et al. The cellular plasticity of human adipocytes. Ann Plast Surg
54, 651-656 (2005).
Spiegelman, B. M. & Ginty, C. A. Fibronectin modulation of cell shape and
lipogenic gene expression in 3T3-adipocytes. Cell 35, 657-666 (1983).
McBeath, R., Pirone, D. M., Nelson, C. M., Bhadriraju, K. & Chen, C. S. Cell shape,
cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell
6, 483-495 (2004).
Ruoslahti, E. RGD and other recognition sequences for integrins. Annu Rev Cell
Dev Biol 12, 697-715, doi:10.1146/annurev.cellbio.12.1.697 (1996).
D'Souza, S. E., Ginsberg, M. H. & Plow, E. F. Arginyl-glycyl-aspartic acid (RGD): a
cell adhesion motif. Trends Biochem. Sci. 16, 246-250 (1991).
Pfaff, M. et al. Selective recognition of cyclic RGD peptides of NMR defined
conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins.
The Journal of biological chemistry 269, 20233-20238 (1994).
Zuk, P. A. et al. Human adipose tissue is a source of multipotent stem cells. Mol
Biol Cell 13, 4279-4295, doi:10.1091/mbc.E02-02-0105 (2002).
Zuk, P. A. et al. Multilineage cells from human adipose tissue: implications for
cell-based therapies. Tissue Eng 7, 211-228, doi:10.1089/107632701300062859
(2001).
Zhu, Y. et al. Adipose-derived stem cell: a better stem cell than BMSC. Cell
biochemistry and function 26, 664-675, doi:10.1002/cbf.1488 (2008).
Matsuoka, F. et al. Morphology-based prediction of osteogenic differentiation
potential of human mesenchymal stem cells. PloS one 8, e55082,
doi:10.1371/journal.pone.0055082 (2013).
Hauselmann, H. J. et al. Phenotypic stability of bovine articular chondrocytes
after long-term culture in alginate beads. J Cell Sci 107 ( Pt 1), 17-27 (1994).
Stains, J. P. & Civitelli, R. Cell-cell interactions in regulating osteogenesis and
osteoblast function. Birth Defects Res C Embryo Today 75, 72-80,
doi:10.1002/bdrc.20034 (2005).
Benton, J. A., Fairbanks, B. D. & Anseth, K. S. Characterization of valvular
interstitial cell function in three dimensional matrix metalloproteinase

123

193

194
195
196
197
198

199

200

201
202
203
204
205

206
207

208

degradable PEG hydrogels. Biomaterials 30, 6593-6603,
doi:10.1016/j.biomaterials.2009.08.031 (2009).
Yellowley, C. E., Hancox, J. C. & Donahue, H. J. Effects of cell swelling on
intracellular calcium and membrane currents in bovine articular chondrocytes.
Journal of cellular biochemistry 86, 290-301, doi:10.1002/jcb.10217 (2002).
Pataky, K. et al. Microdrop printing of hydrogel bioinks into 3D tissue-like
geometries. Adv Mater 24, 391-396, doi:10.1002/adma.201102800 (2012).
Hollister, S. J. Porous scaffold design for tissue engineering. Nat Mater 4, 518524, doi:10.1038/nmat1421 (2005).
Langer, R. & Vacanti, J. P. Tissue engineering. Science 260, 920-926 (1993).
Mironov, V. et al. Organ printing: tissue spheroids as building blocks.
Biomaterials 30, 2164-2174, doi:10.1016/j.biomaterials.2008.12.084 (2009).
Tan, Y. et al. Cell number per spheroid and electrical conductivity of nanowires
influence the function of silicon nanowired human cardiac spheroids. Acta
Biomater 51, 495-504, doi:10.1016/j.actbio.2017.01.029 (2017).
Schmidt, V., Wittemann, J. V., Senz, S. & Gosele, U. Silicon Nanowires: A Review
on Aspects of their Growth and their Electrical Properties. Adv Mater 21, 26812702 (2009).
Tian, B. & Lieber, C. M. Synthetic nanoelectronic probes for biological cells and
tissues. Annual review of analytical chemistry 6, 31-51, doi:10.1146/annurevanchem-062012-092623 (2013).
Zheng, G. F., Lu, W., Jin, S. & Lieber, C. M. Synthesis and fabrication of high
performace n-type silison nanowire transistors. Adv Mater 16, 1890-1893 (2004).
Mazzoleni, A. P., Sisken, B. F. & Kahler, R. L. Conductivity values of tissue culture
medium from 20 degrees C to 40 degrees C. Bioelectromagnetics 7, 95-99 (1986).
Garipcan, B. et al. In Vitro Biocompatibility of n-Type and Undoped Silicon
Nanowires. Adv. Eng. Mater. 13, B3-B9 (2009).
Zimmerman, J. F. et al. Cellular uptake and dynamics of unlabeled freestanding
silicon nanowires. Sci Adv 2, e1601039, doi:10.1126/sciadv.1601039 (2016).
Jiang, K. et al. Medicinal surface modification of silicon nanowires: impact on
calcification and stromal cell proliferation. ACS applied materials & interfaces 1,
266-269, doi:10.1021/am800219r (2009).
Nagesha, D. K., Whitehead, M. A. & Coffer, J. L. Biorelevant Calcification and
Non-Cytotoxic Behavior in Silicon Nanowires. Adv Mater 17, 921-924 (2005).
Anderson, S. H. C., Elliott, H., Wallis, D. J., Canham, L. T. & Powell, J. J. Dissolution
of different forms of partially porous silicon wafers under simulated physiological
conditions. phys. stat. sol (a) 197, 331-335 (2003).
Zhou, W. et al. Long term stability of nanowire nanoelectronics in physiological
environments. Nano letters 14, 1614-1619, doi:10.1021/nl500070h (2014).

124

209

210

211

212

213

214

215
216

217

218

219

220
221

Tolli, M. A. et al. In vivo biocompatibility of porous silicon biomaterials for drug
delivery to the heart. Biomaterials 35, 8394-8405,
doi:10.1016/j.biomaterials.2014.05.078 (2014).
Inoue, N. et al. Rapid electrical stimulation of contraction modulates gap junction
protein in neonatal rat cultured cardiomyocytes: involvement of mitogenactivated protein kinases and effects of angiotensin II-receptor antagonist.
Journal of the American College of Cardiology 44, 914-922,
doi:10.1016/j.jacc.2004.05.054 (2004).
Au, H. T., Cheng, I., Chowdhury, M. F. & Radisic, M. Interactive effects of surface
topography and pulsatile electrical field stimulation on orientation and
elongation of fibroblasts and cardiomyocytes. Biomaterials 28, 4277-4293,
doi:10.1016/j.biomaterials.2007.06.001 (2007).
Kato, S., Ivester, C. T., Cooper, G. t., Zile, M. R. & McDermott, P. J. Growth effects
of electrically stimulated contraction on adult feline cardiocytes in primary
culture. Am J Physiol 268, H2495-2504 (1995).
Palatinus, J. A., Rhett, J. M. & Gourdie, R. G. The connexin43 carboxyl terminus
and cardiac gap junction organization. Biochimica et biophysica acta 1818, 18311843, doi:10.1016/j.bbamem.2011.08.006 (2012).
Vreeker, A. et al. Assembly of the cardiac intercalated disk during pre- and
postnatal development of the human heart. PloS one 9, e94722,
doi:10.1371/journal.pone.0094722 (2014).
Giepmans, B. N. Gap junctions and connexin-interacting proteins. Cardiovascular
research 62, 233-245, doi:10.1016/j.cardiores.2003.12.009 (2004).
Shaw, R. M. et al. Microtubule plus-end-tracking proteins target gap junctions
directly from the cell interior to adherens junctions. Cell 128, 547-560,
doi:10.1016/j.cell.2006.12.037 (2007).
Miyata, S., Minobe, W., Bristow, M. R. & Leinwand, L. A. Myosin heavy chain
isoform expression in the failing and nonfailing human heart. Circulation
research 86, 386-390 (2000).
Krenz, M. & Robbins, J. Impact of beta-myosin heavy chain expression on cardiac
function during stress. Journal of the American College of Cardiology 44, 23902397, doi:10.1016/j.jacc.2004.09.044 (2004).
Lompre, A. M., Nadal-Ginard, B. & Mahdavi, V. Expression of the cardiac
ventricular alpha- and beta-myosin heavy chain genes is developmentally and
hormonally regulated. The Journal of biological chemistry 259, 6437-6446 (1984).
Pope, B., Hoh, J. F. & Weeds, A. The ATPase activities of rat cardiac myosin
isoenzymes. FEBS letters 118, 205-208 (1980).
Bedada, F. B. et al. Acquisition of a quantitative, stoichiometrically conserved
ratiometric marker of maturation status in stem cell-derived cardiac myocytes.
Stem cell reports 3, 594-605, doi:10.1016/j.stemcr.2014.07.012 (2014).

125

222

223

224

225

226

227
228

229

230

231

232
233
234

Schwan, J. & Campbell, S. G. Prospects for In Vitro Myofilament Maturation in
Stem Cell-Derived Cardiac Myocytes. Biomark Insights 10, 91-103,
doi:10.4137/BMI.S23912 (2015).
Kim, C. et al. Non-cardiomyocytes influence the electrophysiological maturation
of human embryonic stem cell-derived cardiomyocytes during differentiation.
Stem cells and development 19, 783-795, doi:10.1089/scd.2009.0349 (2010).
Sizarov, A. et al. Molecular analysis of patterning of conduction tissues in the
developing human heart. Circ Arrhythm Electrophysiol 4, 532-542,
doi:10.1161/CIRCEP.111.963421 (2011).
Bett, G. C. et al. Electronic "expression" of the inward rectifier in cardiocytes
derived from human-induced pluripotent stem cells. Heart rhythm : the official
journal of the Heart Rhythm Society 10, 1903-1910,
doi:10.1016/j.hrthm.2013.09.061 (2013).
Menasche, P. Stem cell therapy for heart failure: are arrhythmias a real safety
concern? Circulation 119, 2735-2740,
doi:10.1161/CIRCULATIONAHA.108.812693 (2009).
Silvestre, J. & Menasche, P. The evolution of stem cell theory for heart failure.
EBioMedicine (2015 ).
Quijada, P. & Sussman, M. A. Making it stick: chasing the optimal stem cells for
cardiac regeneration. Expert Rev Cardiovasc Ther 12, 1275-1288,
doi:10.1586/14779072.2014.972941 (2014).
Lee, W. Y. et al. Enhancement of cell retention and functional benefits in
myocardial infarction using human amniotic-fluid stem-cell bodies enriched with
endogenous ECM. Biomaterials 32, 5558-5567,
doi:10.1016/j.biomaterials.2011.04.031 (2011).
Moon, S. H. et al. The use of aggregates of purified cardiomyocytes derived from
human ESCs for functional engraftment after myocardial infarction. Biomaterials
34, 4013-4026, doi:10.1016/j.biomaterials.2013.02.022 (2013).
Fernandes, S. et al. Comparison of Human Embryonic Stem Cell-Derived
Cardiomyocytes, Cardiovascular Progenitors, and Bone Marrow Mononuclear
Cells for Cardiac Repair. Stem cell reports 5, 753-762,
doi:10.1016/j.stemcr.2015.09.011 (2015).
Wu, Y. et al. Controlled Growth and Structures of Molecular-Scale Silicon
Nanowires. Nano Lett. 4, 433-436, doi:10.1021/nl035162i (2004).
Takebe, T. et al. Vascularized and functional human liver from an iPSC-derived
organ bud transplant. Nature 499, 481-484, doi:10.1038/nature12271 (2013).
Takasato, M. et al. Kidney organoids from human iPS cells contain multiple
lineages and model human nephrogenesis. Nature 526, 564-568,
doi:10.1038/nature15695 (2015).

126

235

236

237

238

239

240

241

242

243

244

245

246

247

Dye, B. R. et al. A bioengineered niche promotes in vivo engraftment and
maturation of pluripotent stem cell derived human lung organoids. eLife 5,
doi:10.7554/eLife.19732 (2016).
Shkumatov, A., Baek, K. & Kong, H. Matrix rigidity-modulated cardiovascular
organoid formation from embryoid bodies. PloS one 9, e94764,
doi:10.1371/journal.pone.0094764 (2014).
Takebe, T. et al. Vascularized and Complex Organ Buds from Diverse Tissues via
Mesenchymal Cell-Driven Condensation. Cell stem cell 16, 556-565,
doi:10.1016/j.stem.2015.03.004 (2015).
Gunter, J. et al. Microtissues in Cardiovascular Medicine: Regenerative Potential
Based on a 3D Microenvironment. Stem Cells Int 2016, 9098523,
doi:10.1155/2016/9098523 (2016).
Matsa, E., Ahrens, J. H. & Wu, J. C. Human Induced Pluripotent Stem Cells as a
Platform for Personalized and Precision Cardiovascular Medicine. Physiol. Rev.
96, 1093-1126, doi:10.1152/physrev.00036.2015 (2016).
Matsa, E. et al. Transcriptome Profiling of Patient-Specific Human iPSCCardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro.
Cell stem cell, doi:10.1016/j.stem.2016.07.006 (2016).
Ogle, B. M. et al. Distilling complexity to advance cardiac tissue engineering.
Science translational medicine 8, 342ps313, doi:10.1126/scitranslmed.aad2304
(2016).
Ribas, J. et al. Cardiovascular Organ-on-a-Chip Platform for Drug Discovery and
Development. Applied In Vitro Toxicology 2, 82-96, doi:10.1089/aivt.2016.0002
(2016).
Tiburcy, M. et al. Defined Engineered Human Myocardium with Advanced
Maturation for Applications in Heart Failure Modelling and Repair. Circulation,
doi:10.1161/CIRCULATIONAHA.116.024145 (2017).
Kelm, J. M. et al. Tissue-transplant fusion and vascularization of myocardial
microtissues and macrotissues implanted into chicken embryos and rats. Tissue
Eng 12, 2541-2553, doi:10.1089/ten.2006.12.2541 (2006).
Burridge, P. W. et al. Multi-cellular interactions sustain long-term contractility of
human pluripotent stem cell-derived cardiomyocytes. American journal of
translational research 6, 724-735 (2014).
Kaneko, T., Nomura, F. & Yasuda, K. On-chip constructive cell-network study (I):
contribution of cardiac fibroblasts to cardiomyocyte beating synchronization and
community effect. J Nanobiotechnology 9, 21, doi:10.1186/1477-3155-9-21
(2011).
Roberts, M. A. et al. Stromal Cells in Dense Collagen Promote Cardiomyocyte and
Microvascular Patterning in Engineered Human Heart Tissue. Tissue engineering.
Part A 22, 633-644, doi:10.1089/ten.TEA.2015.0482 (2016).

127

248
249

250

251

252

253
254

255

256
257

258

259

260

261

Kelm, J. M. et al. VEGF profiling and angiogenesis in human microtissues. J
Biotechnol 118, 213-229, doi:10.1016/j.jbiotec.2005.03.016 (2005).
Garzoni, L. R. et al. Dissecting coronary angiogenesis: 3D co-culture of
cardiomyocytes with endothelial or mesenchymal cells. Exp Cell Res 315, 34063418, doi:10.1016/j.yexcr.2009.09.016 (2009).
Smart, N., Dube, K. N. & Riley, P. R. Coronary vessel development and insight
towards neovascular therapy. Int J Exp Pathol 90, 262-283, doi:10.1111/j.13652613.2009.00646.x (2009).
Dyer, L., Pi, X. & Patterson, C. Connecting the coronaries: how the coronary
plexus develops and is functionalized. Dev Biol 395, 111-119,
doi:10.1016/j.ydbio.2014.08.024 (2014).
Olivey, H. E. & Svensson, E. C. Epicardial-myocardial signaling directing coronary
vasculogenesis. Circulation research 106, 818-832,
doi:10.1161/CIRCRESAHA.109.209197 (2010).
Reese, D. E., Mikawa, T. & Bader, D. M. Development of the coronary vessel
system. Circulation research 91, 761-768 (2002).
de Bakker, B. S., de Jong, K. H., Hagoort, J., Oostra, R. J. & Moorman, A. F.
Towards a 3-dimensional atlas of the developing human embryo: the Amsterdam
experience. Reprod. Toxicol. 34, 225-236, doi:10.1016/j.reprotox.2012.05.087
(2012).
de Boer, B. A., van den Berg, G., de Boer, P. A., Moorman, A. F. & Ruijter, J. M.
Growth of the developing mouse heart: an interactive qualitative and
quantitative 3D atlas. Dev Biol 368, 203-213, doi:10.1016/j.ydbio.2012.05.001
(2012).
Wong, M. D. et al. 4D atlas of the mouse embryo for precise morphological
staging. Development 142, 3583-3591, doi:10.1242/dev.125872 (2015).
Madden, L., Juhas, M., Kraus, W. E., Truskey, G. A. & Bursac, N. Bioengineered
human myobundles mimic clinical responses of skeletal muscle to drugs. eLife 4,
doi:10.7554/eLife.04885 (2015).
Jackman, C. P., Carlson, A. L. & Bursac, N. Dynamic culture yields engineered
myocardium with near-adult functional output. Biomaterials 111, 66-79,
doi:10.1016/j.biomaterials.2016.09.024 (2016).
Adler, C. P. Relationship between deoxyribonucleic acid content and nucleoli in
human heart muscle cells and estimation of cell number during cardiac growth
and hyperfunction. Recent Adv Stud Cardiac Struct Metab 8, 373-386 (1975).
Adler, C. P. & Friedburg, H. Myocardial DNA content, ploidy level and cell number
in geriatric hearts: post-mortem examinations of human myocardium in old age.
Journal of molecular and cellular cardiology 18, 39-53 (1986).
Banerjee, I., Fuseler, J. W., Price, R. L., Borg, T. K. & Baudino, T. A. Determination
of cell types and numbers during cardiac development in the neonatal and adult

128

262

263

264
265
266
267

268
269

270

271
272

273

274

rat and mouse. American journal of physiology. Heart and circulatory physiology
293, H1883-1891, doi:10.1152/ajpheart.00514.2007 (2007).
Rubina, K. et al. Adipose stromal cells stimulate angiogenesis via promoting
progenitor cell differentiation, secretion of angiogenic factors, and enhancing
vessel maturation. Tissue engineering. Part A 15, 2039-2050,
doi:10.1089/ten.tea.2008.0359 (2009).
Strassburg, S., Nienhueser, H., Bjorn Stark, G., Finkenzeller, G. & Torio-Padron, N.
Co-culture of adipose-derived stem cells and endothelial cells in fibrin induces
angiogenesis and vasculogenesis in a chorioallantoic membrane model. Journal
of tissue engineering and regenerative medicine 10, 496-506,
doi:10.1002/term.1769 (2016).
Crisan, M. et al. A perivascular origin for mesenchymal stem cells in multiple
human organs. Cell stem cell 3, 301-313, doi:10.1016/j.stem.2008.07.003 (2008).
Caplan, A. I. The new MSC: MSCs as pericytes are sentinels and gatekeepers. J
Orthop Res, doi:10.1002/jor.23560 (2017).
Caplan, A. I. All MSCs are pericytes? Cell stem cell 3, 229-230,
doi:10.1016/j.stem.2008.08.008 (2008).
Zhang, W. et al. Maturation of human embryonic stem cell-derived
cardiomyocytes (hESC-CMs) in 3D collagen matrix: Effects of niche cell
supplementation and mechanical stimulation. Acta Biomater 49, 204-217,
doi:10.1016/j.actbio.2016.11.058 (2017).
Steinberg, M. S. Differential adhesion in morphogenesis: a modern view. Curr.
Opin. Genet. Dev. 17, 281-286, doi:10.1016/j.gde.2007.05.002 (2007).
Tomanek, R. J., Ratajska, A., Kitten, G. T., Yue, X. & Sandra, A. Vascular
endothelial growth factor expression coincides with coronary vasculogenesis and
angiogenesis. Dev Dyn 215, 54-61, doi:10.1002/(SICI)10970177(199905)215:1<54::AID-DVDY6>3.0.CO;2-0 (1999).
Radisic, M. et al. Oxygen gradients correlate with cell density and cell viability in
engineered cardiac tissue. Biotechnology and bioengineering 93, 332-343,
doi:10.1002/bit.20722 (2006).
Folkman, J. & Hochberg, M. Self-regulation of growth in three dimensions. J. Exp.
Med. 138, 745-753 (1973).
Caspi, O. et al. Tissue engineering of vascularized cardiac muscle from human
embryonic stem cells. Circulation research 100, 263-272,
doi:10.1161/01.RES.0000257776.05673.ff (2007).
Kreutziger, K. L. et al. Developing vasculature and stroma in engineered human
myocardium. Tissue engineering. Part A 17, 1219-1228,
doi:10.1089/ten.TEA.2010.0557 (2011).
Stoehr, A. et al. Spontaneous Formation of Extensive Vessel-Like Structures in
Murine Engineered Heart Tissue. Tissue engineering. Part A 22, 326-335,
doi:10.1089/ten.TEA.2015.0242 (2016).

129

275

276

277

278

279

280

281

282

283

284

285

286
287

Rouwkema, J., Koopman, B., Blitterswijk, C., Dhert, W. & Malda, J. Supply of
nutrients to cells in engineered tissues. Biotechnol Genet Eng Rev 26, 163-178
(2010).
Monsuur, H. N. et al. Extensive Characterization and Comparison of Endothelial
Cells Derived from Dermis and Adipose Tissue: Potential Use in Tissue
Engineering. PloS one 11, e0167056, doi:10.1371/journal.pone.0167056 (2016).
Melero-Martin, J. M. et al. In vivo vasculogenic potential of human blood-derived
endothelial progenitor cells. Blood 109, 4761-4768, doi:10.1182/blood-2006-12062471 (2007).
Langley, R. R. et al. Tissue-specific microvascular endothelial cell lines from H2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res. 63,
2971-2976 (2003).
Craig, L. E., Spelman, J. P., Strandberg, J. D. & Zink, M. C. Endothelial cells from
diverse tissues exhibit differences in growth and morphology. Microvasc Res 55,
65-76, doi:10.1006/mvre.1997.2045 (1998).
Langenkamp, E. & Molema, G. Microvascular endothelial cell heterogeneity:
general concepts and pharmacological consequences for anti-angiogenic therapy
of cancer. Cell and tissue research 335, 205-222, doi:10.1007/s00441-008-0642-4
(2009).
Jackson, C. J. & Nguyen, M. Human microvascular endothelial cells differ from
macrovascular endothelial cells in their expression of matrix metalloproteinases.
Int J Biochem Cell Biol 29, 1167-1177 (1997).
Camelliti, P., Borg, T. K. & Kohl, P. Structural and functional characterisation of
cardiac fibroblasts. Cardiovascular research 65, 40-51,
doi:10.1016/j.cardiores.2004.08.020 (2005).
Puissant, B. et al. Immunomodulatory effect of human adipose tissue-derived
adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J
Haematol 129, 118-129, doi:10.1111/j.1365-2141.2005.05409.x (2005).
Williams, C., Quinn, K. P., Georgakoudi, I. & Black, L. D., 3rd. Young
developmental age cardiac extracellular matrix promotes the expansion of
neonatal cardiomyocytes in vitro. Acta Biomater 10, 194-204,
doi:10.1016/j.actbio.2013.08.037 (2014).
Konstandin, M. H. et al. Fibronectin contributes to pathological cardiac
hypertrophy but not physiological growth. Basic research in cardiology 108, 375,
doi:10.1007/s00395-013-0375-8 (2013).
Mamuya, W. S. & Brecher, P. Fibronectin expression in the normal and
hypertrophic rat heart. J Clin Invest 89, 392-401, doi:10.1172/JCI115598 (1992).
Sevilla, C. A., Dalecki, D. & Hocking, D. C. Regional fibronectin and collagen fibril
co-assembly directs cell proliferation and microtissue morphology. PloS one 8,
e77316, doi:10.1371/journal.pone.0077316 (2013).

130

288

289

290

291

292

293

294
295

296

297

298

299

300

Sevilla, C. A., Dalecki, D. & Hocking, D. C. Extracellular matrix fibronectin
stimulates the self-assembly of microtissues on native collagen gels. Tissue
engineering. Part A 16, 3805-3819, doi:10.1089/ten.TEA.2010.0316 (2010).
Shiraishi, I., Takamatsu, T. & Fujita, S. Three-dimensional observation with a
confocal scanning laser microscope of fibronectin immunolabeling during cardiac
looping in the chick embryo. Anat Embryol (Berl) 191, 183-189 (1995).
Sottile, J. & Hocking, D. C. Fibronectin polymerization regulates the composition
and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol Biol Cell
13, 3546-3559, doi:10.1091/mbc.E02-01-0048 (2002).
Herron, T. J. et al. Extracellular Matrix-Mediated Maturation of Human
Pluripotent Stem Cell-Derived Cardiac Monolayer Structure and
Electrophysiological Function. Circ Arrhythm Electrophysiol 9,
doi:10.1161/CIRCEP.113.003638 (2016).
Westermann, D. et al. Cardiac inflammation contributes to changes in the
extracellular matrix in patients with heart failure and normal ejection fraction.
Circulation. Heart failure 4, 44-52, doi:10.1161/CIRCHEARTFAILURE.109.931451
(2011).
Deb, A. & Ubil, E. Cardiac fibroblast in development and wound healing. Journal
of molecular and cellular cardiology 70, 47-55, doi:10.1016/j.yjmcc.2014.02.017
(2014).
Madamanchi, A. Beta-adrenergic receptor signaling in cardiac function and heart
failure. Mcgill J Med 10, 99-104 (2007).
Matsa, E., Burridge, P. W. & Wu, J. C. Human stem cells for modeling heart
disease and for drug discovery. Science translational medicine 6, 239ps236,
doi:10.1126/scitranslmed.3008921 (2014).
Dell'Era, P. et al. Cardiac disease modeling using induced pluripotent stem cellderived human cardiomyocytes. World J Stem Cells 7, 329-342,
doi:10.4252/wjsc.v7.i2.329 (2015).
Sala, L., Bellin, M. & Mummery, C. L. Integrating cardiomyocytes from human
pluripotent stem cells in safety pharmacology: has the time come? Br J
Pharmacol, doi:10.1111/bph.13577 (2016).
Mozaffarian, D. et al. Heart disease and stroke statistics--2015 update: a report
from the American Heart Association. Circulation 131, e29-322,
doi:10.1161/CIR.0000000000000152 (2015).
Nian, M., Lee, P., Khaper, N. & Liu, P. Inflammatory cytokines and postmyocardial
infarction remodeling. Circulation research 94, 1543-1553,
doi:10.1161/01.RES.0000130526.20854.fa (2004).
Hsieh, P. C., Davis, M. E., Lisowski, L. K. & Lee, R. T. Endothelial-cardiomyocyte
interactions in cardiac development and repair. Annu. Rev. Physiol. 68, 51-66,
doi:10.1146/annurev.physiol.68.040104.124629 (2006).

131

301

Fan, D., Takawale, A., Lee, J. & Kassiri, Z. Cardiac fibroblasts, fibrosis and
extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair 5, 15,
doi:10.1186/1755-1536-5-15 (2012).

132

